id	sid	tid	token	lemma	pos
dpc-1025	1	1	dermatology	dermatology	NOUN
dpc-1025	1	2	:	:	PUNCT
dpc-1025	1	3	practical	practical	ADJ
dpc-1025	1	4	and	and	CCONJ
dpc-1025	1	5	conceptual	conceptual	ADJ
dpc-1025	1	6	research	research	NOUN
dpc-1025	1	7	|	|	ADV
dpc-1025	1	8	dermatol	dermatol	ADJ
dpc-1025	1	9	pract	pract	NOUN
dpc-1025	1	10	concept	concept	NOUN
dpc-1025	1	11	2020;10(1):e2020010	2020;10(1):e2020010	NUM
dpc-1025	1	12	1	1	NUM
dpc-1025	1	13	dermatology	dermatology	NOUN
dpc-1025	1	14	practical	practical	ADJ
dpc-1025	1	15	&	&	CCONJ
dpc-1025	1	16	conceptual	conceptual	ADJ
dpc-1025	1	17	serum	serum	PROPN
dpc-1025	1	18	total	total	ADJ
dpc-1025	1	19	25	25	NUM
dpc-1025	1	20	-	-	PUNCT
dpc-1025	1	21	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	1	22	d	d	NOUN
dpc-1025	1	23	levels	level	NOUN
dpc-1025	1	24	in	in	ADP
dpc-1025	1	25	patients	patient	NOUN
dpc-1025	1	26	with	with	ADP
dpc-1025	1	27	cutaneous	cutaneous	ADJ
dpc-1025	1	28	malignant	malignant	ADJ
dpc-1025	1	29	melanoma	melanoma	NOUN
dpc-1025	1	30	:	:	PUNCT
dpc-1025	1	31	a	a	DET
dpc-1025	1	32	case	case	NOUN
dpc-1025	1	33	-	-	PUNCT
dpc-1025	1	34	control	control	NOUN
dpc-1025	1	35	study	study	NOUN
dpc-1025	1	36	in	in	ADP
dpc-1025	1	37	a	a	DET
dpc-1025	1	38	low	low	ADJ
dpc-1025	1	39	-	-	PUNCT
dpc-1025	1	40	risk	risk	NOUN
dpc-1025	1	41	southern	southern	ADJ
dpc-1025	1	42	european	european	ADJ
dpc-1025	1	43	population	population	PROPN
dpc-1025	1	44	angeliki	angeliki	PROPN
dpc-1025	1	45	befon,1	befon,1	PROPN
dpc-1025	1	46	alexander	alexander	PROPN
dpc-1025	1	47	c.	c.	PROPN
dpc-1025	1	48	katoulis,2	katoulis,2	PROPN
dpc-1025	1	49	sofia	sofia	PROPN
dpc-1025	1	50	georgala,1	georgala,1	PROPN
dpc-1025	1	51	andreas	andreas	PROPN
dpc-1025	1	52	katsampas,1	katsampas,1	PROPN
dpc-1025	1	53	vasiliki	vasiliki	PROPN
dpc-1025	1	54	chardalia,1	chardalia,1	PROPN
dpc-1025	1	55	aggeliki	aggeliki	PROPN
dpc-1025	1	56	melpidou,3	melpidou,3	PROPN
dpc-1025	1	57	vasiliki	vasiliki	PROPN
dpc-1025	1	58	tzanetakou,1	tzanetakou,1	ADJ
dpc-1025	1	59	vasiliki	vasiliki	PROPN
dpc-1025	1	60	chasapi,1	chasapi,1	PROPN
dpc-1025	1	61	dorothea	dorothea	PROPN
dpc-1025	1	62	polydorou,1	polydorou,1	PROPN
dpc-1025	1	63	clio	clio	PROPN
dpc-1025	1	64	desinioti,1	desinioti,1	PROPN
dpc-1025	1	65	micaela	micaela	PROPN
dpc-1025	1	66	plaka,1	plaka,1	NOUN
dpc-1025	1	67	dimitris	dimitris	PROPN
dpc-1025	1	68	rigopoulos,1	rigopoulos,1	PROPN
dpc-1025	1	69	alexandros	alexandros	PROPN
dpc-1025	1	70	j.	j.	PROPN
dpc-1025	1	71	stratigos1	stratigos1	PROPN
dpc-1025	1	72	1	1	NUM
dpc-1025	1	73	first	first	ADJ
dpc-1025	1	74	department	department	NOUN
dpc-1025	1	75	of	of	ADP
dpc-1025	1	76	dermatology	dermatology	NOUN
dpc-1025	1	77	and	and	CCONJ
dpc-1025	1	78	venereology	venereology	NOUN
dpc-1025	1	79	,	,	PUNCT
dpc-1025	1	80	national	national	ADJ
dpc-1025	1	81	and	and	CCONJ
dpc-1025	1	82	kapodistrian	kapodistrian	ADJ
dpc-1025	1	83	university	university	PROPN
dpc-1025	1	84	of	of	ADP
dpc-1025	1	85	athens	athens	PROPN
dpc-1025	1	86	,	,	PUNCT
dpc-1025	1	87	medical	medical	ADJ
dpc-1025	1	88	school	school	NOUN
dpc-1025	1	89	,	,	PUNCT
dpc-1025	1	90	andreas	andreas	PROPN
dpc-1025	1	91	syggros	syggros	PROPN
dpc-1025	1	92	hospital	hospital	PROPN
dpc-1025	1	93	for	for	ADP
dpc-1025	1	94	skin	skin	NOUN
dpc-1025	1	95	and	and	CCONJ
dpc-1025	1	96	venereal	venereal	ADJ
dpc-1025	1	97	diseases	disease	NOUN
dpc-1025	1	98	,	,	PUNCT
dpc-1025	1	99	athens	athens	PROPN
dpc-1025	1	100	,	,	PUNCT
dpc-1025	1	101	greece	greece	PROPN
dpc-1025	1	102	2	2	NUM
dpc-1025	1	103	second	second	ADJ
dpc-1025	1	104	department	department	NOUN
dpc-1025	1	105	of	of	ADP
dpc-1025	1	106	dermatology	dermatology	NOUN
dpc-1025	1	107	and	and	CCONJ
dpc-1025	1	108	venereology	venereology	NOUN
dpc-1025	1	109	,	,	PUNCT
dpc-1025	1	110	attikon	attikon	PROPN
dpc-1025	1	111	general	general	ADJ
dpc-1025	1	112	university	university	NOUN
dpc-1025	1	113	hospital	hospital	NOUN
dpc-1025	1	114	,	,	PUNCT
dpc-1025	1	115	national	national	ADJ
dpc-1025	1	116	and	and	CCONJ
dpc-1025	1	117	kapodistrian	kapodistrian	ADJ
dpc-1025	1	118	university	university	PROPN
dpc-1025	1	119	of	of	ADP
dpc-1025	1	120	athens	athens	PROPN
dpc-1025	1	121	,	,	PUNCT
dpc-1025	1	122	greece	greece	PROPN
dpc-1025	1	123	3	3	NUM
dpc-1025	1	124	biochemistry	biochemistry	NOUN
dpc-1025	1	125	laboratory	laboratory	NOUN
dpc-1025	1	126	,	,	PUNCT
dpc-1025	1	127	evangelismos	evangelismos	PROPN
dpc-1025	1	128	general	general	PROPN
dpc-1025	1	129	hospital	hospital	PROPN
dpc-1025	1	130	of	of	ADP
dpc-1025	1	131	athens	athens	PROPN
dpc-1025	1	132	,	,	PUNCT
dpc-1025	1	133	greece	greece	PROPN
dpc-1025	1	134	keywords	keyword	NOUN
dpc-1025	1	135	:	:	PUNCT
dpc-1025	1	136	malignant	malignant	ADJ
dpc-1025	1	137	melanoma	melanoma	NOUN
dpc-1025	1	138	,	,	PUNCT
dpc-1025	1	139	vitamin	vitamin	NOUN
dpc-1025	1	140	d	d	NOUN
dpc-1025	1	141	,	,	PUNCT
dpc-1025	1	142	breslow	breslow	ADJ
dpc-1025	1	143	thickness	thickness	NOUN
dpc-1025	1	144	,	,	PUNCT
dpc-1025	1	145	ulceration	ulceration	NOUN
dpc-1025	1	146	,	,	PUNCT
dpc-1025	1	147	risk	risk	NOUN
dpc-1025	1	148	factors	factor	NOUN
dpc-1025	1	149	,	,	PUNCT
dpc-1025	1	150	prognosis	prognosis	NOUN
dpc-1025	1	151	.	.	PUNCT
dpc-1025	2	1	citation	citation	NOUN
dpc-1025	2	2	:	:	PUNCT
dpc-1025	2	3	befon	befon	PROPN
dpc-1025	2	4	a	a	PROPN
dpc-1025	2	5	,	,	PUNCT
dpc-1025	2	6	katoulis	katoulis	PROPN
dpc-1025	2	7	ac	ac	PROPN
dpc-1025	2	8	,	,	PUNCT
dpc-1025	2	9	georgala	georgala	PROPN
dpc-1025	2	10	s	s	PROPN
dpc-1025	2	11	,	,	PUNCT
dpc-1025	2	12	katsampas	katsampas	VERB
dpc-1025	2	13	a	a	PRON
dpc-1025	2	14	,	,	PUNCT
dpc-1025	2	15	chardalia	chardalia	PROPN
dpc-1025	2	16	v	v	NOUN
dpc-1025	2	17	,	,	PUNCT
dpc-1025	2	18	melpidou	melpidou	VERB
dpc-1025	2	19	a	a	PRON
dpc-1025	2	20	,	,	PUNCT
dpc-1025	2	21	tzanetakou	tzanetakou	NOUN
dpc-1025	2	22	v	v	NOUN
dpc-1025	2	23	,	,	PUNCT
dpc-1025	2	24	chasapi	chasapi	NOUN
dpc-1025	2	25	v	v	NOUN
dpc-1025	2	26	,	,	PUNCT
dpc-1025	2	27	polydorou	polydorou	PROPN
dpc-1025	2	28	d	d	PROPN
dpc-1025	2	29	,	,	PUNCT
dpc-1025	2	30	desinioti	desinioti	ADJ
dpc-1025	2	31	c	c	PROPN
dpc-1025	2	32	,	,	PUNCT
dpc-1025	2	33	plaka	plaka	PROPN
dpc-1025	2	34	m	m	PROPN
dpc-1025	2	35	,	,	PUNCT
dpc-1025	2	36	rigopoulos	rigopoulos	PROPN
dpc-1025	2	37	d	d	PROPN
dpc-1025	2	38	,	,	PUNCT
dpc-1025	2	39	stratigos	stratigos	PROPN
dpc-1025	2	40	aj	aj	PROPN
dpc-1025	2	41	.	.	PROPN
dpc-1025	2	42	serum	serum	PROPN
dpc-1025	2	43	total	total	ADJ
dpc-1025	2	44	25	25	NUM
dpc-1025	2	45	-	-	PUNCT
dpc-1025	2	46	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	2	47	d	d	NOUN
dpc-1025	2	48	levels	level	NOUN
dpc-1025	2	49	in	in	ADP
dpc-1025	2	50	patients	patient	NOUN
dpc-1025	2	51	with	with	ADP
dpc-1025	2	52	cutaneous	cutaneous	ADJ
dpc-1025	2	53	malignant	malignant	ADJ
dpc-1025	2	54	melanoma	melanoma	NOUN
dpc-1025	2	55	:	:	PUNCT
dpc-1025	2	56	a	a	DET
dpc-1025	2	57	casecontrol	casecontrol	NOUN
dpc-1025	2	58	study	study	NOUN
dpc-1025	2	59	in	in	ADP
dpc-1025	2	60	a	a	DET
dpc-1025	2	61	low	low	ADJ
dpc-1025	2	62	-	-	PUNCT
dpc-1025	2	63	risk	risk	NOUN
dpc-1025	2	64	southern	southern	ADJ
dpc-1025	2	65	european	european	ADJ
dpc-1025	2	66	population	population	NOUN
dpc-1025	2	67	.	.	PUNCT
dpc-1025	3	1	dermatol	dermatol	NOUN
dpc-1025	3	2	pract	pract	PROPN
dpc-1025	3	3	concept	concept	NOUN
dpc-1025	3	4	.	.	PUNCT
dpc-1025	4	1	2020;10(1):e2020010	2020;10(1):e2020010	X
dpc-1025	4	2	.	.	PUNCT
dpc-1025	5	1	doi	doi	PROPN
dpc-1025	5	2	:	:	PUNCT
dpc-1025	5	3	https://doi.org/10.5826/	https://doi.org/10.5826/	PROPN
dpc-1025	5	4	dpc.1001a10	dpc.1001a10	AUX
dpc-1025	5	5	accepted	accept	VERB
dpc-1025	5	6	:	:	PUNCT
dpc-1025	5	7	september	september	PROPN
dpc-1025	5	8	24	24	NUM
dpc-1025	5	9	,	,	PUNCT
dpc-1025	5	10	2019	2019	NUM
dpc-1025	5	11	;	;	PUNCT
dpc-1025	5	12	published	publish	VERB
dpc-1025	5	13	:	:	PUNCT
dpc-1025	5	14	december	december	PROPN
dpc-1025	5	15	31	31	NUM
dpc-1025	5	16	,	,	PUNCT
dpc-1025	5	17	2019	2019	NUM
dpc-1025	5	18	copyright	copyright	NOUN
dpc-1025	5	19	:	:	PUNCT
dpc-1025	6	1	©	©	PROPN
dpc-1025	6	2	2019	2019	NUM
dpc-1025	6	3	befon	befon	NOUN
dpc-1025	6	4	et	et	PROPN
dpc-1025	6	5	al	al	PROPN
dpc-1025	6	6	.	.	PUNCT
dpc-1025	7	1	this	this	PRON
dpc-1025	7	2	is	be	AUX
dpc-1025	7	3	an	an	DET
dpc-1025	7	4	open	open	ADJ
dpc-1025	7	5	-	-	PUNCT
dpc-1025	7	6	access	access	NOUN
dpc-1025	7	7	article	article	NOUN
dpc-1025	7	8	distributed	distribute	VERB
dpc-1025	7	9	under	under	ADP
dpc-1025	7	10	the	the	DET
dpc-1025	7	11	terms	term	NOUN
dpc-1025	7	12	of	of	ADP
dpc-1025	7	13	the	the	DET
dpc-1025	7	14	creative	creative	ADJ
dpc-1025	7	15	commons	common	NOUN
dpc-1025	7	16	attribution	attribution	NOUN
dpc-1025	7	17	license	license	NOUN
dpc-1025	7	18	,	,	PUNCT
dpc-1025	7	19	which	which	PRON
dpc-1025	7	20	permits	permit	VERB
dpc-1025	7	21	unrestricted	unrestricted	ADJ
dpc-1025	7	22	use	use	NOUN
dpc-1025	7	23	,	,	PUNCT
dpc-1025	7	24	distribution	distribution	NOUN
dpc-1025	7	25	,	,	PUNCT
dpc-1025	7	26	and	and	CCONJ
dpc-1025	7	27	reproduction	reproduction	NOUN
dpc-1025	7	28	in	in	ADP
dpc-1025	7	29	any	any	DET
dpc-1025	7	30	medium	medium	NOUN
dpc-1025	7	31	,	,	PUNCT
dpc-1025	7	32	provided	provide	VERB
dpc-1025	7	33	the	the	DET
dpc-1025	7	34	original	original	ADJ
dpc-1025	7	35	author	author	NOUN
dpc-1025	7	36	and	and	CCONJ
dpc-1025	7	37	source	source	NOUN
dpc-1025	7	38	are	be	AUX
dpc-1025	7	39	credited	credit	VERB
dpc-1025	7	40	.	.	PUNCT
dpc-1025	8	1	funding	funding	NOUN
dpc-1025	8	2	:	:	PUNCT
dpc-1025	8	3	none	none	NOUN
dpc-1025	8	4	.	.	PUNCT
dpc-1025	9	1	competing	compete	VERB
dpc-1025	9	2	interests	interest	NOUN
dpc-1025	9	3	:	:	PUNCT
dpc-1025	9	4	the	the	DET
dpc-1025	9	5	authors	author	NOUN
dpc-1025	9	6	have	have	VERB
dpc-1025	9	7	no	no	DET
dpc-1025	9	8	conflicts	conflict	NOUN
dpc-1025	9	9	of	of	ADP
dpc-1025	9	10	interest	interest	NOUN
dpc-1025	9	11	to	to	PART
dpc-1025	9	12	disclose	disclose	VERB
dpc-1025	9	13	.	.	PUNCT
dpc-1025	10	1	authorship	authorship	NOUN
dpc-1025	10	2	:	:	PUNCT
dpc-1025	10	3	all	all	DET
dpc-1025	10	4	authors	author	NOUN
dpc-1025	10	5	have	have	AUX
dpc-1025	10	6	contributed	contribute	VERB
dpc-1025	10	7	significantly	significantly	ADV
dpc-1025	10	8	to	to	ADP
dpc-1025	10	9	this	this	DET
dpc-1025	10	10	publication	publication	NOUN
dpc-1025	10	11	.	.	PUNCT
dpc-1025	11	1	corresponding	correspond	VERB
dpc-1025	11	2	author	author	NOUN
dpc-1025	11	3	:	:	PUNCT
dpc-1025	11	4	dr	dr	PROPN
dpc-1025	11	5	.	.	PROPN
dpc-1025	11	6	angeliki	angeliki	PROPN
dpc-1025	11	7	befon	befon	PROPN
dpc-1025	11	8	,	,	PUNCT
dpc-1025	11	9	first	first	ADJ
dpc-1025	11	10	department	department	NOUN
dpc-1025	11	11	of	of	ADP
dpc-1025	11	12	dermatology	dermatology	NOUN
dpc-1025	11	13	and	and	CCONJ
dpc-1025	11	14	venereology	venereology	NOUN
dpc-1025	11	15	,	,	PUNCT
dpc-1025	11	16	university	university	NOUN
dpc-1025	11	17	of	of	ADP
dpc-1025	11	18	athens	athens	PROPN
dpc-1025	11	19	,	,	PUNCT
dpc-1025	11	20	andreas	andreas	PROPN
dpc-1025	11	21	syggros	syggros	PROPN
dpc-1025	11	22	hospital	hospital	PROPN
dpc-1025	11	23	,	,	PUNCT
dpc-1025	11	24	5	5	NUM
dpc-1025	11	25	dragoumi	dragoumi	PROPN
dpc-1025	11	26	str	str	PROPN
dpc-1025	11	27	,	,	PUNCT
dpc-1025	11	28	athens	athens	PROPN
dpc-1025	11	29	16121	16121	NUM
dpc-1025	11	30	,	,	PUNCT
dpc-1025	11	31	greece	greece	PROPN
dpc-1025	11	32	.	.	PUNCT
dpc-1025	12	1	e	e	X
dpc-1025	12	2	-	-	NOUN
dpc-1025	12	3	mail	mail	NOUN
dpc-1025	12	4	:	:	PUNCT
dpc-1025	12	5	drbefon@yahoo.gr	drbefon@yahoo.gr	VERB
dpc-1025	12	6	background	background	NOUN
dpc-1025	12	7	:	:	PUNCT
dpc-1025	12	8	recent	recent	ADJ
dpc-1025	12	9	data	datum	NOUN
dpc-1025	12	10	have	have	AUX
dpc-1025	12	11	shown	show	VERB
dpc-1025	12	12	an	an	DET
dpc-1025	12	13	inverse	inverse	NOUN
dpc-1025	12	14	association	association	NOUN
dpc-1025	12	15	between	between	ADP
dpc-1025	12	16	serum	serum	NOUN
dpc-1025	12	17	25	25	NUM
dpc-1025	12	18	-	-	PUNCT
dpc-1025	12	19	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	12	20	d	d	NOUN
dpc-1025	12	21	concentration	concentration	NOUN
dpc-1025	12	22	and	and	CCONJ
dpc-1025	12	23	incidence	incidence	NOUN
dpc-1025	12	24	of	of	ADP
dpc-1025	12	25	several	several	ADJ
dpc-1025	12	26	cancers	cancer	NOUN
dpc-1025	12	27	,	,	PUNCT
dpc-1025	12	28	including	include	VERB
dpc-1025	12	29	cutaneous	cutaneous	ADJ
dpc-1025	12	30	malignant	malignant	ADJ
dpc-1025	12	31	melanoma	melanoma	NOUN
dpc-1025	12	32	(	(	PUNCT
dpc-1025	12	33	cmm	cmm	NOUN
dpc-1025	12	34	)	)	PUNCT
dpc-1025	12	35	.	.	PUNCT
dpc-1025	13	1	in	in	ADP
dpc-1025	13	2	addition	addition	NOUN
dpc-1025	13	3	,	,	PUNCT
dpc-1025	13	4	lower	low	ADJ
dpc-1025	13	5	serum	serum	NOUN
dpc-1025	13	6	25	25	NUM
dpc-1025	13	7	-	-	PUNCT
dpc-1025	13	8	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	13	9	d	d	NOUN
dpc-1025	13	10	levels	level	NOUN
dpc-1025	13	11	have	have	AUX
dpc-1025	13	12	been	be	AUX
dpc-1025	13	13	associated	associate	VERB
dpc-1025	13	14	with	with	ADP
dpc-1025	13	15	thicker	thick	ADJ
dpc-1025	13	16	or	or	CCONJ
dpc-1025	13	17	higher	high	ADJ
dpc-1025	13	18	stage	stage	NOUN
dpc-1025	13	19	melanomas	melanomas	NOUN
dpc-1025	13	20	and	and	CCONJ
dpc-1025	13	21	worse	bad	ADJ
dpc-1025	13	22	survival	survival	NOUN
dpc-1025	13	23	in	in	ADP
dpc-1025	13	24	observational	observational	ADJ
dpc-1025	13	25	studies	study	NOUN
dpc-1025	13	26	.	.	PUNCT
dpc-1025	14	1	materials	material	NOUN
dpc-1025	14	2	and	and	CCONJ
dpc-1025	14	3	methods	method	NOUN
dpc-1025	14	4	:	:	PUNCT
dpc-1025	14	5	ninety	ninety	NUM
dpc-1025	14	6	-	-	PUNCT
dpc-1025	14	7	nine	nine	NUM
dpc-1025	14	8	patients	patient	NOUN
dpc-1025	14	9	diagnosed	diagnose	VERB
dpc-1025	14	10	with	with	ADP
dpc-1025	14	11	primary	primary	ADJ
dpc-1025	14	12	cmm	cmm	NOUN
dpc-1025	14	13	and	and	CCONJ
dpc-1025	14	14	97	97	NUM
dpc-1025	14	15	matched	match	VERB
dpc-1025	14	16	healthy	healthy	ADJ
dpc-1025	14	17	controls	control	NOUN
dpc-1025	14	18	entered	enter	VERB
dpc-1025	14	19	the	the	DET
dpc-1025	14	20	study	study	NOUN
dpc-1025	14	21	.	.	PUNCT
dpc-1025	15	1	demographic	demographic	ADJ
dpc-1025	15	2	characteristics	characteristic	NOUN
dpc-1025	15	3	,	,	PUNCT
dpc-1025	15	4	risk	risk	NOUN
dpc-1025	15	5	factors	factor	NOUN
dpc-1025	15	6	for	for	ADP
dpc-1025	15	7	cmm	cmm	NOUN
dpc-1025	15	8	,	,	PUNCT
dpc-1025	15	9	and	and	CCONJ
dpc-1025	15	10	clinical	clinical	ADJ
dpc-1025	15	11	and	and	CCONJ
dpc-1025	15	12	histological	histological	ADJ
dpc-1025	15	13	characteristics	characteristic	NOUN
dpc-1025	15	14	were	be	AUX
dpc-1025	15	15	recorded	record	VERB
dpc-1025	15	16	for	for	ADP
dpc-1025	15	17	patients	patient	NOUN
dpc-1025	15	18	with	with	ADP
dpc-1025	15	19	primary	primary	ADJ
dpc-1025	15	20	cmm	cmm	NOUN
dpc-1025	15	21	.	.	PUNCT
dpc-1025	16	1	total	total	ADJ
dpc-1025	16	2	serum	serum	NOUN
dpc-1025	16	3	25	25	NUM
dpc-1025	16	4	-	-	PUNCT
dpc-1025	16	5	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	16	6	d	d	NOUN
dpc-1025	16	7	levels	level	NOUN
dpc-1025	16	8	of	of	ADP
dpc-1025	16	9	melanoma	melanoma	NOUN
dpc-1025	16	10	patients	patient	NOUN
dpc-1025	16	11	measured	measure	VERB
dpc-1025	16	12	by	by	ADP
dpc-1025	16	13	fully	fully	ADV
dpc-1025	16	14	automated	automate	VERB
dpc-1025	16	15	chemiluminescent	chemiluminescent	NOUN
dpc-1025	16	16	vitamin	vitamin	NOUN
dpc-1025	16	17	d	d	NOUN
dpc-1025	16	18	total	total	ADJ
dpc-1025	16	19	immunoassay	immunoassay	NOUN
dpc-1025	16	20	(	(	PUNCT
dpc-1025	16	21	elecsys	elecsys	PROPN
dpc-1025	16	22	vitamin	vitamin	NOUN
dpc-1025	16	23	d	d	X
dpc-1025	16	24	total	total	NOUN
dpc-1025	16	25	,	,	PUNCT
dpc-1025	16	26	roche	roche	PROPN
dpc-1025	16	27	)	)	PUNCT
dpc-1025	16	28	at	at	ADP
dpc-1025	16	29	the	the	DET
dpc-1025	16	30	time	time	NOUN
dpc-1025	16	31	of	of	ADP
dpc-1025	16	32	diagnosis	diagnosis	NOUN
dpc-1025	16	33	were	be	AUX
dpc-1025	16	34	compared	compare	VERB
dpc-1025	16	35	with	with	ADP
dpc-1025	16	36	those	those	PRON
dpc-1025	16	37	of	of	ADP
dpc-1025	16	38	healthy	healthy	ADJ
dpc-1025	16	39	controls	control	NOUN
dpc-1025	16	40	.	.	PUNCT
dpc-1025	17	1	in	in	ADP
dpc-1025	17	2	addition	addition	NOUN
dpc-1025	17	3	,	,	PUNCT
dpc-1025	17	4	we	we	PRON
dpc-1025	17	5	tested	test	VERB
dpc-1025	17	6	the	the	DET
dpc-1025	17	7	association	association	NOUN
dpc-1025	17	8	of	of	ADP
dpc-1025	17	9	serum	serum	PROPN
dpc-1025	17	10	total	total	ADJ
dpc-1025	17	11	25	25	NUM
dpc-1025	17	12	-	-	PUNCT
dpc-1025	17	13	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	17	14	d	d	NOUN
dpc-1025	17	15	levels	level	NOUN
dpc-1025	17	16	at	at	ADP
dpc-1025	17	17	melanoma	melanoma	ADJ
dpc-1025	17	18	diagnosis	diagnosis	NOUN
dpc-1025	17	19	with	with	ADP
dpc-1025	17	20	known	know	VERB
dpc-1025	17	21	risk	risk	NOUN
dpc-1025	17	22	and	and	CCONJ
dpc-1025	17	23	prognostic	prognostic	ADJ
dpc-1025	17	24	factors	factor	NOUN
dpc-1025	17	25	for	for	ADP
dpc-1025	17	26	cmm	cmm	NOUN
dpc-1025	17	27	.	.	PUNCT
dpc-1025	18	1	results	result	NOUN
dpc-1025	18	2	:	:	PUNCT
dpc-1025	18	3	of	of	ADP
dpc-1025	18	4	the	the	DET
dpc-1025	18	5	melanoma	melanoma	NOUN
dpc-1025	18	6	patients	patient	NOUN
dpc-1025	18	7	,	,	PUNCT
dpc-1025	18	8	49	49	NUM
dpc-1025	18	9	(	(	PUNCT
dpc-1025	18	10	49.49	49.49	NUM
dpc-1025	18	11	%	%	NOUN
dpc-1025	18	12	)	)	PUNCT
dpc-1025	18	13	had	have	VERB
dpc-1025	18	14	deficient	deficient	ADJ
dpc-1025	18	15	serum	serum	NOUN
dpc-1025	18	16	total	total	ADJ
dpc-1025	18	17	25	25	NUM
dpc-1025	18	18	-	-	PUNCT
dpc-1025	18	19	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	18	20	d	d	NOUN
dpc-1025	18	21	levels	level	NOUN
dpc-1025	18	22	(	(	PUNCT
dpc-1025	18	23	<	<	X
dpc-1025	18	24	20	20	NUM
dpc-1025	18	25	ng	ng	PROPN
dpc-1025	18	26	/	/	SYM
dpc-1025	18	27	ml	ml	PROPN
dpc-1025	18	28	)	)	PUNCT
dpc-1025	18	29	,	,	PUNCT
dpc-1025	18	30	23	23	NUM
dpc-1025	18	31	(	(	PUNCT
dpc-1025	18	32	23.23	23.23	NUM
dpc-1025	18	33	%	%	NOUN
dpc-1025	18	34	)	)	PUNCT
dpc-1025	18	35	had	have	VERB
dpc-1025	18	36	insufficient	insufficient	ADJ
dpc-1025	18	37	levels	level	NOUN
dpc-1025	18	38	(	(	PUNCT
dpc-1025	18	39	21	21	NUM
dpc-1025	18	40	-	-	SYM
dpc-1025	18	41	29	29	NUM
dpc-1025	18	42	ng	ng	PROPN
dpc-1025	18	43	/	/	SYM
dpc-1025	18	44	ml	ml	NOUN
dpc-1025	18	45	)	)	PUNCT
dpc-1025	18	46	,	,	PUNCT
dpc-1025	18	47	and	and	CCONJ
dpc-1025	18	48	27	27	NUM
dpc-1025	18	49	(	(	PUNCT
dpc-1025	18	50	27.27	27.27	NUM
dpc-1025	18	51	%	%	NOUN
dpc-1025	18	52	)	)	PUNCT
dpc-1025	18	53	had	have	VERB
dpc-1025	18	54	adequate	adequate	ADJ
dpc-1025	19	1	abstract	abstract	ADJ
dpc-1025	19	2	mailto:drbefon@yahoo.gr	mailto:drbefon@yahoo.gr	ADJ
dpc-1025	19	3	2	2	NUM
dpc-1025	19	4	research	research	NOUN
dpc-1025	20	1	|	|	ADV
dpc-1025	20	2	dermatol	dermatol	NOUN
dpc-1025	20	3	pract	pract	NOUN
dpc-1025	20	4	concept	concept	NOUN
dpc-1025	20	5	2020;10(1):e2020010	2020;10(1):e2020010	NUM
dpc-1025	20	6	of	of	ADP
dpc-1025	20	7	matched	match	VERB
dpc-1025	20	8	healthy	healthy	ADJ
dpc-1025	20	9	controls	control	NOUN
dpc-1025	20	10	.	.	PUNCT
dpc-1025	21	1	in	in	ADP
dpc-1025	21	2	addition	addition	NOUN
dpc-1025	21	3	,	,	PUNCT
dpc-1025	21	4	we	we	PRON
dpc-1025	21	5	tested	test	VERB
dpc-1025	21	6	the	the	DET
dpc-1025	21	7	association	association	NOUN
dpc-1025	21	8	of	of	ADP
dpc-1025	21	9	serum	serum	NOUN
dpc-1025	21	10	25	25	NUM
dpc-1025	21	11	-	-	PUNCT
dpc-1025	21	12	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	21	13	d	d	NOUN
dpc-1025	21	14	levels	level	NOUN
dpc-1025	21	15	at	at	ADP
dpc-1025	21	16	the	the	DET
dpc-1025	21	17	time	time	NOUN
dpc-1025	21	18	of	of	ADP
dpc-1025	21	19	melanoma	melanoma	ADJ
dpc-1025	21	20	diagnosis	diagnosis	NOUN
dpc-1025	21	21	with	with	ADP
dpc-1025	21	22	known	know	VERB
dpc-1025	21	23	risk	risk	NOUN
dpc-1025	21	24	and	and	CCONJ
dpc-1025	21	25	prognostic	prognostic	ADJ
dpc-1025	21	26	factors	factor	NOUN
dpc-1025	21	27	for	for	ADP
dpc-1025	21	28	cmm	cmm	NOUN
dpc-1025	21	29	,	,	PUNCT
dpc-1025	21	30	in	in	ADP
dpc-1025	21	31	an	an	DET
dpc-1025	21	32	attempt	attempt	NOUN
dpc-1025	21	33	to	to	PART
dpc-1025	21	34	assess	assess	VERB
dpc-1025	21	35	their	their	PRON
dpc-1025	21	36	prognostic	prognostic	ADJ
dpc-1025	21	37	value	value	NOUN
dpc-1025	21	38	.	.	PUNCT
dpc-1025	22	1	materials	material	NOUN
dpc-1025	22	2	and	and	CCONJ
dpc-1025	22	3	methods	method	NOUN
dpc-1025	22	4	study	study	NOUN
dpc-1025	22	5	design	design	VERB
dpc-1025	22	6	this	this	DET
dpc-1025	22	7	prospective	prospective	ADJ
dpc-1025	22	8	cohort	cohort	NOUN
dpc-1025	22	9	study	study	NOUN
dpc-1025	22	10	was	be	AUX
dpc-1025	22	11	conducted	conduct	VERB
dpc-1025	22	12	at	at	ADP
dpc-1025	22	13	the	the	DET
dpc-1025	22	14	melanoma	melanoma	ADJ
dpc-1025	22	15	unit	unit	NOUN
dpc-1025	22	16	of	of	ADP
dpc-1025	22	17	the	the	DET
dpc-1025	22	18	first	first	ADJ
dpc-1025	22	19	department	department	NOUN
dpc-1025	22	20	of	of	ADP
dpc-1025	22	21	dermatology	dermatology	NOUN
dpc-1025	22	22	and	and	CCONJ
dpc-1025	22	23	venereology	venereology	NOUN
dpc-1025	22	24	,	,	PUNCT
dpc-1025	22	25	andreas	andreas	PROPN
dpc-1025	22	26	syggros	syggros	PROPN
dpc-1025	22	27	hospital	hospital	PROPN
dpc-1025	22	28	,	,	PUNCT
dpc-1025	22	29	athens	athens	PROPN
dpc-1025	22	30	,	,	PUNCT
dpc-1025	22	31	greece	greece	PROPN
dpc-1025	22	32	.	.	PUNCT
dpc-1025	23	1	the	the	DET
dpc-1025	23	2	study	study	NOUN
dpc-1025	23	3	was	be	AUX
dpc-1025	23	4	approved	approve	VERB
dpc-1025	23	5	by	by	ADP
dpc-1025	23	6	the	the	DET
dpc-1025	23	7	ethics	ethic	NOUN
dpc-1025	23	8	committee	committee	PROPN
dpc-1025	23	9	of	of	ADP
dpc-1025	23	10	the	the	DET
dpc-1025	23	11	hospital	hospital	NOUN
dpc-1025	23	12	.	.	PUNCT
dpc-1025	24	1	written	write	VERB
dpc-1025	24	2	informed	informed	ADJ
dpc-1025	24	3	consent	consent	NOUN
dpc-1025	24	4	was	be	AUX
dpc-1025	24	5	obtained	obtain	VERB
dpc-1025	24	6	for	for	ADP
dpc-1025	24	7	all	all	DET
dpc-1025	24	8	entered	enter	VERB
dpc-1025	24	9	patients	patient	NOUN
dpc-1025	24	10	and	and	CCONJ
dpc-1025	24	11	controls	control	NOUN
dpc-1025	24	12	.	.	PUNCT
dpc-1025	25	1	patient	patient	ADJ
dpc-1025	25	2	recruitment	recruitment	NOUN
dpc-1025	25	3	took	take	VERB
dpc-1025	25	4	place	place	NOUN
dpc-1025	25	5	from	from	ADP
dpc-1025	25	6	april	april	PROPN
dpc-1025	25	7	2011	2011	NUM
dpc-1025	25	8	to	to	ADP
dpc-1025	25	9	march	march	PROPN
dpc-1025	25	10	2014	2014	NUM
dpc-1025	25	11	.	.	PUNCT
dpc-1025	26	1	consecutive	consecutive	ADJ
dpc-1025	26	2	patients	patient	NOUN
dpc-1025	26	3	diagnosed	diagnose	VERB
dpc-1025	26	4	with	with	ADP
dpc-1025	26	5	primary	primary	ADJ
dpc-1025	26	6	invasive	invasive	ADJ
dpc-1025	26	7	cmm	cmm	NOUN
dpc-1025	26	8	of	of	ADP
dpc-1025	26	9	any	any	DET
dpc-1025	26	10	stage	stage	NOUN
dpc-1025	26	11	were	be	AUX
dpc-1025	26	12	enrolled	enrol	VERB
dpc-1025	26	13	.	.	PUNCT
dpc-1025	27	1	the	the	DET
dpc-1025	27	2	diagnosis	diagnosis	NOUN
dpc-1025	27	3	of	of	ADP
dpc-1025	27	4	cmm	cmm	PROPN
dpc-1025	27	5	was	be	AUX
dpc-1025	27	6	made	make	VERB
dpc-1025	27	7	on	on	ADP
dpc-1025	27	8	histological	histological	ADJ
dpc-1025	27	9	grounds	ground	NOUN
dpc-1025	27	10	.	.	PUNCT
dpc-1025	28	1	exclusion	exclusion	NOUN
dpc-1025	28	2	criteria	criterion	NOUN
dpc-1025	28	3	included	include	VERB
dpc-1025	28	4	the	the	DET
dpc-1025	28	5	following	following	NOUN
dpc-1025	28	6	:	:	PUNCT
dpc-1025	28	7	patients	patient	NOUN
dpc-1025	28	8	with	with	ADP
dpc-1025	28	9	noncutaneous	noncutaneous	ADJ
dpc-1025	28	10	melanoma	melanoma	NOUN
dpc-1025	28	11	or	or	CCONJ
dpc-1025	28	12	metastatic	metastatic	ADJ
dpc-1025	28	13	melanoma	melanoma	NOUN
dpc-1025	28	14	of	of	ADP
dpc-1025	28	15	unknown	unknown	ADJ
dpc-1025	28	16	primary	primary	NOUN
dpc-1025	28	17	;	;	PUNCT
dpc-1025	28	18	patients	patient	NOUN
dpc-1025	28	19	with	with	ADP
dpc-1025	28	20	self	self	NOUN
dpc-1025	28	21	-	-	PUNCT
dpc-1025	28	22	reported	report	VERB
dpc-1025	28	23	preexisting	preexist	VERB
dpc-1025	28	24	conditions	condition	NOUN
dpc-1025	28	25	that	that	PRON
dpc-1025	28	26	could	could	AUX
dpc-1025	28	27	interfere	interfere	VERB
dpc-1025	28	28	with	with	ADP
dpc-1025	28	29	vitamin	vitamin	NOUN
dpc-1025	28	30	d	d	NOUN
dpc-1025	28	31	metabolism	metabolism	NOUN
dpc-1025	28	32	,	,	PUNCT
dpc-1025	28	33	such	such	ADJ
dpc-1025	28	34	as	as	ADP
dpc-1025	28	35	chronic	chronic	ADJ
dpc-1025	28	36	liver	liver	NOUN
dpc-1025	28	37	or	or	CCONJ
dpc-1025	28	38	kidney	kidney	NOUN
dpc-1025	28	39	disease	disease	NOUN
dpc-1025	28	40	;	;	PUNCT
dpc-1025	28	41	transplant	transplant	NOUN
dpc-1025	28	42	recipients	recipient	NOUN
dpc-1025	28	43	or	or	CCONJ
dpc-1025	28	44	those	those	PRON
dpc-1025	28	45	with	with	ADP
dpc-1025	28	46	other	other	ADJ
dpc-1025	28	47	causes	cause	NOUN
dpc-1025	28	48	of	of	ADP
dpc-1025	28	49	immunosuppression	immunosuppression	NOUN
dpc-1025	28	50	;	;	PUNCT
dpc-1025	28	51	patients	patient	NOUN
dpc-1025	28	52	receiving	receive	VERB
dpc-1025	28	53	high	high	ADJ
dpc-1025	28	54	-	-	PUNCT
dpc-1025	28	55	dose	dose	NOUN
dpc-1025	28	56	calcium	calcium	NOUN
dpc-1025	28	57	therapy	therapy	NOUN
dpc-1025	28	58	;	;	PUNCT
dpc-1025	28	59	and	and	CCONJ
dpc-1025	28	60	patients	patient	NOUN
dpc-1025	28	61	receiving	receive	VERB
dpc-1025	28	62	vitamin	vitamin	NOUN
dpc-1025	28	63	d	d	NOUN
dpc-1025	28	64	supplementation	supplementation	NOUN
dpc-1025	28	65	during	during	ADP
dpc-1025	28	66	the	the	DET
dpc-1025	28	67	previous	previous	ADJ
dpc-1025	28	68	6	6	NUM
dpc-1025	28	69	months	month	NOUN
dpc-1025	28	70	.	.	PUNCT
dpc-1025	29	1	for	for	ADP
dpc-1025	29	2	all	all	DET
dpc-1025	29	3	recruited	recruit	VERB
dpc-1025	29	4	melanoma	melanoma	NOUN
dpc-1025	29	5	patients	patient	NOUN
dpc-1025	29	6	,	,	PUNCT
dpc-1025	29	7	complete	complete	ADJ
dpc-1025	29	8	personal	personal	ADJ
dpc-1025	29	9	and	and	CCONJ
dpc-1025	29	10	family	family	NOUN
dpc-1025	29	11	history	history	NOUN
dpc-1025	29	12	was	be	AUX
dpc-1025	29	13	obtained	obtain	VERB
dpc-1025	29	14	and	and	CCONJ
dpc-1025	29	15	total	total	ADJ
dpc-1025	29	16	body	body	NOUN
dpc-1025	29	17	skin	skin	NOUN
dpc-1025	29	18	examination	examination	NOUN
dpc-1025	29	19	was	be	AUX
dpc-1025	29	20	performed	perform	VERB
dpc-1025	29	21	.	.	PUNCT
dpc-1025	30	1	demographic	demographic	ADJ
dpc-1025	30	2	characteristics	characteristic	NOUN
dpc-1025	30	3	such	such	ADJ
dpc-1025	30	4	as	as	ADP
dpc-1025	30	5	age	age	NOUN
dpc-1025	30	6	,	,	PUNCT
dpc-1025	30	7	sex	sex	NOUN
dpc-1025	30	8	,	,	PUNCT
dpc-1025	30	9	race	race	NOUN
dpc-1025	30	10	,	,	PUNCT
dpc-1025	30	11	occupation	occupation	NOUN
dpc-1025	30	12	;	;	PUNCT
dpc-1025	30	13	body	body	NOUN
dpc-1025	30	14	measurements	measurement	NOUN
dpc-1025	30	15	,	,	PUNCT
dpc-1025	30	16	ie	ie	X
dpc-1025	30	17	,	,	PUNCT
dpc-1025	30	18	height	height	NOUN
dpc-1025	30	19	and	and	CCONJ
dpc-1025	30	20	weight	weight	NOUN
dpc-1025	30	21	to	to	PART
dpc-1025	30	22	calculate	calculate	VERB
dpc-1025	30	23	body	body	NOUN
dpc-1025	30	24	mass	mass	NOUN
dpc-1025	30	25	index	index	NOUN
dpc-1025	30	26	(	(	PUNCT
dpc-1025	30	27	bmi	bmi	PROPN
dpc-1025	30	28	)	)	PUNCT
dpc-1025	30	29	;	;	PUNCT
dpc-1025	30	30	risk	risk	NOUN
dpc-1025	30	31	factors	factor	NOUN
dpc-1025	30	32	for	for	ADP
dpc-1025	30	33	cmm	cmm	NOUN
dpc-1025	30	34	including	include	VERB
dpc-1025	30	35	hair	hair	NOUN
dpc-1025	30	36	color	color	NOUN
dpc-1025	30	37	,	,	PUNCT
dpc-1025	30	38	skin	skin	NOUN
dpc-1025	30	39	color	color	NOUN
dpc-1025	30	40	,	,	PUNCT
dpc-1025	30	41	skin	skin	NOUN
dpc-1025	30	42	phototype	phototype	NOUN
dpc-1025	30	43	,	,	PUNCT
dpc-1025	30	44	occupational	occupational	ADJ
dpc-1025	30	45	and	and	CCONJ
dpc-1025	30	46	recreational	recreational	ADJ
dpc-1025	30	47	sun	sun	NOUN
dpc-1025	30	48	exposure	exposure	NOUN
dpc-1025	30	49	,	,	PUNCT
dpc-1025	30	50	sunburns	sunburn	NOUN
dpc-1025	30	51	during	during	ADP
dpc-1025	30	52	childhood	childhood	NOUN
dpc-1025	30	53	;	;	PUNCT
dpc-1025	30	54	presence	presence	NOUN
dpc-1025	30	55	of	of	ADP
dpc-1025	30	56	dysplastic	dysplastic	ADJ
dpc-1025	30	57	nevi	nevi	NOUN
dpc-1025	30	58	,	,	PUNCT
dpc-1025	30	59	number	number	NOUN
dpc-1025	30	60	of	of	ADP
dpc-1025	30	61	melanocytic	melanocytic	ADJ
dpc-1025	30	62	nevi	nevi	NOUN
dpc-1025	30	63	,	,	PUNCT
dpc-1025	30	64	personal	personal	ADJ
dpc-1025	30	65	or	or	CCONJ
dpc-1025	30	66	family	family	NOUN
dpc-1025	30	67	history	history	NOUN
dpc-1025	30	68	of	of	ADP
dpc-1025	30	69	cmm	cmm	NOUN
dpc-1025	30	70	,	,	PUNCT
dpc-1025	30	71	have	have	AUX
dpc-1025	30	72	all	all	PRON
dpc-1025	30	73	been	be	AUX
dpc-1025	30	74	recorded	record	VERB
dpc-1025	30	75	.	.	PUNCT
dpc-1025	31	1	clinical	clinical	ADJ
dpc-1025	31	2	type	type	NOUN
dpc-1025	31	3	of	of	ADP
dpc-1025	31	4	cmm	cmm	NOUN
dpc-1025	31	5	and	and	CCONJ
dpc-1025	31	6	localization	localization	NOUN
dpc-1025	31	7	in	in	ADP
dpc-1025	31	8	sun	sun	NOUN
dpc-1025	31	9	-	-	PUNCT
dpc-1025	31	10	exposed	expose	VERB
dpc-1025	31	11	or	or	CCONJ
dpc-1025	31	12	sun	sun	NOUN
dpc-1025	31	13	-	-	PUNCT
dpc-1025	31	14	protected	protect	VERB
dpc-1025	31	15	areas	area	NOUN
dpc-1025	31	16	were	be	AUX
dpc-1025	31	17	assessed	assess	VERB
dpc-1025	31	18	.	.	PUNCT
dpc-1025	32	1	breslow	breslow	ADJ
dpc-1025	32	2	thickness	thickness	NOUN
dpc-1025	32	3	and	and	CCONJ
dpc-1025	32	4	presence	presence	NOUN
dpc-1025	32	5	or	or	CCONJ
dpc-1025	32	6	absence	absence	NOUN
dpc-1025	32	7	of	of	ADP
dpc-1025	32	8	ulceration	ulceration	NOUN
dpc-1025	32	9	were	be	AUX
dpc-1025	32	10	obtained	obtain	VERB
dpc-1025	32	11	from	from	ADP
dpc-1025	32	12	the	the	DET
dpc-1025	32	13	histology	histology	NOUN
dpc-1025	32	14	report	report	NOUN
dpc-1025	32	15	at	at	ADP
dpc-1025	32	16	the	the	DET
dpc-1025	32	17	time	time	NOUN
dpc-1025	32	18	of	of	ADP
dpc-1025	32	19	diagnosis	diagnosis	NOUN
dpc-1025	32	20	.	.	PUNCT
dpc-1025	33	1	for	for	ADP
dpc-1025	33	2	cmm	cmm	NOUN
dpc-1025	33	3	staging	staging	NOUN
dpc-1025	33	4	,	,	PUNCT
dpc-1025	33	5	the	the	DET
dpc-1025	33	6	seventh	seventh	ADJ
dpc-1025	33	7	edition	edition	NOUN
dpc-1025	33	8	of	of	ADP
dpc-1025	33	9	the	the	DET
dpc-1025	33	10	american	american	PROPN
dpc-1025	33	11	joint	joint	PROPN
dpc-1025	33	12	committee	committee	PROPN
dpc-1025	33	13	on	on	ADP
dpc-1025	33	14	canintroduction	canintroduction	NOUN
dpc-1025	33	15	the	the	DET
dpc-1025	33	16	incidence	incidence	NOUN
dpc-1025	33	17	of	of	ADP
dpc-1025	33	18	cutaneous	cutaneous	ADJ
dpc-1025	33	19	malignant	malignant	ADJ
dpc-1025	33	20	melanoma	melanoma	NOUN
dpc-1025	33	21	(	(	PUNCT
dpc-1025	33	22	cmm	cmm	NOUN
dpc-1025	33	23	)	)	PUNCT
dpc-1025	33	24	has	have	AUX
dpc-1025	33	25	increased	increase	VERB
dpc-1025	33	26	steeply	steeply	ADV
dpc-1025	33	27	over	over	ADP
dpc-1025	33	28	recent	recent	ADJ
dpc-1025	33	29	decades	decade	NOUN
dpc-1025	33	30	and	and	CCONJ
dpc-1025	33	31	continues	continue	VERB
dpc-1025	33	32	to	to	PART
dpc-1025	33	33	grow	grow	VERB
dpc-1025	33	34	worldwide	worldwide	ADV
dpc-1025	33	35	despite	despite	SCONJ
dpc-1025	33	36	intense	intense	ADJ
dpc-1025	33	37	efforts	effort	NOUN
dpc-1025	33	38	at	at	ADP
dpc-1025	33	39	primary	primary	ADJ
dpc-1025	33	40	prevention	prevention	NOUN
dpc-1025	33	41	.	.	PUNCT
dpc-1025	34	1	cmm	cmm	PROPN
dpc-1025	34	2	results	result	NOUN
dpc-1025	34	3	from	from	ADP
dpc-1025	34	4	complex	complex	ADJ
dpc-1025	34	5	interactions	interaction	NOUN
dpc-1025	34	6	between	between	ADP
dpc-1025	34	7	genetic	genetic	ADJ
dpc-1025	34	8	and	and	CCONJ
dpc-1025	34	9	environmental	environmental	ADJ
dpc-1025	34	10	factors	factor	NOUN
dpc-1025	34	11	.	.	PUNCT
dpc-1025	35	1	excessive	excessive	ADJ
dpc-1025	35	2	intermittent	intermittent	ADJ
dpc-1025	35	3	ultraviolet	ultraviolet	ADJ
dpc-1025	35	4	radiation	radiation	NOUN
dpc-1025	35	5	(	(	PUNCT
dpc-1025	35	6	uvr	uvr	NOUN
dpc-1025	35	7	)	)	PUNCT
dpc-1025	35	8	exposure	exposure	NOUN
dpc-1025	35	9	and	and	CCONJ
dpc-1025	35	10	sunburns	sunburn	NOUN
dpc-1025	35	11	during	during	ADP
dpc-1025	35	12	childhood	childhood	NOUN
dpc-1025	35	13	are	be	AUX
dpc-1025	35	14	considered	consider	VERB
dpc-1025	35	15	as	as	ADP
dpc-1025	35	16	the	the	DET
dpc-1025	35	17	principal	principal	ADJ
dpc-1025	35	18	causes	cause	NOUN
dpc-1025	35	19	of	of	ADP
dpc-1025	35	20	cmm	cmm	PROPN
dpc-1025	35	21	insurgence	insurgence	NOUN
dpc-1025	35	22	in	in	ADP
dpc-1025	35	23	adults	adult	NOUN
dpc-1025	35	24	,	,	PUNCT
dpc-1025	35	25	with	with	ADP
dpc-1025	35	26	double	double	DET
dpc-1025	35	27	the	the	DET
dpc-1025	35	28	risk	risk	NOUN
dpc-1025	35	29	relative	relative	ADJ
dpc-1025	35	30	to	to	ADP
dpc-1025	35	31	a	a	DET
dpc-1025	35	32	nonexposed	nonexposed	ADJ
dpc-1025	35	33	population	population	NOUN
dpc-1025	35	34	[	[	X
dpc-1025	35	35	1,2	1,2	NUM
dpc-1025	35	36	]	]	PUNCT
dpc-1025	35	37	.	.	PUNCT
dpc-1025	36	1	on	on	ADP
dpc-1025	36	2	the	the	DET
dpc-1025	36	3	other	other	ADJ
dpc-1025	36	4	hand	hand	NOUN
dpc-1025	36	5	,	,	PUNCT
dpc-1025	36	6	uvr	uvr	NOUN
dpc-1025	36	7	stimulates	stimulate	VERB
dpc-1025	36	8	the	the	DET
dpc-1025	36	9	endogenous	endogenous	ADJ
dpc-1025	36	10	production	production	NOUN
dpc-1025	36	11	of	of	ADP
dpc-1025	36	12	pre	pre	ADJ
dpc-1025	36	13	-	-	ADJ
dpc-1025	36	14	vitamin	vitamin	ADJ
dpc-1025	36	15	d3	d3	NOUN
dpc-1025	36	16	in	in	ADP
dpc-1025	36	17	the	the	DET
dpc-1025	36	18	skin	skin	NOUN
dpc-1025	36	19	,	,	PUNCT
dpc-1025	36	20	which	which	PRON
dpc-1025	36	21	supplies	supply	VERB
dpc-1025	36	22	>	>	X
dpc-1025	36	23	90	90	NUM
dpc-1025	36	24	%	%	NOUN
dpc-1025	36	25	of	of	ADP
dpc-1025	36	26	the	the	DET
dpc-1025	36	27	body	body	NOUN
dpc-1025	36	28	’s	’s	PART
dpc-1025	36	29	requirements	requirement	NOUN
dpc-1025	36	30	 	 	SPACE
dpc-1025	37	1	[	[	X
dpc-1025	37	2	3	3	NUM
dpc-1025	37	3	]	]	PUNCT
dpc-1025	37	4	.	.	PUNCT
dpc-1025	38	1	in	in	ADP
dpc-1025	38	2	vivo	vivo	ADJ
dpc-1025	38	3	vitamin	vitamin	NOUN
dpc-1025	38	4	d	d	NOUN
dpc-1025	38	5	demonstrates	demonstrate	VERB
dpc-1025	38	6	pleiotropic	pleiotropic	ADJ
dpc-1025	38	7	effects	effect	NOUN
dpc-1025	38	8	.	.	PUNCT
dpc-1025	39	1	beyond	beyond	ADP
dpc-1025	39	2	its	its	PRON
dpc-1025	39	3	role	role	NOUN
dpc-1025	39	4	in	in	ADP
dpc-1025	39	5	homeostasis	homeostasis	NOUN
dpc-1025	39	6	of	of	ADP
dpc-1025	39	7	calcium	calcium	NOUN
dpc-1025	39	8	and	and	CCONJ
dpc-1025	39	9	phosphorus	phosphorus	NOUN
dpc-1025	39	10	,	,	PUNCT
dpc-1025	39	11	it	it	PRON
dpc-1025	39	12	modulates	modulate	VERB
dpc-1025	39	13	cellular	cellular	ADJ
dpc-1025	39	14	functions	function	NOUN
dpc-1025	39	15	,	,	PUNCT
dpc-1025	39	16	such	such	ADJ
dpc-1025	39	17	as	as	ADP
dpc-1025	39	18	innate	innate	ADJ
dpc-1025	39	19	and	and	CCONJ
dpc-1025	39	20	adaptive	adaptive	ADJ
dpc-1025	39	21	immunity	immunity	NOUN
dpc-1025	39	22	through	through	ADP
dpc-1025	39	23	the	the	DET
dpc-1025	39	24	suppression	suppression	NOUN
dpc-1025	39	25	of	of	ADP
dpc-1025	39	26	inflammation	inflammation	NOUN
dpc-1025	39	27	,	,	PUNCT
dpc-1025	39	28	cell	cell	NOUN
dpc-1025	39	29	proliferation	proliferation	NOUN
dpc-1025	39	30	,	,	PUNCT
dpc-1025	39	31	differentiation	differentiation	NOUN
dpc-1025	39	32	,	,	PUNCT
dpc-1025	39	33	apoptosis	apoptosis	NOUN
dpc-1025	39	34	,	,	PUNCT
dpc-1025	39	35	and	and	CCONJ
dpc-1025	39	36	metastatic	metastatic	ADJ
dpc-1025	39	37	potential	potential	NOUN
dpc-1025	39	38	[	[	X
dpc-1025	39	39	4	4	NUM
dpc-1025	39	40	-	-	SYM
dpc-1025	39	41	8	8	NUM
dpc-1025	39	42	]	]	PUNCT
dpc-1025	39	43	.	.	PUNCT
dpc-1025	40	1	recent	recent	ADJ
dpc-1025	40	2	data	datum	NOUN
dpc-1025	40	3	have	have	AUX
dpc-1025	40	4	linked	link	VERB
dpc-1025	40	5	low	low	ADJ
dpc-1025	40	6	serum	serum	NOUN
dpc-1025	40	7	vitamin	vitamin	NOUN
dpc-1025	40	8	d	d	NOUN
dpc-1025	40	9	levels	level	NOUN
dpc-1025	40	10	to	to	ADP
dpc-1025	40	11	a	a	DET
dpc-1025	40	12	wide	wide	ADJ
dpc-1025	40	13	range	range	NOUN
dpc-1025	40	14	of	of	ADP
dpc-1025	40	15	diseases	disease	NOUN
dpc-1025	40	16	,	,	PUNCT
dpc-1025	40	17	including	include	VERB
dpc-1025	40	18	cardiovascular	cardiovascular	ADJ
dpc-1025	40	19	disease	disease	NOUN
dpc-1025	40	20	,	,	PUNCT
dpc-1025	40	21	insulin	insulin	NOUN
dpc-1025	40	22	resistance	resistance	NOUN
dpc-1025	40	23	,	,	PUNCT
dpc-1025	40	24	autoimmune	autoimmune	ADJ
dpc-1025	40	25	disease	disease	NOUN
dpc-1025	40	26	,	,	PUNCT
dpc-1025	40	27	and	and	CCONJ
dpc-1025	40	28	infection	infection	NOUN
dpc-1025	40	29	.	.	PUNCT
dpc-1025	41	1	most	most	ADV
dpc-1025	41	2	importantly	importantly	ADV
dpc-1025	41	3	,	,	PUNCT
dpc-1025	41	4	they	they	PRON
dpc-1025	41	5	have	have	AUX
dpc-1025	41	6	been	be	AUX
dpc-1025	41	7	linked	link	VERB
dpc-1025	41	8	with	with	ADP
dpc-1025	41	9	increased	increase	VERB
dpc-1025	41	10	incidence	incidence	NOUN
dpc-1025	41	11	of	of	ADP
dpc-1025	41	12	several	several	ADJ
dpc-1025	41	13	malignancies	malignancy	NOUN
dpc-1025	41	14	,	,	PUNCT
dpc-1025	41	15	such	such	ADJ
dpc-1025	41	16	as	as	ADP
dpc-1025	41	17	breast	breast	NOUN
dpc-1025	41	18	,	,	PUNCT
dpc-1025	41	19	colorectal	colorectal	NOUN
dpc-1025	41	20	,	,	PUNCT
dpc-1025	41	21	kidney	kidney	NOUN
dpc-1025	41	22	,	,	PUNCT
dpc-1025	41	23	lung	lung	NOUN
dpc-1025	41	24	,	,	PUNCT
dpc-1025	41	25	and	and	CCONJ
dpc-1025	41	26	pancreatic	pancreatic	ADJ
dpc-1025	41	27	cancer	cancer	NOUN
dpc-1025	41	28	[	[	X
dpc-1025	41	29	6	6	NUM
dpc-1025	41	30	-	-	SYM
dpc-1025	41	31	10	10	NUM
dpc-1025	41	32	]	]	PUNCT
dpc-1025	41	33	.	.	PUNCT
dpc-1025	42	1	the	the	DET
dpc-1025	42	2	relationship	relationship	NOUN
dpc-1025	42	3	between	between	ADP
dpc-1025	42	4	vitamin	vitamin	NOUN
dpc-1025	42	5	d	d	NOUN
dpc-1025	42	6	levels	level	NOUN
dpc-1025	42	7	and	and	CCONJ
dpc-1025	42	8	cmm	cmm	NOUN
dpc-1025	42	9	seems	seem	VERB
dpc-1025	42	10	to	to	PART
dpc-1025	42	11	be	be	AUX
dpc-1025	42	12	more	more	ADV
dpc-1025	42	13	intricate	intricate	ADJ
dpc-1025	42	14	,	,	PUNCT
dpc-1025	42	15	compared	compare	VERB
dpc-1025	42	16	with	with	ADP
dpc-1025	42	17	other	other	ADJ
dpc-1025	42	18	malignancies	malignancy	NOUN
dpc-1025	42	19	[	[	X
dpc-1025	42	20	1	1	NUM
dpc-1025	42	21	]	]	PUNCT
dpc-1025	42	22	.	.	PUNCT
dpc-1025	43	1	vitamin	vitamin	NOUN
dpc-1025	43	2	d	d	PROPN
dpc-1025	43	3	receptor	receptor	NOUN
dpc-1025	43	4	is	be	AUX
dpc-1025	43	5	present	present	ADJ
dpc-1025	43	6	in	in	ADP
dpc-1025	43	7	normal	normal	ADJ
dpc-1025	43	8	melanocytes	melanocyte	NOUN
dpc-1025	43	9	and	and	CCONJ
dpc-1025	43	10	in	in	ADP
dpc-1025	43	11	certain	certain	ADJ
dpc-1025	43	12	cell	cell	NOUN
dpc-1025	43	13	lines	line	NOUN
dpc-1025	43	14	of	of	ADP
dpc-1025	43	15	melanoma	melanoma	NOUN
dpc-1025	43	16	[	[	X
dpc-1025	43	17	11	11	NUM
dpc-1025	43	18	]	]	PUNCT
dpc-1025	43	19	.	.	PUNCT
dpc-1025	44	1	in	in	ADP
dpc-1025	44	2	vitro	vitro	X
dpc-1025	44	3	studies	study	NOUN
dpc-1025	44	4	have	have	AUX
dpc-1025	44	5	shown	show	VERB
dpc-1025	44	6	that	that	SCONJ
dpc-1025	44	7	a	a	DET
dpc-1025	44	8	proportion	proportion	NOUN
dpc-1025	44	9	of	of	ADP
dpc-1025	44	10	melanoma	melanoma	NOUN
dpc-1025	44	11	cell	cell	NOUN
dpc-1025	44	12	lines	line	NOUN
dpc-1025	44	13	in	in	ADP
dpc-1025	44	14	culture	culture	NOUN
dpc-1025	44	15	respond	respond	VERB
dpc-1025	44	16	to	to	ADP
dpc-1025	44	17	the	the	DET
dpc-1025	44	18	antiproliferative	antiproliferative	ADJ
dpc-1025	44	19	effect	effect	NOUN
dpc-1025	44	20	of	of	ADP
dpc-1025	44	21	active	active	ADJ
dpc-1025	44	22	vitamin	vitamin	NOUN
dpc-1025	44	23	d	d	NOUN
dpc-1025	44	24	analogs	analog	NOUN
dpc-1025	44	25	[	[	X
dpc-1025	44	26	12,13	12,13	NUM
dpc-1025	44	27	]	]	PUNCT
dpc-1025	44	28	.	.	PUNCT
dpc-1025	45	1	serum	serum	NOUN
dpc-1025	45	2	vitamin	vitamin	PROPN
dpc-1025	45	3	d	d	PROPN
dpc-1025	45	4	levels	level	NOUN
dpc-1025	45	5	have	have	AUX
dpc-1025	45	6	been	be	AUX
dpc-1025	45	7	examined	examine	VERB
dpc-1025	45	8	as	as	ADP
dpc-1025	45	9	a	a	DET
dpc-1025	45	10	marker	marker	NOUN
dpc-1025	45	11	for	for	ADP
dpc-1025	45	12	increased	increase	VERB
dpc-1025	45	13	risk	risk	NOUN
dpc-1025	45	14	for	for	ADP
dpc-1025	45	15	cmm	cmm	PROPN
dpc-1025	45	16	development	development	PROPN
dpc-1025	45	17	.	.	PUNCT
dpc-1025	46	1	lower	low	ADJ
dpc-1025	46	2	serum	serum	NOUN
dpc-1025	46	3	vitamin	vitamin	NOUN
dpc-1025	46	4	d	d	NOUN
dpc-1025	46	5	levels	level	NOUN
dpc-1025	46	6	have	have	AUX
dpc-1025	46	7	been	be	AUX
dpc-1025	46	8	associated	associate	VERB
dpc-1025	46	9	with	with	ADP
dpc-1025	46	10	thicker	thick	ADJ
dpc-1025	46	11	or	or	CCONJ
dpc-1025	46	12	higher	high	ADJ
dpc-1025	46	13	stage	stage	NOUN
dpc-1025	46	14	melanomas	melanomas	NOUN
dpc-1025	47	1	[	[	X
dpc-1025	47	2	14	14	NUM
dpc-1025	47	3	-	-	SYM
dpc-1025	47	4	20	20	NUM
dpc-1025	47	5	]	]	PUNCT
dpc-1025	47	6	.	.	PUNCT
dpc-1025	48	1	two	two	NUM
dpc-1025	48	2	recent	recent	ADJ
dpc-1025	48	3	large	large	ADJ
dpc-1025	48	4	cohort	cohort	NOUN
dpc-1025	48	5	studies	study	NOUN
dpc-1025	48	6	have	have	AUX
dpc-1025	48	7	shown	show	VERB
dpc-1025	48	8	that	that	SCONJ
dpc-1025	48	9	vitamin	vitamin	NOUN
dpc-1025	48	10	d	d	NOUN
dpc-1025	48	11	levels	level	NOUN
dpc-1025	48	12	were	be	AUX
dpc-1025	48	13	significantly	significantly	ADV
dpc-1025	48	14	associated	associate	VERB
dpc-1025	48	15	with	with	ADP
dpc-1025	48	16	overall	overall	ADJ
dpc-1025	48	17	survival	survival	NOUN
dpc-1025	48	18	,	,	PUNCT
dpc-1025	48	19	melanoma	melanoma	NOUN
dpc-1025	48	20	-	-	PUNCT
dpc-1025	48	21	specific	specific	ADJ
dpc-1025	48	22	survival	survival	NOUN
dpc-1025	48	23	,	,	PUNCT
dpc-1025	48	24	and	and	CCONJ
dpc-1025	48	25	disease	disease	NOUN
dpc-1025	48	26	-	-	PUNCT
dpc-1025	48	27	free	free	ADJ
dpc-1025	48	28	survival	survival	NOUN
dpc-1025	49	1	[	[	X
dpc-1025	49	2	21,22	21,22	X
dpc-1025	49	3	]	]	X
dpc-1025	49	4	.	.	PUNCT
dpc-1025	49	5	 	 	SPACE
dpc-1025	49	6	in	in	ADP
dpc-1025	49	7	the	the	DET
dpc-1025	49	8	present	present	ADJ
dpc-1025	49	9	study	study	NOUN
dpc-1025	49	10	,	,	PUNCT
dpc-1025	49	11	we	we	PRON
dpc-1025	49	12	sought	seek	VERB
dpc-1025	49	13	to	to	PART
dpc-1025	49	14	investigate	investigate	VERB
dpc-1025	49	15	serum	serum	NOUN
dpc-1025	49	16	total	total	ADJ
dpc-1025	49	17	25	25	NUM
dpc-1025	49	18	-	-	PUNCT
dpc-1025	49	19	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	49	20	d	d	NOUN
dpc-1025	49	21	levels	level	NOUN
dpc-1025	49	22	in	in	ADP
dpc-1025	49	23	a	a	DET
dpc-1025	49	24	cohort	cohort	NOUN
dpc-1025	49	25	of	of	ADP
dpc-1025	49	26	patients	patient	NOUN
dpc-1025	49	27	diagnosed	diagnose	VERB
dpc-1025	49	28	with	with	ADP
dpc-1025	49	29	primary	primary	ADJ
dpc-1025	49	30	cmm	cmm	NOUN
dpc-1025	49	31	and	and	CCONJ
dpc-1025	49	32	compare	compare	VERB
dpc-1025	49	33	them	they	PRON
dpc-1025	49	34	with	with	ADP
dpc-1025	49	35	those	those	DET
dpc-1025	49	36	levels	level	NOUN
dpc-1025	49	37	(	(	PUNCT
dpc-1025	49	38	>	>	SYM
dpc-1025	49	39	30	30	NUM
dpc-1025	49	40	ng	ng	NOUN
dpc-1025	49	41	/	/	SYM
dpc-1025	49	42	ml	ml	NOUN
dpc-1025	49	43	)	)	PUNCT
dpc-1025	49	44	.	.	PUNCT
dpc-1025	50	1	the	the	DET
dpc-1025	50	2	median	median	PROPN
dpc-1025	50	3	serum	serum	NOUN
dpc-1025	50	4	total	total	ADJ
dpc-1025	50	5	25	25	NUM
dpc-1025	50	6	-	-	PUNCT
dpc-1025	50	7	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	50	8	d	d	NOUN
dpc-1025	50	9	levels	level	NOUN
dpc-1025	50	10	were	be	AUX
dpc-1025	50	11	significantly	significantly	ADV
dpc-1025	50	12	lower	low	ADJ
dpc-1025	50	13	in	in	ADP
dpc-1025	50	14	melanoma	melanoma	NOUN
dpc-1025	50	15	patients	patient	NOUN
dpc-1025	50	16	(	(	PUNCT
dpc-1025	50	17	20.62	20.62	NUM
dpc-1025	50	18	ng	ng	NOUN
dpc-1025	50	19	/	/	SYM
dpc-1025	50	20	ml	ml	VERB
dpc-1025	50	21	)	)	PUNCT
dpc-1025	50	22	compared	compare	VERB
dpc-1025	50	23	with	with	ADP
dpc-1025	50	24	healthy	healthy	ADJ
dpc-1025	50	25	controls	control	NOUN
dpc-1025	50	26	(	(	PUNCT
dpc-1025	50	27	24.71	24.71	NUM
dpc-1025	50	28	ng	ng	NOUN
dpc-1025	50	29	/	/	SYM
dpc-1025	50	30	ml	ml	PROPN
dpc-1025	50	31	)	)	PUNCT
dpc-1025	50	32	,	,	PUNCT
dpc-1025	50	33	but	but	CCONJ
dpc-1025	50	34	statistical	statistical	ADJ
dpc-1025	50	35	significance	significance	NOUN
dpc-1025	50	36	was	be	AUX
dpc-1025	50	37	not	not	PART
dpc-1025	50	38	reached	reach	VERB
dpc-1025	50	39	(	(	PUNCT
dpc-1025	50	40	chi	chi	ADJ
dpc-1025	50	41	-	-	PUNCT
dpc-1025	50	42	square	square	ADJ
dpc-1025	50	43	test	test	NOUN
dpc-1025	50	44	,	,	PUNCT
dpc-1025	50	45	p	p	X
dpc-1025	50	46	=	=	PROPN
dpc-1025	50	47	0.051	0.051	NUM
dpc-1025	50	48	)	)	PUNCT
dpc-1025	50	49	no	no	DET
dpc-1025	50	50	statistically	statistically	ADV
dpc-1025	50	51	significant	significant	ADJ
dpc-1025	50	52	association	association	NOUN
dpc-1025	50	53	was	be	AUX
dpc-1025	50	54	found	find	VERB
dpc-1025	50	55	between	between	ADP
dpc-1025	50	56	serum	serum	NOUN
dpc-1025	50	57	total	total	ADJ
dpc-1025	50	58	25	25	NUM
dpc-1025	50	59	-	-	PUNCT
dpc-1025	50	60	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	50	61	d	d	NOUN
dpc-1025	50	62	levels	level	NOUN
dpc-1025	50	63	and	and	CCONJ
dpc-1025	50	64	demographic	demographic	ADJ
dpc-1025	50	65	characteristics	characteristic	NOUN
dpc-1025	50	66	;	;	PUNCT
dpc-1025	50	67	risk	risk	NOUN
dpc-1025	50	68	factors	factor	NOUN
dpc-1025	50	69	for	for	ADP
dpc-1025	50	70	cmm	cmm	NOUN
dpc-1025	50	71	;	;	PUNCT
dpc-1025	50	72	prognostic	prognostic	ADJ
dpc-1025	50	73	factors	factor	NOUN
dpc-1025	50	74	,	,	PUNCT
dpc-1025	50	75	such	such	ADJ
dpc-1025	50	76	as	as	ADP
dpc-1025	50	77	breslow	breslow	ADJ
dpc-1025	50	78	thickness	thickness	NOUN
dpc-1025	50	79	and	and	CCONJ
dpc-1025	50	80	ulceration	ulceration	NOUN
dpc-1025	50	81	;	;	PUNCT
dpc-1025	50	82	as	as	ADV
dpc-1025	50	83	well	well	ADV
dpc-1025	50	84	as	as	ADP
dpc-1025	50	85	clinical	clinical	ADJ
dpc-1025	50	86	characteristics	characteristic	NOUN
dpc-1025	50	87	,	,	PUNCT
dpc-1025	50	88	such	such	ADJ
dpc-1025	50	89	as	as	ADP
dpc-1025	50	90	melanoma	melanoma	NOUN
dpc-1025	50	91	stage	stage	NOUN
dpc-1025	50	92	,	,	PUNCT
dpc-1025	50	93	clinical	clinical	ADJ
dpc-1025	50	94	type	type	NOUN
dpc-1025	50	95	,	,	PUNCT
dpc-1025	50	96	and	and	CCONJ
dpc-1025	50	97	location	location	NOUN
dpc-1025	50	98	.	.	PUNCT
dpc-1025	51	1	conclusions	conclusion	NOUN
dpc-1025	51	2	:	:	PUNCT
dpc-1025	51	3	lower	low	ADJ
dpc-1025	51	4	serum	serum	VERB
dpc-1025	51	5	25	25	NUM
dpc-1025	51	6	-	-	PUNCT
dpc-1025	51	7	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	51	8	d	d	NOUN
dpc-1025	51	9	levels	level	NOUN
dpc-1025	51	10	were	be	AUX
dpc-1025	51	11	found	find	VERB
dpc-1025	51	12	in	in	ADP
dpc-1025	51	13	our	our	PRON
dpc-1025	51	14	greek	greek	ADJ
dpc-1025	51	15	cohort	cohort	NOUN
dpc-1025	51	16	of	of	ADP
dpc-1025	51	17	melanoma	melanoma	NOUN
dpc-1025	51	18	patients	patient	NOUN
dpc-1025	51	19	compared	compare	VERB
dpc-1025	51	20	with	with	ADP
dpc-1025	51	21	healthy	healthy	ADJ
dpc-1025	51	22	controls	control	NOUN
dpc-1025	51	23	,	,	PUNCT
dpc-1025	51	24	without	without	ADP
dpc-1025	51	25	reaching	reach	VERB
dpc-1025	51	26	,	,	PUNCT
dpc-1025	51	27	however	however	ADV
dpc-1025	51	28	,	,	PUNCT
dpc-1025	51	29	statistical	statistical	ADJ
dpc-1025	51	30	significance	significance	NOUN
dpc-1025	51	31	;	;	PUNCT
dpc-1025	51	32	these	these	DET
dpc-1025	51	33	levels	level	NOUN
dpc-1025	51	34	were	be	AUX
dpc-1025	51	35	not	not	PART
dpc-1025	51	36	statistically	statistically	ADV
dpc-1025	51	37	associated	associate	VERB
dpc-1025	51	38	with	with	ADP
dpc-1025	51	39	established	establish	VERB
dpc-1025	51	40	risk	risk	NOUN
dpc-1025	51	41	and	and	CCONJ
dpc-1025	51	42	prognostic	prognostic	ADJ
dpc-1025	51	43	factors	factor	NOUN
dpc-1025	51	44	for	for	ADP
dpc-1025	51	45	cmm	cmm	NOUN
dpc-1025	51	46	.	.	PUNCT
dpc-1025	52	1	abstract	abstract	ADJ
dpc-1025	52	2	research	research	NOUN
dpc-1025	52	3	|	|	ADV
dpc-1025	52	4	dermatol	dermatol	NOUN
dpc-1025	52	5	pract	pract	NOUN
dpc-1025	52	6	concept	concept	NOUN
dpc-1025	52	7	2020;10(1):e2020010	2020;10(1):e2020010	NUM
dpc-1025	52	8	3	3	NUM
dpc-1025	52	9	results	result	VERB
dpc-1025	52	10	a	a	DET
dpc-1025	52	11	total	total	NOUN
dpc-1025	52	12	of	of	ADP
dpc-1025	52	13	105	105	NUM
dpc-1025	52	14	patients	patient	NOUN
dpc-1025	52	15	were	be	AUX
dpc-1025	52	16	diagnosed	diagnose	VERB
dpc-1025	52	17	with	with	ADP
dpc-1025	52	18	primary	primary	ADJ
dpc-1025	52	19	cmm	cmm	NOUN
dpc-1025	52	20	at	at	ADP
dpc-1025	52	21	our	our	PRON
dpc-1025	52	22	academic	academic	ADJ
dpc-1025	52	23	department	department	NOUN
dpc-1025	52	24	during	during	ADP
dpc-1025	52	25	the	the	DET
dpc-1025	52	26	study	study	NOUN
dpc-1025	52	27	period	period	NOUN
dpc-1025	52	28	.	.	PUNCT
dpc-1025	53	1	six	six	NUM
dpc-1025	53	2	of	of	ADP
dpc-1025	53	3	them	they	PRON
dpc-1025	53	4	were	be	AUX
dpc-1025	53	5	excluded	exclude	VERB
dpc-1025	53	6	because	because	SCONJ
dpc-1025	53	7	they	they	PRON
dpc-1025	53	8	had	have	AUX
dpc-1025	53	9	been	be	AUX
dpc-1025	53	10	using	use	VERB
dpc-1025	53	11	oral	oral	ADJ
dpc-1025	53	12	vitamin	vitamin	NOUN
dpc-1025	53	13	d	d	NOUN
dpc-1025	53	14	supplements	supplement	NOUN
dpc-1025	53	15	;	;	PUNCT
dpc-1025	53	16	thus	thus	ADV
dpc-1025	53	17	99	99	NUM
dpc-1025	53	18	patients	patient	NOUN
dpc-1025	53	19	were	be	AUX
dpc-1025	53	20	included	include	VERB
dpc-1025	53	21	in	in	ADP
dpc-1025	53	22	the	the	DET
dpc-1025	53	23	study	study	NOUN
dpc-1025	53	24	.	.	PUNCT
dpc-1025	54	1	of	of	ADP
dpc-1025	54	2	the	the	DET
dpc-1025	54	3	99	99	NUM
dpc-1025	54	4	patients	patient	NOUN
dpc-1025	54	5	,	,	PUNCT
dpc-1025	54	6	53	53	NUM
dpc-1025	54	7	were	be	AUX
dpc-1025	54	8	female	female	ADJ
dpc-1025	54	9	(	(	PUNCT
dpc-1025	54	10	53.54	53.54	NUM
dpc-1025	54	11	%	%	NOUN
dpc-1025	54	12	)	)	PUNCT
dpc-1025	54	13	.	.	PUNCT
dpc-1025	55	1	their	their	PRON
dpc-1025	55	2	age	age	NOUN
dpc-1025	55	3	ranged	range	VERB
dpc-1025	55	4	from	from	ADP
dpc-1025	55	5	37	37	NUM
dpc-1025	55	6	to	to	PART
dpc-1025	55	7	64	64	NUM
dpc-1025	55	8	years	year	NOUN
dpc-1025	55	9	(	(	PUNCT
dpc-1025	55	10	median	median	NOUN
dpc-1025	55	11	50	50	NUM
dpc-1025	55	12	years	year	NOUN
dpc-1025	55	13	)	)	PUNCT
dpc-1025	55	14	.	.	PUNCT
dpc-1025	56	1	the	the	DET
dpc-1025	56	2	demographic	demographic	ADJ
dpc-1025	56	3	characteristics	characteristic	NOUN
dpc-1025	56	4	of	of	ADP
dpc-1025	56	5	melanoma	melanoma	NOUN
dpc-1025	56	6	patients	patient	NOUN
dpc-1025	56	7	(	(	PUNCT
dpc-1025	56	8	n	n	NOUN
dpc-1025	56	9	=	=	SYM
dpc-1025	56	10	99	99	NUM
dpc-1025	56	11	)	)	PUNCT
dpc-1025	56	12	and	and	CCONJ
dpc-1025	56	13	healthy	healthy	ADJ
dpc-1025	56	14	controls	control	NOUN
dpc-1025	56	15	(	(	PUNCT
dpc-1025	56	16	n	n	NOUN
dpc-1025	56	17	=	=	SYM
dpc-1025	56	18	97	97	NUM
dpc-1025	56	19	)	)	PUNCT
dpc-1025	56	20	are	be	AUX
dpc-1025	56	21	presented	present	VERB
dpc-1025	56	22	in	in	ADP
dpc-1025	56	23	table	table	NOUN
dpc-1025	56	24	1	1	NUM
dpc-1025	56	25	.	.	PUNCT
dpc-1025	57	1	regarding	regard	VERB
dpc-1025	57	2	risk	risk	NOUN
dpc-1025	57	3	factors	factor	NOUN
dpc-1025	57	4	for	for	ADP
dpc-1025	57	5	cmm	cmm	NOUN
dpc-1025	57	6	among	among	ADP
dpc-1025	57	7	melanoma	melanoma	NOUN
dpc-1025	57	8	patients	patient	NOUN
dpc-1025	57	9	,	,	PUNCT
dpc-1025	57	10	there	there	PRON
dpc-1025	57	11	were	be	VERB
dpc-1025	57	12	7	7	NUM
dpc-1025	57	13	patients	patient	NOUN
dpc-1025	57	14	with	with	ADP
dpc-1025	57	15	skin	skin	NOUN
dpc-1025	57	16	phototype	phototype	NOUN
dpc-1025	58	1	i	i	PRON
dpc-1025	58	2	(	(	PUNCT
dpc-1025	58	3	7.07	7.07	NUM
dpc-1025	58	4	%	%	NOUN
dpc-1025	58	5	)	)	PUNCT
dpc-1025	58	6	,	,	PUNCT
dpc-1025	58	7	43	43	NUM
dpc-1025	58	8	with	with	ADP
dpc-1025	58	9	type	type	NOUN
dpc-1025	58	10	ii	ii	PROPN
dpc-1025	58	11	(	(	PUNCT
dpc-1025	58	12	43.43	43.43	NUM
dpc-1025	58	13	%	%	NOUN
dpc-1025	58	14	)	)	PUNCT
dpc-1025	58	15	,	,	PUNCT
dpc-1025	58	16	34	34	NUM
dpc-1025	58	17	with	with	ADP
dpc-1025	58	18	type	type	NOUN
dpc-1025	58	19	iii	iii	X
dpc-1025	58	20	(	(	PUNCT
dpc-1025	58	21	34.34	34.34	NUM
dpc-1025	58	22	%	%	NOUN
dpc-1025	58	23	)	)	PUNCT
dpc-1025	58	24	,	,	PUNCT
dpc-1025	58	25	and	and	CCONJ
dpc-1025	58	26	15	15	NUM
dpc-1025	58	27	with	with	ADP
dpc-1025	58	28	type	type	NOUN
dpc-1025	58	29	iv	iv	NUM
dpc-1025	58	30	(	(	PUNCT
dpc-1025	58	31	15.15	15.15	NUM
dpc-1025	58	32	%	%	NOUN
dpc-1025	58	33	)	)	PUNCT
dpc-1025	58	34	.	.	PUNCT
dpc-1025	59	1	twenty	twenty	NUM
dpc-1025	59	2	patients	patient	NOUN
dpc-1025	59	3	(	(	PUNCT
dpc-1025	59	4	20.20	20.20	NUM
dpc-1025	59	5	%	%	NOUN
dpc-1025	59	6	)	)	PUNCT
dpc-1025	59	7	reported	report	VERB
dpc-1025	59	8	excessive	excessive	ADJ
dpc-1025	59	9	nonintentional	nonintentional	NOUN
dpc-1025	59	10	(	(	PUNCT
dpc-1025	59	11	occuwere	occuwere	X
dpc-1025	59	12	used	use	VERB
dpc-1025	59	13	to	to	PART
dpc-1025	59	14	describe	describe	VERB
dpc-1025	59	15	the	the	DET
dpc-1025	59	16	data	datum	NOUN
dpc-1025	59	17	.	.	PUNCT
dpc-1025	60	1	to	to	PART
dpc-1025	60	2	test	test	VERB
dpc-1025	60	3	the	the	DET
dpc-1025	60	4	relationship	relationship	NOUN
dpc-1025	60	5	between	between	ADP
dpc-1025	60	6	serum	serum	NOUN
dpc-1025	60	7	 	 	SPACE
dpc-1025	60	8	levels	level	NOUN
dpc-1025	60	9	of	of	ADP
dpc-1025	60	10	vitamin	vitamin	NOUN
dpc-1025	60	11	d	d	NOUN
dpc-1025	60	12	and	and	CCONJ
dpc-1025	60	13	various	various	ADJ
dpc-1025	60	14	demographic	demographic	ADJ
dpc-1025	60	15	and	and	CCONJ
dpc-1025	60	16	prognostic	prognostic	ADJ
dpc-1025	60	17	factors	factor	NOUN
dpc-1025	60	18	,	,	PUNCT
dpc-1025	60	19	the	the	DET
dpc-1025	60	20	chi	chi	ADJ
dpc-1025	60	21	-	-	PUNCT
dpc-1025	60	22	square	square	NOUN
dpc-1025	60	23	test	test	NOUN
dpc-1025	60	24	or	or	CCONJ
dpc-1025	60	25	the	the	DET
dpc-1025	60	26	fisher	fisher	PROPN
dpc-1025	60	27	exact	exact	ADJ
dpc-1025	60	28	test	test	NOUN
dpc-1025	60	29	was	be	AUX
dpc-1025	60	30	used	use	VERB
dpc-1025	60	31	.	.	PUNCT
dpc-1025	61	1	in	in	ADP
dpc-1025	61	2	all	all	DET
dpc-1025	61	3	the	the	DET
dpc-1025	61	4	above	above	ADJ
dpc-1025	61	5	comparisons	comparison	NOUN
dpc-1025	61	6	vitamin	vitamin	NOUN
dpc-1025	61	7	d	d	NOUN
dpc-1025	61	8	was	be	AUX
dpc-1025	61	9	used	use	VERB
dpc-1025	61	10	as	as	ADP
dpc-1025	61	11	a	a	DET
dpc-1025	61	12	categorical	categorical	ADJ
dpc-1025	61	13	variable	variable	NOUN
dpc-1025	61	14	with	with	ADP
dpc-1025	61	15	3	3	NUM
dpc-1025	61	16	levels	level	NOUN
dpc-1025	61	17	.	.	PUNCT
dpc-1025	62	1	comparisons	comparison	NOUN
dpc-1025	62	2	of	of	ADP
dpc-1025	62	3	baseline	baseline	ADJ
dpc-1025	62	4	characteristics	characteristic	NOUN
dpc-1025	62	5	between	between	ADP
dpc-1025	62	6	the	the	DET
dpc-1025	62	7	study	study	NOUN
dpc-1025	62	8	groups	group	NOUN
dpc-1025	62	9	were	be	AUX
dpc-1025	62	10	performed	perform	VERB
dpc-1025	62	11	by	by	ADP
dpc-1025	62	12	using	use	VERB
dpc-1025	62	13	 	 	SPACE
dpc-1025	62	14	the	the	DET
dpc-1025	62	15	chi	chi	ADJ
dpc-1025	62	16	-	-	PUNCT
dpc-1025	62	17	square	square	ADJ
dpc-1025	62	18	test	test	NOUN
dpc-1025	62	19	.	.	PUNCT
dpc-1025	62	20	 	 	SPACE
dpc-1025	63	1	for	for	ADP
dpc-1025	63	2	the	the	DET
dpc-1025	63	3	comparison	comparison	NOUN
dpc-1025	63	4	of	of	ADP
dpc-1025	63	5	serum	serum	NOUN
dpc-1025	63	6	vitamin	vitamin	NOUN
dpc-1025	63	7	d	d	NOUN
dpc-1025	63	8	median	median	NOUN
dpc-1025	63	9	between	between	ADP
dpc-1025	63	10	patients	patient	NOUN
dpc-1025	63	11	and	and	CCONJ
dpc-1025	63	12	controls	control	NOUN
dpc-1025	63	13	,	,	PUNCT
dpc-1025	63	14	the	the	DET
dpc-1025	63	15	nonparametric	nonparametric	NOUN
dpc-1025	63	16	 	 	SPACE
dpc-1025	63	17	mann	mann	PROPN
dpc-1025	63	18	-	-	PUNCT
dpc-1025	63	19	whitney	whitney	PROPN
dpc-1025	63	20	u	u	PROPN
dpc-1025	63	21	test	test	NOUN
dpc-1025	63	22	 	 	SPACE
dpc-1025	63	23	was	be	AUX
dpc-1025	63	24	used	use	VERB
dpc-1025	63	25	as	as	SCONJ
dpc-1025	63	26	 	 	SPACE
dpc-1025	63	27	25	25	NUM
dpc-1025	63	28	-	-	PUNCT
dpc-1025	63	29	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	63	30	d	d	NOUN
dpc-1025	63	31	serum	serum	NOUN
dpc-1025	63	32	concentrations	concentration	NOUN
dpc-1025	63	33	could	could	AUX
dpc-1025	63	34	not	not	PART
dpc-1025	63	35	be	be	AUX
dpc-1025	63	36	assumed	assume	VERB
dpc-1025	63	37	to	to	PART
dpc-1025	63	38	be	be	AUX
dpc-1025	63	39	normally	normally	ADV
dpc-1025	63	40	distributed	distribute	VERB
dpc-1025	63	41	(	(	PUNCT
dpc-1025	63	42	demonstrated	demonstrate	VERB
dpc-1025	63	43	by	by	ADP
dpc-1025	63	44	kolmogorov	kolmogorov	ADJ
dpc-1025	63	45	-	-	PUNCT
dpc-1025	63	46	smirnov	smirnov	ADJ
dpc-1025	63	47	test	test	NOUN
dpc-1025	63	48	)	)	PUNCT
dpc-1025	63	49	.	.	PUNCT
dpc-1025	63	50	 	 	SPACE
dpc-1025	64	1	the	the	DET
dpc-1025	64	2	level	level	NOUN
dpc-1025	64	3	of	of	ADP
dpc-1025	64	4	significance	significance	NOUN
dpc-1025	64	5	was	be	AUX
dpc-1025	64	6	set	set	VERB
dpc-1025	64	7	at	at	ADP
dpc-1025	64	8	5	5	NUM
dpc-1025	64	9	%	%	NOUN
dpc-1025	64	10	(	(	PUNCT
dpc-1025	64	11	p	p	X
dpc-1025	64	12	<	<	X
dpc-1025	64	13	 	 	SPACE
dpc-1025	64	14	0.05	0.05	NUM
dpc-1025	64	15	)	)	PUNCT
dpc-1025	64	16	.	.	PUNCT
dpc-1025	65	1	all	all	DET
dpc-1025	65	2	statistical	statistical	ADJ
dpc-1025	65	3	analyses	analysis	NOUN
dpc-1025	65	4	were	be	AUX
dpc-1025	65	5	performed	perform	VERB
dpc-1025	65	6	using	use	VERB
dpc-1025	65	7	the	the	DET
dpc-1025	65	8	statistical	statistical	ADJ
dpc-1025	65	9	package	package	NOUN
dpc-1025	65	10	spss	spss	PROPN
dpc-1025	65	11	version	version	PROPN
dpc-1025	65	12	18	18	NUM
dpc-1025	65	13	(	(	PUNCT
dpc-1025	65	14	ibm	ibm	PROPN
dpc-1025	65	15	,	,	PUNCT
dpc-1025	65	16	usa	usa	PROPN
dpc-1025	65	17	)	)	PUNCT
dpc-1025	65	18	.	.	PUNCT
dpc-1025	66	1	cer	cer	PROPN
dpc-1025	66	2	(	(	PUNCT
dpc-1025	66	3	ajcc	ajcc	PROPN
dpc-1025	66	4	)	)	PUNCT
dpc-1025	66	5	classification	classification	NOUN
dpc-1025	66	6	system	system	NOUN
dpc-1025	66	7	(	(	PUNCT
dpc-1025	66	8	2010	2010	NUM
dpc-1025	66	9	)	)	PUNCT
dpc-1025	66	10	was	be	AUX
dpc-1025	66	11	used	use	VERB
dpc-1025	66	12	.	.	PUNCT
dpc-1025	67	1	patients	patient	NOUN
dpc-1025	67	2	were	be	AUX
dpc-1025	67	3	followed	follow	VERB
dpc-1025	67	4	for	for	ADP
dpc-1025	67	5	42	42	NUM
dpc-1025	67	6	-	-	SYM
dpc-1025	67	7	78	78	NUM
dpc-1025	67	8	months	month	NOUN
dpc-1025	67	9	.	.	PUNCT
dpc-1025	68	1	during	during	ADP
dpc-1025	68	2	follow	follow	NOUN
dpc-1025	68	3	-	-	PUNCT
dpc-1025	68	4	up	up	NOUN
dpc-1025	68	5	,	,	PUNCT
dpc-1025	68	6	recurrences	recurrence	NOUN
dpc-1025	68	7	and	and	CCONJ
dpc-1025	68	8	melanoma	melanoma	NOUN
dpc-1025	68	9	-	-	PUNCT
dpc-1025	68	10	related	relate	VERB
dpc-1025	68	11	deaths	death	NOUN
dpc-1025	68	12	were	be	AUX
dpc-1025	68	13	recorded	record	VERB
dpc-1025	68	14	.	.	PUNCT
dpc-1025	69	1	ageand	ageand	NOUN
dpc-1025	69	2	sex	sex	NOUN
dpc-1025	69	3	-	-	PUNCT
dpc-1025	69	4	matched	match	VERB
dpc-1025	69	5	healthy	healthy	ADJ
dpc-1025	69	6	subjects	subject	NOUN
dpc-1025	69	7	with	with	ADP
dpc-1025	69	8	nonrelated	nonrelate	VERB
dpc-1025	69	9	minor	minor	ADJ
dpc-1025	69	10	skin	skin	NOUN
dpc-1025	69	11	conditions	condition	NOUN
dpc-1025	69	12	from	from	ADP
dpc-1025	69	13	the	the	DET
dpc-1025	69	14	outpatient	outpatient	NOUN
dpc-1025	69	15	dermatology	dermatology	NOUN
dpc-1025	69	16	service	service	NOUN
dpc-1025	69	17	were	be	AUX
dpc-1025	69	18	recruited	recruit	VERB
dpc-1025	69	19	as	as	ADP
dpc-1025	69	20	healthy	healthy	ADJ
dpc-1025	69	21	controls	control	NOUN
dpc-1025	69	22	after	after	SCONJ
dpc-1025	69	23	they	they	PRON
dpc-1025	69	24	had	have	AUX
dpc-1025	69	25	given	give	VERB
dpc-1025	69	26	their	their	PRON
dpc-1025	69	27	informed	informed	ADJ
dpc-1025	69	28	consent	consent	NOUN
dpc-1025	69	29	.	.	PUNCT
dpc-1025	70	1	the	the	DET
dpc-1025	70	2	same	same	ADJ
dpc-1025	70	3	exclusion	exclusion	NOUN
dpc-1025	70	4	criteria	criterion	NOUN
dpc-1025	70	5	as	as	SCONJ
dpc-1025	70	6	for	for	ADP
dpc-1025	70	7	melanoma	melanoma	NOUN
dpc-1025	70	8	patients	patient	NOUN
dpc-1025	70	9	were	be	AUX
dpc-1025	70	10	used	use	VERB
dpc-1025	70	11	.	.	PUNCT
dpc-1025	71	1	assessment	assessment	NOUN
dpc-1025	71	2	of	of	ADP
dpc-1025	71	3	serum	serum	NOUN
dpc-1025	71	4	total	total	ADJ
dpc-1025	71	5	25	25	NUM
dpc-1025	71	6	-	-	PUNCT
dpc-1025	71	7	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	71	8	d	d	NOUN
dpc-1025	71	9	for	for	ADP
dpc-1025	71	10	all	all	DET
dpc-1025	71	11	recruited	recruit	VERB
dpc-1025	71	12	melanoma	melanoma	NOUN
dpc-1025	71	13	patients	patient	NOUN
dpc-1025	71	14	,	,	PUNCT
dpc-1025	71	15	whole	whole	ADJ
dpc-1025	71	16	blood	blood	NOUN
dpc-1025	71	17	was	be	AUX
dpc-1025	71	18	sampled	sample	VERB
dpc-1025	71	19	within	within	ADP
dpc-1025	71	20	1	1	NUM
dpc-1025	71	21	month	month	NOUN
dpc-1025	71	22	from	from	ADP
dpc-1025	71	23	the	the	DET
dpc-1025	71	24	time	time	NOUN
dpc-1025	71	25	of	of	ADP
dpc-1025	71	26	diagnosis	diagnosis	NOUN
dpc-1025	71	27	of	of	ADP
dpc-1025	71	28	cmm	cmm	NOUN
dpc-1025	71	29	.	.	PUNCT
dpc-1025	72	1	in	in	ADP
dpc-1025	72	2	healthy	healthy	ADJ
dpc-1025	72	3	controls	control	NOUN
dpc-1025	72	4	,	,	PUNCT
dpc-1025	72	5	blood	blood	NOUN
dpc-1025	72	6	sampling	sampling	NOUN
dpc-1025	72	7	was	be	AUX
dpc-1025	72	8	performed	perform	VERB
dpc-1025	72	9	at	at	ADP
dpc-1025	72	10	the	the	DET
dpc-1025	72	11	time	time	NOUN
dpc-1025	72	12	of	of	ADP
dpc-1025	72	13	recruitment	recruitment	NOUN
dpc-1025	72	14	.	.	PUNCT
dpc-1025	73	1	to	to	PART
dpc-1025	73	2	avoid	avoid	VERB
dpc-1025	73	3	the	the	DET
dpc-1025	73	4	effect	effect	NOUN
dpc-1025	73	5	of	of	ADP
dpc-1025	73	6	seasonal	seasonal	ADJ
dpc-1025	73	7	variation	variation	NOUN
dpc-1025	73	8	of	of	ADP
dpc-1025	73	9	vitamin	vitamin	NOUN
dpc-1025	73	10	d	d	NOUN
dpc-1025	73	11	levels	level	NOUN
dpc-1025	73	12	,	,	PUNCT
dpc-1025	73	13	for	for	ADP
dpc-1025	73	14	each	each	DET
dpc-1025	73	15	entered	enter	VERB
dpc-1025	73	16	patient	patient	NOUN
dpc-1025	73	17	,	,	PUNCT
dpc-1025	73	18	a	a	DET
dpc-1025	73	19	control	control	NOUN
dpc-1025	73	20	subject	subject	NOUN
dpc-1025	73	21	was	be	AUX
dpc-1025	73	22	recruited	recruit	VERB
dpc-1025	73	23	at	at	ADP
dpc-1025	73	24	the	the	DET
dpc-1025	73	25	same	same	ADJ
dpc-1025	73	26	time	time	NOUN
dpc-1025	73	27	.	.	PUNCT
dpc-1025	74	1	of	of	ADP
dpc-1025	74	2	our	our	PRON
dpc-1025	74	3	melanoma	melanoma	NOUN
dpc-1025	74	4	patients	patient	NOUN
dpc-1025	74	5	,	,	PUNCT
dpc-1025	74	6	61	61	NUM
dpc-1025	74	7	(	(	PUNCT
dpc-1025	74	8	61.61	61.61	NUM
dpc-1025	74	9	%	%	NOUN
dpc-1025	74	10	)	)	PUNCT
dpc-1025	74	11	were	be	AUX
dpc-1025	74	12	diagnosed	diagnose	VERB
dpc-1025	74	13	during	during	ADP
dpc-1025	74	14	spring	spring	NOUN
dpc-1025	74	15	and	and	CCONJ
dpc-1025	74	16	summer	summer	NOUN
dpc-1025	74	17	when	when	SCONJ
dpc-1025	74	18	sun	sun	NOUN
dpc-1025	74	19	exposure	exposure	NOUN
dpc-1025	74	20	is	be	AUX
dpc-1025	74	21	high	high	ADJ
dpc-1025	74	22	,	,	PUNCT
dpc-1025	74	23	and	and	CCONJ
dpc-1025	74	24	this	this	PRON
dpc-1025	74	25	is	be	AUX
dpc-1025	74	26	in	in	ADP
dpc-1025	74	27	accordance	accordance	NOUN
dpc-1025	74	28	with	with	ADP
dpc-1025	74	29	other	other	ADJ
dpc-1025	74	30	reports	report	NOUN
dpc-1025	74	31	worldwide	worldwide	ADV
dpc-1025	74	32	on	on	ADP
dpc-1025	74	33	the	the	DET
dpc-1025	74	34	seasonality	seasonality	NOUN
dpc-1025	74	35	of	of	ADP
dpc-1025	74	36	melanoma	melanoma	ADJ
dpc-1025	74	37	diagnosis	diagnosis	NOUN
dpc-1025	74	38	[	[	X
dpc-1025	74	39	20	20	NUM
dpc-1025	74	40	]	]	PUNCT
dpc-1025	74	41	.	.	PUNCT
dpc-1025	75	1	all	all	DET
dpc-1025	75	2	blood	blood	NOUN
dpc-1025	75	3	samples	sample	NOUN
dpc-1025	75	4	were	be	AUX
dpc-1025	75	5	immediately	immediately	ADV
dpc-1025	75	6	processed	process	VERB
dpc-1025	75	7	and	and	CCONJ
dpc-1025	75	8	centrifuged	centrifuge	VERB
dpc-1025	75	9	.	.	PUNCT
dpc-1025	76	1	serum	serum	PROPN
dpc-1025	76	2	25	25	NUM
dpc-1025	76	3	-	-	PUNCT
dpc-1025	76	4	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	76	5	d	d	NOUN
dpc-1025	76	6	levels	level	NOUN
dpc-1025	76	7	were	be	AUX
dpc-1025	76	8	measured	measure	VERB
dpc-1025	76	9	using	use	VERB
dpc-1025	76	10	a	a	DET
dpc-1025	76	11	commercial	commercial	ADJ
dpc-1025	76	12	,	,	PUNCT
dpc-1025	76	13	fully	fully	ADV
dpc-1025	76	14	automated	automate	VERB
dpc-1025	76	15	chemiluminescent	chemiluminescent	NOUN
dpc-1025	76	16	vitamin	vitamin	NOUN
dpc-1025	76	17	d	d	NOUN
dpc-1025	76	18	total	total	ADJ
dpc-1025	76	19	immunoassay	immunoassay	NOUN
dpc-1025	76	20	(	(	PUNCT
dpc-1025	76	21	elecsys	elecsys	PROPN
dpc-1025	76	22	vitamin	vitamin	NOUN
dpc-1025	76	23	d	d	X
dpc-1025	76	24	total	total	NOUN
dpc-1025	76	25	,	,	PUNCT
dpc-1025	76	26	roche	roche	PROPN
dpc-1025	76	27	)	)	PUNCT
dpc-1025	76	28	.	.	PUNCT
dpc-1025	77	1	measurements	measurement	NOUN
dpc-1025	77	2	were	be	AUX
dpc-1025	77	3	performed	perform	VERB
dpc-1025	77	4	at	at	ADP
dpc-1025	77	5	the	the	DET
dpc-1025	77	6	biochemistry	biochemistry	PROPN
dpc-1025	77	7	department	department	PROPN
dpc-1025	77	8	of	of	ADP
dpc-1025	77	9	evangelismos	evangelismos	PROPN
dpc-1025	77	10	general	general	PROPN
dpc-1025	77	11	hospital	hospital	PROPN
dpc-1025	77	12	of	of	ADP
dpc-1025	77	13	athens	athens	PROPN
dpc-1025	77	14	,	,	PUNCT
dpc-1025	77	15	greece	greece	PROPN
dpc-1025	77	16	.	.	PUNCT
dpc-1025	78	1	according	accord	VERB
dpc-1025	78	2	to	to	ADP
dpc-1025	78	3	the	the	DET
dpc-1025	78	4	endocrine	endocrine	NOUN
dpc-1025	78	5	society	society	NOUN
dpc-1025	78	6	’s	’s	PART
dpc-1025	78	7	clinical	clinical	ADJ
dpc-1025	78	8	guidelines	guideline	NOUN
dpc-1025	78	9	,	,	PUNCT
dpc-1025	78	10	reference	reference	NOUN
dpc-1025	78	11	serum	serum	NOUN
dpc-1025	78	12	values	value	NOUN
dpc-1025	78	13	for	for	ADP
dpc-1025	78	14	vitamin	vitamin	NOUN
dpc-1025	78	15	d	d	NOUN
dpc-1025	78	16	were	be	AUX
dpc-1025	78	17	classified	classify	VERB
dpc-1025	78	18	as	as	SCONJ
dpc-1025	78	19	follows	follow	VERB
dpc-1025	78	20	:	:	PUNCT
dpc-1025	78	21	levels	level	NOUN
dpc-1025	78	22	greater	great	ADJ
dpc-1025	78	23	than	than	ADP
dpc-1025	78	24	30	30	NUM
dpc-1025	78	25	ng	ng	NOUN
dpc-1025	78	26	/	/	SYM
dpc-1025	78	27	ml	ml	NOUN
dpc-1025	78	28	were	be	AUX
dpc-1025	78	29	considered	consider	VERB
dpc-1025	78	30	adequate	adequate	ADJ
dpc-1025	78	31	;	;	PUNCT
dpc-1025	78	32	values	value	NOUN
dpc-1025	78	33	between	between	ADP
dpc-1025	78	34	21	21	NUM
dpc-1025	78	35	and	and	CCONJ
dpc-1025	78	36	29	29	NUM
dpc-1025	78	37	ng	ng	PROPN
dpc-1025	78	38	/	/	SYM
dpc-1025	78	39	ml	ml	PROPN
dpc-1025	78	40	,	,	PUNCT
dpc-1025	78	41	insufficient	insufficient	ADJ
dpc-1025	78	42	;	;	PUNCT
dpc-1025	78	43	and	and	CCONJ
dpc-1025	78	44	levels	level	NOUN
dpc-1025	78	45	lower	low	ADJ
dpc-1025	78	46	than	than	ADP
dpc-1025	78	47	20	20	NUM
dpc-1025	78	48	ng/	ng/	ADJ
dpc-1025	78	49	ml	ml	NOUN
dpc-1025	78	50	,	,	PUNCT
dpc-1025	78	51	deficient	deficient	ADJ
dpc-1025	78	52	.	.	PUNCT
dpc-1025	79	1	statistical	statistical	ADJ
dpc-1025	79	2	analysis	analysis	NOUN
dpc-1025	79	3	median	median	ADJ
dpc-1025	79	4	values	value	NOUN
dpc-1025	79	5	and	and	CCONJ
dpc-1025	79	6	interquartile	interquartile	NOUN
dpc-1025	79	7	ranges	range	NOUN
dpc-1025	79	8	for	for	ADP
dpc-1025	79	9	continuous	continuous	ADJ
dpc-1025	79	10	variables	variable	NOUN
dpc-1025	79	11	,	,	PUNCT
dpc-1025	79	12	or	or	CCONJ
dpc-1025	79	13	number	number	NOUN
dpc-1025	79	14	and	and	CCONJ
dpc-1025	79	15	proportions	proportion	NOUN
dpc-1025	79	16	for	for	ADP
dpc-1025	79	17	categorical	categorical	ADJ
dpc-1025	79	18	variables	variable	NOUN
dpc-1025	79	19	,	,	PUNCT
dpc-1025	79	20	table	table	NOUN
dpc-1025	79	21	1	1	NUM
dpc-1025	79	22	.	.	PUNCT
dpc-1025	79	23	demographic	demographic	ADJ
dpc-1025	79	24	characteristics	characteristic	NOUN
dpc-1025	79	25	and	and	CCONJ
dpc-1025	79	26	serum	serum	NOUN
dpc-1025	79	27	25(oh)d	25(oh)d	NUM
dpc-1025	79	28	levels	level	NOUN
dpc-1025	79	29	for	for	ADP
dpc-1025	79	30	patients	patient	NOUN
dpc-1025	79	31	and	and	CCONJ
dpc-1025	79	32	controls	control	VERB
dpc-1025	79	33	melanoma	melanoma	NOUN
dpc-1025	79	34	patients	patient	NOUN
dpc-1025	79	35	controls	control	VERB
dpc-1025	79	36	p	p	NOUN
dpc-1025	79	37	value	value	NOUN
dpc-1025	79	38	n	n	CCONJ
dpc-1025	79	39	(	(	PUNCT
dpc-1025	79	40	%	%	NOUN
dpc-1025	79	41	)	)	PUNCT
dpc-1025	79	42	n	n	CCONJ
dpc-1025	79	43	(	(	PUNCT
dpc-1025	79	44	%	%	NOUN
dpc-1025	79	45	)	)	PUNCT
dpc-1025	79	46	sex	sex	NOUN
dpc-1025	79	47	0.780a	0.780a	ADJ
dpc-1025	79	48	male	male	NOUN
dpc-1025	79	49	46	46	NUM
dpc-1025	79	50	(	(	PUNCT
dpc-1025	79	51	46.46	46.46	NUM
dpc-1025	79	52	)	)	PUNCT
dpc-1025	79	53	47	47	NUM
dpc-1025	79	54	(	(	PUNCT
dpc-1025	79	55	48.45	48.45	NUM
dpc-1025	79	56	)	)	PUNCT
dpc-1025	79	57	female	female	NOUN
dpc-1025	79	58	53	53	NUM
dpc-1025	79	59	(	(	PUNCT
dpc-1025	79	60	53.54	53.54	NUM
dpc-1025	79	61	)	)	PUNCT
dpc-1025	79	62	50	50	NUM
dpc-1025	79	63	(	(	PUNCT
dpc-1025	79	64	51.55	51.55	NUM
dpc-1025	79	65	)	)	PUNCT
dpc-1025	79	66	age	age	NOUN
dpc-1025	79	67	0.780a	0.780a	ADJ
dpc-1025	79	68	≤40	≤40	ADJ
dpc-1025	79	69	years	year	NOUN
dpc-1025	79	70	31	31	NUM
dpc-1025	79	71	(	(	PUNCT
dpc-1025	79	72	31.31	31.31	NUM
dpc-1025	79	73	)	)	PUNCT
dpc-1025	79	74	34	34	NUM
dpc-1025	79	75	(	(	PUNCT
dpc-1025	79	76	35.05	35.05	NUM
dpc-1025	79	77	)	)	PUNCT
dpc-1025	79	78	>	>	SYM
dpc-1025	79	79	40	40	NUM
dpc-1025	79	80	years	year	NOUN
dpc-1025	79	81	68	68	NUM
dpc-1025	79	82	(	(	PUNCT
dpc-1025	79	83	68.69	68.69	NUM
dpc-1025	79	84	)	)	PUNCT
dpc-1025	79	85	63	63	NUM
dpc-1025	79	86	(	(	PUNCT
dpc-1025	79	87	64.95	64.95	NUM
dpc-1025	79	88	)	)	PUNCT
dpc-1025	79	89	age	age	NOUN
dpc-1025	79	90	,	,	PUNCT
dpc-1025	79	91	median	median	NOUN
dpc-1025	79	92	(	(	PUNCT
dpc-1025	79	93	iqr	iqr	NOUN
dpc-1025	79	94	)	)	PUNCT
dpc-1025	79	95	50	50	NUM
dpc-1025	79	96	(	(	PUNCT
dpc-1025	79	97	37	37	NUM
dpc-1025	79	98	-	-	SYM
dpc-1025	79	99	63.5	63.5	NUM
dpc-1025	79	100	)	)	PUNCT
dpc-1025	79	101	51	51	NUM
dpc-1025	79	102	(	(	PUNCT
dpc-1025	79	103	36	36	NUM
dpc-1025	79	104	-	-	SYM
dpc-1025	79	105	63	63	NUM
dpc-1025	79	106	)	)	PUNCT
dpc-1025	79	107	residence	residence	NOUN
dpc-1025	79	108	0.493a	0.493a	NOUN
dpc-1025	80	1	urban	urban	ADJ
dpc-1025	80	2	67	67	NUM
dpc-1025	80	3	(	(	PUNCT
dpc-1025	80	4	67.68	67.68	NUM
dpc-1025	80	5	)	)	PUNCT
dpc-1025	80	6	70	70	NUM
dpc-1025	80	7	(	(	PUNCT
dpc-1025	80	8	72.2	72.2	NUM
dpc-1025	80	9	)	)	PUNCT
dpc-1025	80	10	rural	rural	ADJ
dpc-1025	80	11	32	32	NUM
dpc-1025	80	12	(	(	PUNCT
dpc-1025	80	13	32.32	32.32	NUM
dpc-1025	80	14	)	)	PUNCT
dpc-1025	80	15	27	27	NUM
dpc-1025	80	16	(	(	PUNCT
dpc-1025	80	17	27.8	27.8	NUM
dpc-1025	80	18	)	)	PUNCT
dpc-1025	80	19	serum	serum	NOUN
dpc-1025	80	20	25(oh)d	25(oh)d	NUM
dpc-1025	80	21	median	median	NOUN
dpc-1025	80	22	(	(	PUNCT
dpc-1025	80	23	iqr	iqr	NOUN
dpc-1025	80	24	)	)	PUNCT
dpc-1025	80	25	median	median	NOUN
dpc-1025	80	26	(	(	PUNCT
dpc-1025	80	27	iqr	iqr	NOUN
dpc-1025	80	28	)	)	PUNCT
dpc-1025	80	29	0.051b	0.051b	NOUN
dpc-1025	80	30	20.62	20.62	NUM
dpc-1025	80	31	(	(	PUNCT
dpc-1025	80	32	13.22	13.22	NUM
dpc-1025	80	33	-	-	SYM
dpc-1025	80	34	29.67	29.67	NUM
dpc-1025	80	35	)	)	PUNCT
dpc-1025	80	36	24.71	24.71	NUM
dpc-1025	80	37	(	(	PUNCT
dpc-1025	80	38	15.37	15.37	NUM
dpc-1025	80	39	-	-	SYM
dpc-1025	80	40	34.65	34.65	NUM
dpc-1025	80	41	)	)	PUNCT
dpc-1025	80	42	n	n	PROPN
dpc-1025	80	43	(	(	PUNCT
dpc-1025	80	44	%	%	NOUN
dpc-1025	80	45	)	)	PUNCT
dpc-1025	80	46	n	n	PROPN
dpc-1025	80	47	(	(	PUNCT
dpc-1025	80	48	%	%	INTJ
dpc-1025	80	49	)	)	PUNCT
dpc-1025	80	50	0.260a	0.260a	NOUN
dpc-1025	81	1	<	<	X
dpc-1025	81	2	20	20	NUM
dpc-1025	81	3	ng	ng	PROPN
dpc-1025	81	4	/	/	SYM
dpc-1025	81	5	ml	ml	PROPN
dpc-1025	81	6	49	49	NUM
dpc-1025	81	7	(	(	PUNCT
dpc-1025	81	8	49.49	49.49	NUM
dpc-1025	81	9	)	)	PUNCT
dpc-1025	81	10	42	42	NUM
dpc-1025	81	11	(	(	PUNCT
dpc-1025	81	12	43.30	43.30	NUM
dpc-1025	81	13	)	)	PUNCT
dpc-1025	81	14	21	21	NUM
dpc-1025	81	15	-	-	SYM
dpc-1025	81	16	29	29	NUM
dpc-1025	81	17	ng	ng	PROPN
dpc-1025	81	18	/	/	SYM
dpc-1025	81	19	ml	ml	PROPN
dpc-1025	81	20	23	23	NUM
dpc-1025	81	21	(	(	PUNCT
dpc-1025	81	22	23.23	23.23	NUM
dpc-1025	81	23	)	)	PUNCT
dpc-1025	81	24	18	18	NUM
dpc-1025	81	25	(	(	PUNCT
dpc-1025	81	26	18.56	18.56	NUM
dpc-1025	81	27	)	)	PUNCT
dpc-1025	81	28	>	>	SYM
dpc-1025	81	29	30	30	NUM
dpc-1025	81	30	ng	ng	NOUN
dpc-1025	81	31	/	/	SYM
dpc-1025	81	32	ml	ml	NOUN
dpc-1025	81	33	27(27.27	27(27.27	NUM
dpc-1025	81	34	)	)	PUNCT
dpc-1025	81	35	37	37	NUM
dpc-1025	81	36	(	(	PUNCT
dpc-1025	81	37	38.14	38.14	NUM
dpc-1025	81	38	)	)	PUNCT
dpc-1025	81	39	bmi	bmi	NOUN
dpc-1025	82	1	≤25	≤25	PROPN
dpc-1025	82	2	42	42	NUM
dpc-1025	82	3	(	(	PUNCT
dpc-1025	82	4	42.42	42.42	NUM
dpc-1025	82	5	)	)	PUNCT
dpc-1025	82	6	na	na	PART
dpc-1025	82	7	>	>	SYM
dpc-1025	82	8	25	25	NUM
dpc-1025	82	9	57	57	NUM
dpc-1025	82	10	(	(	PUNCT
dpc-1025	82	11	57.58	57.58	NUM
dpc-1025	82	12	)	)	PUNCT
dpc-1025	82	13	na	na	ADP
dpc-1025	82	14	achi	achi	ADJ
dpc-1025	82	15	-	-	PUNCT
dpc-1025	82	16	square	square	ADJ
dpc-1025	82	17	test	test	NOUN
dpc-1025	82	18	.	.	PUNCT
dpc-1025	83	1	bmann	bmann	NOUN
dpc-1025	83	2	-	-	PUNCT
dpc-1025	83	3	whitney	whitney	NOUN
dpc-1025	83	4	u	u	PROPN
dpc-1025	83	5	test	test	NOUN
dpc-1025	83	6	.	.	PUNCT
dpc-1025	84	1	n	n	X
dpc-1025	84	2	(	(	PUNCT
dpc-1025	84	3	%	%	INTJ
dpc-1025	84	4	)	)	PUNCT
dpc-1025	84	5	=	=	NOUN
dpc-1025	84	6	frequency	frequency	NOUN
dpc-1025	84	7	(	(	PUNCT
dpc-1025	84	8	percentage	percentage	NOUN
dpc-1025	84	9	)	)	PUNCT
dpc-1025	84	10	;	;	PUNCT
dpc-1025	84	11	25(oh)d	25(oh)d	NUM
dpc-1025	84	12	=	=	SYM
dpc-1025	84	13	25	25	NUM
dpc-1025	84	14	-	-	PUNCT
dpc-1025	84	15	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	84	16	d	d	NOUN
dpc-1025	84	17	;	;	PUNCT
dpc-1025	84	18	bmi	bmi	PROPN
dpc-1025	84	19	=	=	SYM
dpc-1025	84	20	body	body	PROPN
dpc-1025	84	21	mass	mass	PROPN
dpc-1025	84	22	index	index	NOUN
dpc-1025	84	23	;	;	PUNCT
dpc-1025	85	1	iqr	iqr	PROPN
dpc-1025	85	2	=	=	NOUN
dpc-1025	85	3	interquartile	interquartile	NOUN
dpc-1025	85	4	range	range	NOUN
dpc-1025	85	5	;	;	PUNCT
dpc-1025	85	6	na	na	PART
dpc-1025	85	7	 	 	SPACE
dpc-1025	85	8	=	=	NOUN
dpc-1025	85	9	not	not	PART
dpc-1025	85	10	available	available	ADJ
dpc-1025	85	11	.	.	PUNCT
dpc-1025	86	1	4	4	NUM
dpc-1025	86	2	research	research	NOUN
dpc-1025	86	3	|	|	ADV
dpc-1025	86	4	dermatol	dermatol	ADJ
dpc-1025	86	5	pract	pract	NOUN
dpc-1025	86	6	concept	concept	NOUN
dpc-1025	86	7	2020;10(1):e2020010	2020;10(1):e2020010	NUM
dpc-1025	86	8	serum	serum	NOUN
dpc-1025	86	9	total	total	ADJ
dpc-1025	86	10	25	25	NUM
dpc-1025	86	11	-	-	PUNCT
dpc-1025	86	12	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	86	13	d	d	NOUN
dpc-1025	86	14	(	(	PUNCT
dpc-1025	86	15	<	<	X
dpc-1025	86	16	20	20	NUM
dpc-1025	86	17	ng	ng	PROPN
dpc-1025	86	18	/	/	SYM
dpc-1025	86	19	ml	ml	PROPN
dpc-1025	86	20	)	)	PUNCT
dpc-1025	86	21	,	,	PUNCT
dpc-1025	86	22	23	23	NUM
dpc-1025	86	23	(	(	PUNCT
dpc-1025	86	24	23.23	23.23	NUM
dpc-1025	86	25	%	%	NOUN
dpc-1025	86	26	)	)	PUNCT
dpc-1025	86	27	had	have	VERB
dpc-1025	86	28	insufficient	insufficient	ADJ
dpc-1025	86	29	levels	level	NOUN
dpc-1025	86	30	(	(	PUNCT
dpc-1025	86	31	21	21	NUM
dpc-1025	86	32	-	-	SYM
dpc-1025	86	33	29	29	NUM
dpc-1025	86	34	ng	ng	PROPN
dpc-1025	86	35	/	/	SYM
dpc-1025	86	36	ml	ml	NOUN
dpc-1025	86	37	)	)	PUNCT
dpc-1025	86	38	,	,	PUNCT
dpc-1025	86	39	and	and	CCONJ
dpc-1025	86	40	27	27	NUM
dpc-1025	86	41	(	(	PUNCT
dpc-1025	86	42	27.27	27.27	NUM
dpc-1025	86	43	%	%	NOUN
dpc-1025	86	44	)	)	PUNCT
dpc-1025	86	45	had	have	VERB
dpc-1025	86	46	adequate	adequate	ADJ
dpc-1025	86	47	25	25	NUM
dpc-1025	86	48	-	-	PUNCT
dpc-1025	86	49	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	86	50	d	d	NOUN
dpc-1025	86	51	levels	level	NOUN
dpc-1025	86	52	(	(	PUNCT
dpc-1025	86	53	>	>	SYM
dpc-1025	86	54	30	30	NUM
dpc-1025	86	55	ng	ng	NOUN
dpc-1025	86	56	/	/	SYM
dpc-1025	86	57	ml	ml	NOUN
dpc-1025	86	58	)	)	PUNCT
dpc-1025	86	59	.	.	PUNCT
dpc-1025	87	1	two	two	NUM
dpc-1025	87	2	melanoma	melanoma	NOUN
dpc-1025	87	3	patients	patient	NOUN
dpc-1025	87	4	with	with	ADP
dpc-1025	87	5	serum	serum	NOUN
dpc-1025	87	6	total	total	ADJ
dpc-1025	87	7	25	25	NUM
dpc-1025	87	8	-	-	PUNCT
dpc-1025	87	9	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	87	10	d	d	NOUN
dpc-1025	87	11	levels	level	NOUN
dpc-1025	87	12	between	between	ADP
dpc-1025	87	13	20	20	NUM
dpc-1025	87	14	and	and	CCONJ
dpc-1025	87	15	20.9	20.9	NUM
dpc-1025	87	16	ng	ng	NOUN
dpc-1025	87	17	/	/	SYM
dpc-1025	87	18	ml	ml	PROPN
dpc-1025	87	19	and	and	CCONJ
dpc-1025	87	20	3	3	NUM
dpc-1025	87	21	patients	patient	NOUN
dpc-1025	87	22	with	with	ADP
dpc-1025	87	23	values	value	NOUN
dpc-1025	87	24	between	between	ADP
dpc-1025	87	25	29	29	NUM
dpc-1025	87	26	and	and	CCONJ
dpc-1025	87	27	29.9	29.9	NUM
dpc-1025	87	28	ng	ng	NOUN
dpc-1025	87	29	/	/	SYM
dpc-1025	87	30	ml	ml	NOUN
dpc-1025	87	31	were	be	AUX
dpc-1025	87	32	included	include	VERB
dpc-1025	87	33	in	in	ADP
dpc-1025	87	34	the	the	DET
dpc-1025	87	35	insufficient	insufficient	ADJ
dpc-1025	87	36	class	class	NOUN
dpc-1025	87	37	of	of	ADP
dpc-1025	87	38	the	the	DET
dpc-1025	87	39	melanoma	melanoma	NOUN
dpc-1025	87	40	patients	patient	NOUN
dpc-1025	87	41	group	group	NOUN
dpc-1025	87	42	.	.	PUNCT
dpc-1025	88	1	of	of	ADP
dpc-1025	88	2	the	the	DET
dpc-1025	88	3	healthy	healthy	ADJ
dpc-1025	88	4	controls	control	NOUN
dpc-1025	88	5	,	,	PUNCT
dpc-1025	88	6	42	42	NUM
dpc-1025	88	7	(	(	PUNCT
dpc-1025	88	8	43.30	43.30	NUM
dpc-1025	88	9	%	%	NOUN
dpc-1025	88	10	)	)	PUNCT
dpc-1025	88	11	had	have	VERB
dpc-1025	88	12	deficient	deficient	ADJ
dpc-1025	88	13	serum	serum	NOUN
dpc-1025	88	14	levels	level	NOUN
dpc-1025	88	15	of	of	ADP
dpc-1025	88	16	total	total	ADJ
dpc-1025	88	17	25	25	NUM
dpc-1025	88	18	-	-	PUNCT
dpc-1025	88	19	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	88	20	d	d	NOUN
dpc-1025	88	21	(	(	PUNCT
dpc-1025	88	22	<	<	X
dpc-1025	88	23	20	20	NUM
dpc-1025	88	24	ng	ng	PROPN
dpc-1025	88	25	/	/	SYM
dpc-1025	88	26	ml	ml	PROPN
dpc-1025	88	27	)	)	PUNCT
dpc-1025	88	28	,	,	PUNCT
dpc-1025	88	29	18	18	NUM
dpc-1025	88	30	(	(	PUNCT
dpc-1025	88	31	18.56	18.56	NUM
dpc-1025	88	32	%	%	NOUN
dpc-1025	88	33	)	)	PUNCT
dpc-1025	88	34	had	have	VERB
dpc-1025	88	35	insufficient	insufficient	ADJ
dpc-1025	88	36	levels	level	NOUN
dpc-1025	88	37	(	(	PUNCT
dpc-1025	88	38	2129	2129	NUM
dpc-1025	88	39	ng	ng	NOUN
dpc-1025	88	40	/	/	SYM
dpc-1025	88	41	ml	ml	PROPN
dpc-1025	88	42	)	)	PUNCT
dpc-1025	88	43	,	,	PUNCT
dpc-1025	88	44	and	and	CCONJ
dpc-1025	88	45	37	37	NUM
dpc-1025	88	46	(	(	PUNCT
dpc-1025	88	47	38.14	38.14	NUM
dpc-1025	88	48	%	%	NOUN
dpc-1025	88	49	)	)	PUNCT
dpc-1025	88	50	had	have	VERB
dpc-1025	88	51	adequate	adequate	ADJ
dpc-1025	88	52	25	25	NUM
dpc-1025	88	53	-	-	PUNCT
dpc-1025	88	54	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	88	55	d	d	NOUN
dpc-1025	88	56	levels	level	NOUN
dpc-1025	88	57	(	(	PUNCT
dpc-1025	88	58	>	>	SYM
dpc-1025	88	59	30	30	NUM
dpc-1025	88	60	ng	ng	NOUN
dpc-1025	88	61	/	/	SYM
dpc-1025	88	62	ml	ml	NOUN
dpc-1025	88	63	)	)	PUNCT
dpc-1025	88	64	.	.	PUNCT
dpc-1025	89	1	the	the	DET
dpc-1025	89	2	median	median	ADJ
dpc-1025	89	3	serum	serum	NOUN
dpc-1025	89	4	total	total	NOUN
dpc-1025	89	5	25	25	NUM
dpc-1025	89	6	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	89	7	d	d	NOUN
dpc-1025	89	8	levels	level	NOUN
dpc-1025	89	9	were	be	AUX
dpc-1025	89	10	lower	low	ADJ
dpc-1025	89	11	in	in	ADP
dpc-1025	89	12	melanoma	melanoma	NOUN
dpc-1025	89	13	patients	patient	NOUN
dpc-1025	89	14	(	(	PUNCT
dpc-1025	89	15	20.62	20.62	NUM
dpc-1025	89	16	ng	ng	NOUN
dpc-1025	89	17	/	/	SYM
dpc-1025	89	18	ml	ml	ADP
dpc-1025	89	19	vs	vs	ADP
dpc-1025	89	20	24.71	24.71	NUM
dpc-1025	89	21	ng	ng	PROPN
dpc-1025	89	22	/	/	SYM
dpc-1025	89	23	ml	ml	VERB
dpc-1025	89	24	)	)	PUNCT
dpc-1025	89	25	compared	compare	VERB
dpc-1025	89	26	with	with	ADP
dpc-1025	89	27	those	those	PRON
dpc-1025	89	28	in	in	ADP
dpc-1025	89	29	healthy	healthy	ADJ
dpc-1025	89	30	controls	control	NOUN
dpc-1025	89	31	(	(	PUNCT
dpc-1025	89	32	p	p	X
dpc-1025	89	33	=	=	PROPN
dpc-1025	89	34	0.051	0.051	NUM
dpc-1025	89	35	)	)	PUNCT
dpc-1025	89	36	.	.	PUNCT
dpc-1025	90	1	statistical	statistical	ADJ
dpc-1025	90	2	analysis	analysis	NOUN
dpc-1025	90	3	is	be	AUX
dpc-1025	90	4	presented	present	VERB
dpc-1025	90	5	in	in	ADP
dpc-1025	90	6	table	table	NOUN
dpc-1025	90	7	1	1	NUM
dpc-1025	90	8	.	.	PUNCT
dpc-1025	91	1	we	we	PRON
dpc-1025	91	2	tested	test	VERB
dpc-1025	91	3	the	the	DET
dpc-1025	91	4	correlation	correlation	NOUN
dpc-1025	91	5	of	of	ADP
dpc-1025	91	6	serum	serum	NOUN
dpc-1025	91	7	total	total	ADJ
dpc-1025	91	8	25	25	NUM
dpc-1025	91	9	-	-	PUNCT
dpc-1025	91	10	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	91	11	d	d	NOUN
dpc-1025	91	12	levels	level	NOUN
dpc-1025	91	13	at	at	ADP
dpc-1025	91	14	melanoma	melanoma	ADJ
dpc-1025	91	15	diagnosis	diagnosis	NOUN
dpc-1025	91	16	with	with	ADP
dpc-1025	91	17	demographic	demographic	ADJ
dpc-1025	91	18	pational	pational	ADJ
dpc-1025	91	19	)	)	PUNCT
dpc-1025	91	20	sun	sun	NOUN
dpc-1025	91	21	exposure	exposure	NOUN
dpc-1025	91	22	,	,	PUNCT
dpc-1025	91	23	while	while	SCONJ
dpc-1025	91	24	52	52	NUM
dpc-1025	91	25	(	(	PUNCT
dpc-1025	91	26	52.53	52.53	NUM
dpc-1025	91	27	%	%	NOUN
dpc-1025	91	28	)	)	PUNCT
dpc-1025	91	29	reported	report	VERB
dpc-1025	91	30	excessive	excessive	ADJ
dpc-1025	91	31	intentional	intentional	ADJ
dpc-1025	91	32	(	(	PUNCT
dpc-1025	91	33	recreational	recreational	ADJ
dpc-1025	91	34	)	)	PUNCT
dpc-1025	91	35	sun	sun	NOUN
dpc-1025	91	36	exposure	exposure	NOUN
dpc-1025	91	37	.	.	PUNCT
dpc-1025	92	1	thirty	thirty	NUM
dpc-1025	92	2	-	-	PUNCT
dpc-1025	92	3	nine	nine	NUM
dpc-1025	92	4	patients	patient	NOUN
dpc-1025	92	5	(	(	PUNCT
dpc-1025	92	6	39.39	39.39	NUM
dpc-1025	92	7	%	%	NOUN
dpc-1025	92	8	)	)	PUNCT
dpc-1025	92	9	had	have	AUX
dpc-1025	92	10	experienced	experience	VERB
dpc-1025	92	11	blistering	blister	VERB
dpc-1025	92	12	sunburns	sunburn	NOUN
dpc-1025	92	13	during	during	ADP
dpc-1025	92	14	childhood	childhood	NOUN
dpc-1025	92	15	and	and	CCONJ
dpc-1025	92	16	adolescence	adolescence	NOUN
dpc-1025	92	17	and	and	CCONJ
dpc-1025	92	18	35	35	NUM
dpc-1025	92	19	(	(	PUNCT
dpc-1025	92	20	35.35	35.35	NUM
dpc-1025	92	21	%	%	NOUN
dpc-1025	92	22	)	)	PUNCT
dpc-1025	92	23	during	during	ADP
dpc-1025	92	24	adulthood	adulthood	NOUN
dpc-1025	92	25	.	.	PUNCT
dpc-1025	93	1	signs	sign	NOUN
dpc-1025	93	2	of	of	ADP
dpc-1025	93	3	photo	photo	NOUN
dpc-1025	93	4	-	-	PUNCT
dpc-1025	93	5	damaged	damage	VERB
dpc-1025	93	6	skin	skin	NOUN
dpc-1025	93	7	—	—	PUNCT
dpc-1025	93	8	presence	presence	NOUN
dpc-1025	93	9	of	of	ADP
dpc-1025	93	10	elastosis	elastosis	NOUN
dpc-1025	93	11	,	,	PUNCT
dpc-1025	93	12	solar	solar	ADJ
dpc-1025	93	13	lentigines	lentigo	NOUN
dpc-1025	93	14	,	,	PUNCT
dpc-1025	93	15	actinic	actinic	ADJ
dpc-1025	93	16	keratoses	keratose	NOUN
dpc-1025	93	17	—	—	PUNCT
dpc-1025	93	18	were	be	AUX
dpc-1025	93	19	observed	observe	VERB
dpc-1025	93	20	in	in	ADP
dpc-1025	93	21	46	46	NUM
dpc-1025	93	22	patients	patient	NOUN
dpc-1025	93	23	(	(	PUNCT
dpc-1025	93	24	46.46	46.46	NUM
dpc-1025	93	25	%	%	NOUN
dpc-1025	93	26	)	)	PUNCT
dpc-1025	93	27	.	.	PUNCT
dpc-1025	94	1	family	family	NOUN
dpc-1025	94	2	history	history	NOUN
dpc-1025	94	3	of	of	ADP
dpc-1025	94	4	cmm	cmm	PROPN
dpc-1025	94	5	was	be	AUX
dpc-1025	94	6	reported	report	VERB
dpc-1025	94	7	by	by	ADP
dpc-1025	94	8	8	8	NUM
dpc-1025	94	9	patients	patient	NOUN
dpc-1025	94	10	(	(	PUNCT
dpc-1025	94	11	8.08	8.08	NUM
dpc-1025	94	12	%	%	NOUN
dpc-1025	94	13	)	)	PUNCT
dpc-1025	94	14	,	,	PUNCT
dpc-1025	94	15	and	and	CCONJ
dpc-1025	94	16	personal	personal	ADJ
dpc-1025	94	17	history	history	NOUN
dpc-1025	94	18	by	by	ADP
dpc-1025	94	19	1	1	NUM
dpc-1025	94	20	(	(	PUNCT
dpc-1025	94	21	1.01	1.01	NUM
dpc-1025	94	22	%	%	NOUN
dpc-1025	94	23	)	)	PUNCT
dpc-1025	94	24	.	.	PUNCT
dpc-1025	95	1	atypical	atypical	ADJ
dpc-1025	95	2	nevi	nevi	NOUN
dpc-1025	95	3	were	be	AUX
dpc-1025	95	4	present	present	ADJ
dpc-1025	95	5	in	in	ADP
dpc-1025	95	6	32	32	NUM
dpc-1025	95	7	patients	patient	NOUN
dpc-1025	95	8	(	(	PUNCT
dpc-1025	95	9	32.32	32.32	NUM
dpc-1025	95	10	%	%	NOUN
dpc-1025	95	11	)	)	PUNCT
dpc-1025	95	12	.	.	PUNCT
dpc-1025	96	1	risk	risk	NOUN
dpc-1025	96	2	factors	factor	NOUN
dpc-1025	96	3	for	for	ADP
dpc-1025	96	4	cmm	cmm	PROPN
dpc-1025	96	5	among	among	ADP
dpc-1025	96	6	our	our	PRON
dpc-1025	96	7	melanoma	melanoma	NOUN
dpc-1025	96	8	patients	patient	NOUN
dpc-1025	96	9	are	be	AUX
dpc-1025	96	10	depicted	depict	VERB
dpc-1025	96	11	in	in	ADP
dpc-1025	96	12	table	table	NOUN
dpc-1025	96	13	2	2	NUM
dpc-1025	96	14	,	,	PUNCT
dpc-1025	96	15	while	while	SCONJ
dpc-1025	96	16	clinical	clinical	ADJ
dpc-1025	96	17	and	and	CCONJ
dpc-1025	96	18	histological	histological	ADJ
dpc-1025	96	19	characteristics	characteristic	NOUN
dpc-1025	96	20	of	of	ADP
dpc-1025	96	21	melanoma	melanoma	NOUN
dpc-1025	96	22	are	be	AUX
dpc-1025	96	23	presented	present	VERB
dpc-1025	96	24	in	in	ADP
dpc-1025	96	25	table	table	NOUN
dpc-1025	96	26	3	3	NUM
dpc-1025	96	27	.	.	PUNCT
dpc-1025	96	28	serum	serum	PROPN
dpc-1025	96	29	total	total	ADJ
dpc-1025	96	30	25	25	NUM
dpc-1025	96	31	-	-	PUNCT
dpc-1025	96	32	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	96	33	d	d	NOUN
dpc-1025	96	34	levels	level	NOUN
dpc-1025	96	35	were	be	AUX
dpc-1025	96	36	measured	measure	VERB
dpc-1025	96	37	in	in	ADP
dpc-1025	96	38	99	99	NUM
dpc-1025	96	39	melanoma	melanoma	NOUN
dpc-1025	96	40	patients	patient	NOUN
dpc-1025	96	41	at	at	ADP
dpc-1025	96	42	the	the	DET
dpc-1025	96	43	time	time	NOUN
dpc-1025	96	44	of	of	ADP
dpc-1025	96	45	diagnosis	diagnosis	NOUN
dpc-1025	96	46	and	and	CCONJ
dpc-1025	96	47	in	in	ADP
dpc-1025	96	48	97	97	NUM
dpc-1025	96	49	ageand	ageand	NOUN
dpc-1025	96	50	sex	sex	NOUN
dpc-1025	96	51	-	-	PUNCT
dpc-1025	96	52	matched	match	VERB
dpc-1025	96	53	healthy	healthy	ADJ
dpc-1025	96	54	controls	control	NOUN
dpc-1025	96	55	at	at	ADP
dpc-1025	96	56	the	the	DET
dpc-1025	96	57	time	time	NOUN
dpc-1025	96	58	of	of	ADP
dpc-1025	96	59	recruitment	recruitment	NOUN
dpc-1025	96	60	.	.	PUNCT
dpc-1025	97	1	of	of	ADP
dpc-1025	97	2	the	the	DET
dpc-1025	97	3	melanoma	melanoma	NOUN
dpc-1025	97	4	patients	patient	NOUN
dpc-1025	97	5	,	,	PUNCT
dpc-1025	97	6	49	49	NUM
dpc-1025	97	7	(	(	PUNCT
dpc-1025	97	8	49.49	49.49	NUM
dpc-1025	97	9	%	%	NOUN
dpc-1025	97	10	)	)	PUNCT
dpc-1025	97	11	had	have	AUX
dpc-1025	97	12	deficient	deficient	ADJ
dpc-1025	97	13	n	n	CCONJ
dpc-1025	97	14	(	(	PUNCT
dpc-1025	97	15	%	%	INTJ
dpc-1025	97	16	)	)	PUNCT
dpc-1025	98	1	p	p	DET
dpc-1025	98	2	valuea	valuea	ADJ
dpc-1025	98	3	sunburn	sunburn	NOUN
dpc-1025	98	4	during	during	ADP
dpc-1025	98	5	adulthood	adulthood	NOUN
dpc-1025	98	6	(	(	PUNCT
dpc-1025	98	7	>	>	SYM
dpc-1025	98	8	20	20	NUM
dpc-1025	98	9	years	year	NOUN
dpc-1025	98	10	)	)	PUNCT
dpc-1025	98	11	0.408	0.408	NUM
dpc-1025	98	12	no	no	DET
dpc-1025	98	13	64	64	NUM
dpc-1025	98	14	(	(	PUNCT
dpc-1025	98	15	64.65	64.65	NUM
dpc-1025	98	16	)	)	PUNCT
dpc-1025	99	1	yes	yes	INTJ
dpc-1025	99	2	35	35	NUM
dpc-1025	99	3	(	(	PUNCT
dpc-1025	99	4	35.35	35.35	NUM
dpc-1025	99	5	)	)	PUNCT
dpc-1025	99	6	sunscreen	sunscreen	NOUN
dpc-1025	99	7	use	use	NOUN
dpc-1025	99	8	0.845	0.845	NUM
dpc-1025	99	9	never	never	ADV
dpc-1025	99	10	32	32	NUM
dpc-1025	99	11	(	(	PUNCT
dpc-1025	99	12	32.32	32.32	NUM
dpc-1025	99	13	)	)	PUNCT
dpc-1025	99	14	rarely	rarely	ADV
dpc-1025	99	15	29	29	NUM
dpc-1025	99	16	(	(	PUNCT
dpc-1025	99	17	29.29	29.29	NUM
dpc-1025	99	18	)	)	PUNCT
dpc-1025	99	19	during	during	ADP
dpc-1025	99	20	summer	summer	NOUN
dpc-1025	99	21	vacation	vacation	NOUN
dpc-1025	99	22	31	31	NUM
dpc-1025	99	23	(	(	PUNCT
dpc-1025	99	24	31.31	31.31	NUM
dpc-1025	99	25	)	)	PUNCT
dpc-1025	99	26	usually	usually	ADV
dpc-1025	99	27	throughout	throughout	ADP
dpc-1025	99	28	year	year	NOUN
dpc-1025	99	29	7	7	NUM
dpc-1025	99	30	(	(	PUNCT
dpc-1025	99	31	7.07	7.07	NUM
dpc-1025	99	32	)	)	PUNCT
dpc-1025	99	33	nevi	nevi	ADJ
dpc-1025	99	34	count	count	VERB
dpc-1025	99	35	0.982	0.982	NUM
dpc-1025	99	36	<	<	X
dpc-1025	99	37	10	10	NUM
dpc-1025	99	38	41	41	NUM
dpc-1025	99	39	(	(	PUNCT
dpc-1025	99	40	41.41	41.41	NUM
dpc-1025	99	41	)	)	PUNCT
dpc-1025	99	42	10	10	NUM
dpc-1025	99	43	-	-	SYM
dpc-1025	99	44	50	50	NUM
dpc-1025	99	45	40	40	NUM
dpc-1025	99	46	(	(	PUNCT
dpc-1025	99	47	40.40	40.40	NUM
dpc-1025	99	48	)	)	PUNCT
dpc-1025	99	49	>	>	PUNCT
dpc-1025	99	50	50	50	NUM
dpc-1025	99	51	18	18	NUM
dpc-1025	99	52	(	(	PUNCT
dpc-1025	99	53	18.18	18.18	NUM
dpc-1025	99	54	)	)	PUNCT
dpc-1025	99	55	atypical	atypical	ADJ
dpc-1025	99	56	mole	mole	NOUN
dpc-1025	99	57	0.648	0.648	NUM
dpc-1025	100	1	yes	yes	NOUN
dpc-1025	100	2	32	32	NUM
dpc-1025	100	3	(	(	PUNCT
dpc-1025	100	4	32.32	32.32	NUM
dpc-1025	100	5	)	)	PUNCT
dpc-1025	100	6	no	no	PRON
dpc-1025	100	7	67	67	NUM
dpc-1025	100	8	(	(	PUNCT
dpc-1025	100	9	67.68	67.68	NUM
dpc-1025	100	10	)	)	PUNCT
dpc-1025	100	11	family	family	NOUN
dpc-1025	100	12	history	history	NOUN
dpc-1025	100	13	of	of	ADP
dpc-1025	100	14	melanoma	melanoma	NOUN
dpc-1025	100	15	0.977	0.977	NUM
dpc-1025	100	16	yes	yes	NOUN
dpc-1025	100	17	8	8	NUM
dpc-1025	101	1	(	(	PUNCT
dpc-1025	101	2	8.08	8.08	NUM
dpc-1025	101	3	)	)	PUNCT
dpc-1025	101	4	no	no	PRON
dpc-1025	101	5	91	91	NUM
dpc-1025	101	6	(	(	PUNCT
dpc-1025	101	7	91.92	91.92	NUM
dpc-1025	101	8	)	)	PUNCT
dpc-1025	101	9	personal	personal	ADJ
dpc-1025	101	10	history	history	NOUN
dpc-1025	101	11	of	of	ADP
dpc-1025	101	12	melanoma	melanoma	NOUN
dpc-1025	101	13	0.999d	0.999d	NOUN
dpc-1025	102	1	yes	yes	INTJ
dpc-1025	102	2	1	1	NUM
dpc-1025	102	3	(	(	PUNCT
dpc-1025	102	4	1.01	1.01	NUM
dpc-1025	102	5	)	)	PUNCT
dpc-1025	102	6	no	no	DET
dpc-1025	102	7	98	98	NUM
dpc-1025	102	8	(	(	PUNCT
dpc-1025	102	9	98.99	98.99	NUM
dpc-1025	102	10	)	)	PUNCT
dpc-1025	102	11	achi	achi	ADJ
dpc-1025	102	12	-	-	PUNCT
dpc-1025	102	13	square	square	ADJ
dpc-1025	102	14	test	test	NOUN
dpc-1025	102	15	(	(	PUNCT
dpc-1025	102	16	unless	unless	SCONJ
dpc-1025	102	17	specified	specify	VERB
dpc-1025	102	18	otherwise	otherwise	ADV
dpc-1025	102	19	)	)	PUNCT
dpc-1025	102	20	.	.	PUNCT
dpc-1025	103	1	bblue	bblue	NOUN
dpc-1025	103	2	,	,	PUNCT
dpc-1025	103	3	green	green	ADJ
dpc-1025	103	4	,	,	PUNCT
dpc-1025	103	5	and	and	CCONJ
dpc-1025	103	6	light	light	ADJ
dpc-1025	103	7	brown	brown	ADJ
dpc-1025	103	8	eyes	eye	NOUN
dpc-1025	103	9	.	.	PUNCT
dpc-1025	104	1	cblonde	cblonde	NOUN
dpc-1025	104	2	,	,	PUNCT
dpc-1025	104	3	red	red	ADJ
dpc-1025	104	4	,	,	PUNCT
dpc-1025	104	5	and	and	CCONJ
dpc-1025	104	6	light	light	ADJ
dpc-1025	104	7	brown	brown	ADJ
dpc-1025	104	8	hair	hair	NOUN
dpc-1025	104	9	.	.	PUNCT
dpc-1025	105	1	dfisher	dfisher	ADJ
dpc-1025	105	2	exact	exact	ADJ
dpc-1025	105	3	test	test	NOUN
dpc-1025	105	4	.	.	PUNCT
dpc-1025	106	1	n	n	PROPN
dpc-1025	106	2	(	(	PUNCT
dpc-1025	106	3	%	%	INTJ
dpc-1025	106	4	)	)	PUNCT
dpc-1025	106	5	=	=	NOUN
dpc-1025	106	6	frequency	frequency	NOUN
dpc-1025	106	7	(	(	PUNCT
dpc-1025	106	8	percentage	percentage	NOUN
dpc-1025	106	9	)	)	PUNCT
dpc-1025	106	10	.	.	PUNCT
dpc-1025	107	1	n	n	PROPN
dpc-1025	107	2	(	(	PUNCT
dpc-1025	107	3	%	%	INTJ
dpc-1025	107	4	)	)	PUNCT
dpc-1025	107	5	p	p	NOUN
dpc-1025	107	6	valuea	valuea	NOUN
dpc-1025	107	7	eye	eye	NOUN
dpc-1025	107	8	color	color	NOUN
dpc-1025	107	9	0.120	0.120	NUM
dpc-1025	107	10	lightb	lightb	NOUN
dpc-1025	107	11	77	77	NUM
dpc-1025	107	12	(	(	PUNCT
dpc-1025	107	13	77.78	77.78	NUM
dpc-1025	107	14	)	)	PUNCT
dpc-1025	107	15	dark	dark	ADJ
dpc-1025	107	16	22	22	NUM
dpc-1025	107	17	(	(	PUNCT
dpc-1025	107	18	22.22	22.22	NUM
dpc-1025	107	19	)	)	PUNCT
dpc-1025	107	20	hair	hair	NOUN
dpc-1025	107	21	color	color	NOUN
dpc-1025	107	22	0.948	0.948	NUM
dpc-1025	107	23	lightc	lightc	NOUN
dpc-1025	107	24	52	52	NUM
dpc-1025	107	25	(	(	PUNCT
dpc-1025	107	26	52.53	52.53	NUM
dpc-1025	107	27	)	)	PUNCT
dpc-1025	107	28	dark	dark	NOUN
dpc-1025	107	29	47	47	NUM
dpc-1025	107	30	(	(	PUNCT
dpc-1025	107	31	47.47	47.47	NUM
dpc-1025	107	32	)	)	PUNCT
dpc-1025	107	33	skin	skin	NOUN
dpc-1025	107	34	color	color	NOUN
dpc-1025	107	35	0.910	0.910	NUM
dpc-1025	107	36	white	white	ADJ
dpc-1025	107	37	58	58	NUM
dpc-1025	107	38	(	(	PUNCT
dpc-1025	107	39	58.59	58.59	NUM
dpc-1025	107	40	)	)	PUNCT
dpc-1025	107	41	light	light	ADJ
dpc-1025	107	42	brown	brown	NOUN
dpc-1025	107	43	38	38	NUM
dpc-1025	107	44	(	(	PUNCT
dpc-1025	107	45	38.38	38.38	NUM
dpc-1025	107	46	)	)	PUNCT
dpc-1025	107	47	dark	dark	ADJ
dpc-1025	107	48	3	3	NUM
dpc-1025	107	49	(	(	PUNCT
dpc-1025	107	50	3.03	3.03	NUM
dpc-1025	107	51	)	)	PUNCT
dpc-1025	107	52	phototype	phototype	NOUN
dpc-1025	107	53	0.813	0.813	NUM
dpc-1025	107	54	type	type	NOUN
dpc-1025	107	55	i	i	PRON
dpc-1025	107	56	7	7	NUM
dpc-1025	107	57	(	(	PUNCT
dpc-1025	107	58	7.07	7.07	NUM
dpc-1025	107	59	)	)	PUNCT
dpc-1025	107	60	type	type	NOUN
dpc-1025	107	61	ii	ii	NOUN
dpc-1025	107	62	43	43	NUM
dpc-1025	107	63	(	(	PUNCT
dpc-1025	107	64	43.43	43.43	NUM
dpc-1025	107	65	)	)	PUNCT
dpc-1025	107	66	type	type	NOUN
dpc-1025	107	67	iii	iii	NOUN
dpc-1025	107	68	34	34	NUM
dpc-1025	107	69	(	(	PUNCT
dpc-1025	107	70	34.34	34.34	NUM
dpc-1025	107	71	)	)	PUNCT
dpc-1025	107	72	type	type	NOUN
dpc-1025	107	73	iv	iv	NUM
dpc-1025	107	74	15	15	NUM
dpc-1025	107	75	(	(	PUNCT
dpc-1025	107	76	15.15	15.15	NUM
dpc-1025	107	77	)	)	PUNCT
dpc-1025	107	78	occupational	occupational	ADJ
dpc-1025	107	79	sun	sun	NOUN
dpc-1025	107	80	exposure	exposure	NOUN
dpc-1025	107	81	0.077	0.077	NUM
dpc-1025	107	82	yes	yes	NOUN
dpc-1025	107	83	20	20	NUM
dpc-1025	107	84	(	(	PUNCT
dpc-1025	107	85	20.20	20.20	NUM
dpc-1025	107	86	)	)	PUNCT
dpc-1025	107	87	no	no	DET
dpc-1025	107	88	79	79	NUM
dpc-1025	107	89	(	(	PUNCT
dpc-1025	107	90	79.80	79.80	NUM
dpc-1025	107	91	)	)	PUNCT
dpc-1025	107	92	recreational	recreational	ADJ
dpc-1025	107	93	sun	sun	NOUN
dpc-1025	107	94	exposure	exposure	NOUN
dpc-1025	107	95	0.104	0.104	NUM
dpc-1025	108	1	yes	yes	NOUN
dpc-1025	108	2	52	52	NUM
dpc-1025	108	3	(	(	PUNCT
dpc-1025	108	4	52.53	52.53	NUM
dpc-1025	108	5	)	)	PUNCT
dpc-1025	108	6	no	no	DET
dpc-1025	108	7	47	47	NUM
dpc-1025	108	8	(	(	PUNCT
dpc-1025	108	9	47.47	47.47	NUM
dpc-1025	108	10	)	)	PUNCT
dpc-1025	108	11	photoaging	photoage	VERB
dpc-1025	108	12	0.903	0.903	NUM
dpc-1025	109	1	yes	yes	NOUN
dpc-1025	109	2	46	46	NUM
dpc-1025	109	3	(	(	PUNCT
dpc-1025	109	4	46.46	46.46	NUM
dpc-1025	109	5	)	)	PUNCT
dpc-1025	109	6	no	no	PRON
dpc-1025	109	7	53	53	NUM
dpc-1025	109	8	(	(	PUNCT
dpc-1025	109	9	53.54	53.54	NUM
dpc-1025	109	10	)	)	PUNCT
dpc-1025	109	11	sunburn	sunburn	NOUN
dpc-1025	109	12	during	during	ADP
dpc-1025	109	13	childhood	childhood	NOUN
dpc-1025	109	14	(	(	PUNCT
dpc-1025	109	15	<	<	X
dpc-1025	109	16	20	20	NUM
dpc-1025	109	17	years	year	NOUN
dpc-1025	109	18	)	)	PUNCT
dpc-1025	109	19	0.356	0.356	NUM
dpc-1025	109	20	no	no	DET
dpc-1025	109	21	60	60	NUM
dpc-1025	109	22	(	(	PUNCT
dpc-1025	109	23	60.61	60.61	NUM
dpc-1025	109	24	)	)	PUNCT
dpc-1025	110	1	yes	yes	INTJ
dpc-1025	110	2	39	39	NUM
dpc-1025	110	3	(	(	PUNCT
dpc-1025	110	4	39.39	39.39	NUM
dpc-1025	110	5	)	)	PUNCT
dpc-1025	110	6	(	(	PUNCT
dpc-1025	110	7	data	datum	NOUN
dpc-1025	110	8	continues	continue	VERB
dpc-1025	110	9	next	next	ADJ
dpc-1025	110	10	column	column	NOUN
dpc-1025	110	11	)	)	PUNCT
dpc-1025	110	12	table	table	NOUN
dpc-1025	111	1	2	2	NUM
dpc-1025	111	2	.	.	PUNCT
dpc-1025	111	3	descriptive	descriptive	ADJ
dpc-1025	111	4	statistics	statistic	NOUN
dpc-1025	111	5	of	of	ADP
dpc-1025	111	6	risk	risk	NOUN
dpc-1025	111	7	factors	factor	NOUN
dpc-1025	111	8	and	and	CCONJ
dpc-1025	111	9	association	association	NOUN
dpc-1025	111	10	with	with	ADP
dpc-1025	111	11	serum	serum	NOUN
dpc-1025	111	12	25	25	NUM
dpc-1025	111	13	-	-	PUNCT
dpc-1025	111	14	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	111	15	d	d	NOUN
dpc-1025	111	16	research	research	NOUN
dpc-1025	111	17	|	|	ADV
dpc-1025	111	18	dermatol	dermatol	ADJ
dpc-1025	111	19	pract	pract	NOUN
dpc-1025	111	20	concept	concept	NOUN
dpc-1025	111	21	2020;10(1):e2020010	2020;10(1):e2020010	NUM
dpc-1025	111	22	5	5	NUM
dpc-1025	111	23	at	at	ADP
dpc-1025	111	24	diagnosis	diagnosis	NOUN
dpc-1025	111	25	and	and	CCONJ
dpc-1025	111	26	were	be	AUX
dpc-1025	111	27	independently	independently	ADV
dpc-1025	111	28	protective	protective	ADJ
dpc-1025	111	29	of	of	ADP
dpc-1025	111	30	relapse	relapse	NOUN
dpc-1025	111	31	and	and	CCONJ
dpc-1025	111	32	death	death	NOUN
dpc-1025	112	1	[	[	X
dpc-1025	112	2	14	14	NUM
dpc-1025	112	3	]	]	PUNCT
dpc-1025	112	4	.	.	PUNCT
dpc-1025	113	1	among	among	ADP
dpc-1025	113	2	2,182	2,182	NUM
dpc-1025	113	3	participants	participant	NOUN
dpc-1025	113	4	in	in	ADP
dpc-1025	113	5	the	the	DET
dpc-1025	113	6	leeds	leeds	PROPN
dpc-1025	113	7	melanoma	melanoma	PROPN
dpc-1025	113	8	cohort	cohort	NOUN
dpc-1025	113	9	,	,	PUNCT
dpc-1025	113	10	lower	low	ADJ
dpc-1025	113	11	25	25	NUM
dpc-1025	113	12	-	-	PUNCT
dpc-1025	113	13	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	113	14	d	d	NOUN
dpc-1025	113	15	levels	level	NOUN
dpc-1025	113	16	and	and	CCONJ
dpc-1025	113	17	smoking	smoking	NOUN
dpc-1025	113	18	were	be	AUX
dpc-1025	113	19	associated	associate	VERB
dpc-1025	113	20	with	with	ADP
dpc-1025	113	21	ulceration	ulceration	NOUN
dpc-1025	113	22	of	of	ADP
dpc-1025	113	23	primary	primary	ADJ
dpc-1025	113	24	melanomas	melanoma	NOUN
dpc-1025	113	25	and	and	CCONJ
dpc-1025	113	26	poorer	poor	ADJ
dpc-1025	113	27	melanoma	melanoma	NOUN
dpc-1025	113	28	-	-	PUNCT
dpc-1025	113	29	specific	specific	ADJ
dpc-1025	113	30	survival	survival	NOUN
dpc-1025	113	31	[	[	X
dpc-1025	113	32	15	15	NUM
dpc-1025	113	33	]	]	PUNCT
dpc-1025	113	34	.	.	PUNCT
dpc-1025	114	1	in	in	ADP
dpc-1025	114	2	accordance	accordance	NOUN
dpc-1025	114	3	with	with	ADP
dpc-1025	114	4	these	these	DET
dpc-1025	114	5	findings	finding	NOUN
dpc-1025	114	6	,	,	PUNCT
dpc-1025	114	7	other	other	ADJ
dpc-1025	114	8	authors	author	NOUN
dpc-1025	114	9	have	have	AUX
dpc-1025	114	10	found	find	VERB
dpc-1025	114	11	significantly	significantly	ADV
dpc-1025	114	12	lower	low	ADJ
dpc-1025	114	13	median	median	ADJ
dpc-1025	114	14	serum	serum	NOUN
dpc-1025	114	15	25	25	NUM
dpc-1025	114	16	-	-	PUNCT
dpc-1025	114	17	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	114	18	d	d	NOUN
dpc-1025	114	19	concentrations	concentration	NOUN
dpc-1025	114	20	in	in	ADP
dpc-1025	114	21	melanoma	melanoma	NOUN
dpc-1025	114	22	patients	patient	NOUN
dpc-1025	114	23	compared	compare	VERB
dpc-1025	114	24	with	with	ADP
dpc-1025	114	25	healthy	healthy	ADJ
dpc-1025	114	26	controls	control	NOUN
dpc-1025	114	27	and	and	CCONJ
dpc-1025	114	28	combined	combine	VERB
dpc-1025	114	29	these	these	DET
dpc-1025	114	30	lower	low	ADJ
dpc-1025	114	31	serum	serum	NOUN
dpc-1025	114	32	25	25	NUM
dpc-1025	114	33	-	-	PUNCT
dpc-1025	114	34	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	114	35	d	d	NOUN
dpc-1025	114	36	concentrations	concentration	NOUN
dpc-1025	114	37	found	find	VERB
dpc-1025	114	38	in	in	ADP
dpc-1025	114	39	melanoma	melanoma	NOUN
dpc-1025	114	40	patients	patient	NOUN
dpc-1025	114	41	with	with	ADP
dpc-1025	114	42	greater	great	ADJ
dpc-1025	114	43	breslow	breslow	ADJ
dpc-1025	114	44	thickness	thickness	NOUN
dpc-1025	114	45	characteristics	characteristic	NOUN
dpc-1025	114	46	and	and	CCONJ
dpc-1025	114	47	risk	risk	NOUN
dpc-1025	114	48	factors	factor	NOUN
dpc-1025	114	49	for	for	ADP
dpc-1025	114	50	cmm	cmm	NOUN
dpc-1025	114	51	.	.	PUNCT
dpc-1025	115	1	no	no	DET
dpc-1025	115	2	statistically	statistically	ADV
dpc-1025	115	3	significant	significant	ADJ
dpc-1025	115	4	association	association	NOUN
dpc-1025	115	5	between	between	ADP
dpc-1025	115	6	serum	serum	NOUN
dpc-1025	115	7	total	total	ADJ
dpc-1025	115	8	25	25	NUM
dpc-1025	115	9	-	-	PUNCT
dpc-1025	115	10	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	115	11	d	d	NOUN
dpc-1025	115	12	levels	level	NOUN
dpc-1025	115	13	and	and	CCONJ
dpc-1025	115	14	the	the	DET
dpc-1025	115	15	tested	test	VERB
dpc-1025	115	16	parameters	parameter	NOUN
dpc-1025	115	17	was	be	AUX
dpc-1025	115	18	found	find	VERB
dpc-1025	115	19	(	(	PUNCT
dpc-1025	115	20	table	table	NOUN
dpc-1025	115	21	2	2	NUM
dpc-1025	115	22	)	)	PUNCT
dpc-1025	115	23	.	.	PUNCT
dpc-1025	116	1	we	we	PRON
dpc-1025	116	2	also	also	ADV
dpc-1025	116	3	tested	test	VERB
dpc-1025	116	4	the	the	DET
dpc-1025	116	5	correlation	correlation	NOUN
dpc-1025	116	6	of	of	ADP
dpc-1025	116	7	serum	serum	NOUN
dpc-1025	116	8	total	total	ADJ
dpc-1025	116	9	25	25	NUM
dpc-1025	116	10	-	-	PUNCT
dpc-1025	116	11	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	116	12	d	d	NOUN
dpc-1025	116	13	levels	level	NOUN
dpc-1025	116	14	at	at	ADP
dpc-1025	116	15	melanoma	melanoma	ADJ
dpc-1025	116	16	diagnosis	diagnosis	NOUN
dpc-1025	116	17	with	with	ADP
dpc-1025	116	18	prognostic	prognostic	ADJ
dpc-1025	116	19	factors	factor	NOUN
dpc-1025	116	20	,	,	PUNCT
dpc-1025	116	21	such	such	ADJ
dpc-1025	116	22	as	as	ADP
dpc-1025	116	23	breslow	breslow	ADJ
dpc-1025	116	24	thickness	thickness	NOUN
dpc-1025	116	25	and	and	CCONJ
dpc-1025	116	26	ulceration	ulceration	NOUN
dpc-1025	116	27	,	,	PUNCT
dpc-1025	116	28	as	as	ADV
dpc-1025	116	29	well	well	ADV
dpc-1025	116	30	as	as	ADP
dpc-1025	116	31	with	with	ADP
dpc-1025	116	32	clinical	clinical	ADJ
dpc-1025	116	33	characteristics	characteristic	NOUN
dpc-1025	116	34	,	,	PUNCT
dpc-1025	116	35	such	such	ADJ
dpc-1025	116	36	as	as	ADP
dpc-1025	116	37	melanoma	melanoma	NOUN
dpc-1025	116	38	stage	stage	NOUN
dpc-1025	116	39	,	,	PUNCT
dpc-1025	116	40	clinical	clinical	ADJ
dpc-1025	116	41	type	type	NOUN
dpc-1025	116	42	,	,	PUNCT
dpc-1025	116	43	and	and	CCONJ
dpc-1025	116	44	location	location	NOUN
dpc-1025	116	45	,	,	PUNCT
dpc-1025	116	46	after	after	ADP
dpc-1025	116	47	classifying	classify	VERB
dpc-1025	116	48	patients	patient	NOUN
dpc-1025	116	49	into	into	ADP
dpc-1025	116	50	2	2	NUM
dpc-1025	116	51	groups	group	NOUN
dpc-1025	116	52	:	:	PUNCT
dpc-1025	116	53	those	those	PRON
dpc-1025	116	54	with	with	ADP
dpc-1025	116	55	bmi	bmi	PROPN
dpc-1025	116	56	>	>	X
dpc-1025	116	57	25	25	NUM
dpc-1025	116	58	(	(	PUNCT
dpc-1025	116	59	n	n	NOUN
dpc-1025	116	60	=	=	SYM
dpc-1025	116	61	57	57	NUM
dpc-1025	116	62	)	)	PUNCT
dpc-1025	116	63	and	and	CCONJ
dpc-1025	116	64	those	those	PRON
dpc-1025	116	65	with	with	ADP
dpc-1025	116	66	bmi	bmi	PROPN
dpc-1025	116	67	≤25	≤25	PROPN
dpc-1025	116	68	(	(	PUNCT
dpc-1025	116	69	n	n	NOUN
dpc-1025	116	70	=	=	SYM
dpc-1025	116	71	42	42	NUM
dpc-1025	116	72	)	)	PUNCT
dpc-1025	116	73	(	(	PUNCT
dpc-1025	116	74	see	see	VERB
dpc-1025	116	75	table	table	NOUN
dpc-1025	116	76	e1	e1	NOUN
dpc-1025	116	77	of	of	ADP
dpc-1025	116	78	supplementary	supplementary	ADJ
dpc-1025	116	79	content	content	NOUN
dpc-1025	116	80	)	)	PUNCT
dpc-1025	116	81	.	.	PUNCT
dpc-1025	117	1	although	although	SCONJ
dpc-1025	117	2	no	no	DET
dpc-1025	117	3	statistical	statistical	ADJ
dpc-1025	117	4	difference	difference	NOUN
dpc-1025	117	5	was	be	AUX
dpc-1025	117	6	documented	document	VERB
dpc-1025	117	7	,	,	PUNCT
dpc-1025	117	8	we	we	PRON
dpc-1025	117	9	observed	observe	VERB
dpc-1025	117	10	that	that	SCONJ
dpc-1025	117	11	a	a	DET
dpc-1025	117	12	higher	high	ADJ
dpc-1025	117	13	percentage	percentage	NOUN
dpc-1025	117	14	(	(	PUNCT
dpc-1025	117	15	33.33	33.33	NUM
dpc-1025	117	16	%	%	NOUN
dpc-1025	117	17	)	)	PUNCT
dpc-1025	117	18	of	of	ADP
dpc-1025	117	19	melanoma	melanoma	NOUN
dpc-1025	117	20	patients	patient	NOUN
dpc-1025	117	21	with	with	ADP
dpc-1025	117	22	ulceration	ulceration	NOUN
dpc-1025	117	23	and	and	CCONJ
dpc-1025	117	24	bmi	bmi	NOUN
dpc-1025	117	25	>	>	X
dpc-1025	117	26	25	25	NUM
dpc-1025	117	27	had	have	VERB
dpc-1025	117	28	insufficient	insufficient	ADJ
dpc-1025	117	29	serum	serum	NOUN
dpc-1025	117	30	total	total	ADJ
dpc-1025	117	31	25	25	NUM
dpc-1025	117	32	-	-	PUNCT
dpc-1025	117	33	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	117	34	d	d	NOUN
dpc-1025	117	35	levels	level	NOUN
dpc-1025	117	36	compared	compare	VERB
dpc-1025	117	37	with	with	ADP
dpc-1025	117	38	those	those	PRON
dpc-1025	117	39	(	(	PUNCT
dpc-1025	117	40	23.81	23.81	NUM
dpc-1025	117	41	%	%	NOUN
dpc-1025	117	42	)	)	PUNCT
dpc-1025	117	43	without	without	ADP
dpc-1025	117	44	ulceration	ulceration	NOUN
dpc-1025	117	45	.	.	PUNCT
dpc-1025	118	1	moreover	moreover	ADV
dpc-1025	118	2	,	,	PUNCT
dpc-1025	118	3	breslow	breslow	ADJ
dpc-1025	118	4	thickness	thickness	NOUN
dpc-1025	118	5	was	be	AUX
dpc-1025	118	6	not	not	PART
dpc-1025	118	7	associated	associate	VERB
dpc-1025	118	8	with	with	ADP
dpc-1025	118	9	serum	serum	NOUN
dpc-1025	118	10	concentrations	concentration	NOUN
dpc-1025	118	11	of	of	ADP
dpc-1025	118	12	25	25	NUM
dpc-1025	118	13	-	-	PUNCT
dpc-1025	118	14	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	118	15	d	d	NOUN
dpc-1025	118	16	(	(	PUNCT
dpc-1025	118	17	p	p	X
dpc-1025	118	18	=	=	NOUN
dpc-1025	118	19	0.370	0.370	NUM
dpc-1025	118	20	)	)	PUNCT
dpc-1025	118	21	,	,	PUNCT
dpc-1025	118	22	and	and	CCONJ
dpc-1025	118	23	the	the	DET
dpc-1025	118	24	correlation	correlation	NOUN
dpc-1025	118	25	remained	remain	VERB
dpc-1025	118	26	nonsignificant	nonsignificant	ADJ
dpc-1025	118	27	even	even	ADV
dpc-1025	118	28	when	when	SCONJ
dpc-1025	118	29	the	the	DET
dpc-1025	118	30	patients	patient	NOUN
dpc-1025	118	31	were	be	AUX
dpc-1025	118	32	classified	classify	VERB
dpc-1025	118	33	into	into	ADP
dpc-1025	118	34	2	2	NUM
dpc-1025	118	35	subgroups	subgroup	NOUN
dpc-1025	118	36	of	of	ADP
dpc-1025	118	37	early	early	ADJ
dpc-1025	118	38	-	-	PUNCT
dpc-1025	118	39	onset	onset	NOUN
dpc-1025	118	40	(	(	PUNCT
dpc-1025	118	41	<	<	X
dpc-1025	118	42	40	40	NUM
dpc-1025	118	43	years	year	NOUN
dpc-1025	118	44	,	,	PUNCT
dpc-1025	118	45	p	p	X
dpc-1025	118	46	=	=	NOUN
dpc-1025	118	47	0.295	0.295	NUM
dpc-1025	118	48	)	)	PUNCT
dpc-1025	118	49	and	and	CCONJ
dpc-1025	118	50	late	late	ADJ
dpc-1025	118	51	-	-	PUNCT
dpc-1025	118	52	onset	onset	NOUN
dpc-1025	118	53	melanoma	melanoma	NOUN
dpc-1025	118	54	(	(	PUNCT
dpc-1025	118	55	>	>	SYM
dpc-1025	118	56	40	40	NUM
dpc-1025	118	57	years	year	NOUN
dpc-1025	118	58	,	,	PUNCT
dpc-1025	118	59	p	p	NOUN
dpc-1025	118	60	=	=	NOUN
dpc-1025	118	61	0.284	0.284	NUM
dpc-1025	118	62	)	)	PUNCT
dpc-1025	118	63	(	(	PUNCT
dpc-1025	118	64	see	see	VERB
dpc-1025	118	65	table	table	NOUN
dpc-1025	118	66	e2	e2	PROPN
dpc-1025	118	67	of	of	ADP
dpc-1025	118	68	supplementary	supplementary	ADJ
dpc-1025	118	69	content	content	NOUN
dpc-1025	118	70	)	)	PUNCT
dpc-1025	118	71	.	.	PUNCT
dpc-1025	119	1	discussion	discussion	NOUN
dpc-1025	119	2	in	in	ADP
dpc-1025	119	3	the	the	DET
dpc-1025	119	4	present	present	ADJ
dpc-1025	119	5	study	study	NOUN
dpc-1025	119	6	,	,	PUNCT
dpc-1025	119	7	we	we	PRON
dpc-1025	119	8	found	find	VERB
dpc-1025	119	9	lower	low	ADJ
dpc-1025	119	10	median	median	ADJ
dpc-1025	119	11	serum	serum	NOUN
dpc-1025	119	12	total	total	ADJ
dpc-1025	119	13	25	25	NUM
dpc-1025	119	14	-	-	PUNCT
dpc-1025	119	15	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	119	16	d	d	PROPN
dpc-1025	119	17	levels	level	NOUN
dpc-1025	119	18	among	among	ADP
dpc-1025	119	19	melanoma	melanoma	NOUN
dpc-1025	119	20	patients	patient	NOUN
dpc-1025	119	21	compared	compare	VERB
dpc-1025	119	22	with	with	ADP
dpc-1025	119	23	healthy	healthy	ADJ
dpc-1025	119	24	controls	control	NOUN
dpc-1025	119	25	,	,	PUNCT
dpc-1025	119	26	but	but	CCONJ
dpc-1025	119	27	the	the	DET
dpc-1025	119	28	difference	difference	NOUN
dpc-1025	119	29	did	do	AUX
dpc-1025	119	30	not	not	PART
dpc-1025	119	31	reach	reach	VERB
dpc-1025	119	32	statistical	statistical	ADJ
dpc-1025	119	33	significance	significance	NOUN
dpc-1025	119	34	(	(	PUNCT
dpc-1025	119	35	p	p	X
dpc-1025	119	36	=	=	PROPN
dpc-1025	119	37	0.051	0.051	NUM
dpc-1025	119	38	)	)	PUNCT
dpc-1025	119	39	.	.	PUNCT
dpc-1025	120	1	possible	possible	ADJ
dpc-1025	120	2	explanations	explanation	NOUN
dpc-1025	120	3	for	for	ADP
dpc-1025	120	4	this	this	DET
dpc-1025	120	5	finding	finding	NOUN
dpc-1025	120	6	may	may	AUX
dpc-1025	120	7	be	be	AUX
dpc-1025	120	8	the	the	DET
dpc-1025	120	9	relatively	relatively	ADV
dpc-1025	120	10	small	small	ADJ
dpc-1025	120	11	number	number	NOUN
dpc-1025	120	12	of	of	ADP
dpc-1025	120	13	patients	patient	NOUN
dpc-1025	120	14	,	,	PUNCT
dpc-1025	120	15	though	though	SCONJ
dpc-1025	120	16	representative	representative	NOUN
dpc-1025	120	17	of	of	ADP
dpc-1025	120	18	the	the	DET
dpc-1025	120	19	low	low	ADJ
dpc-1025	120	20	incidence	incidence	NOUN
dpc-1025	120	21	of	of	ADP
dpc-1025	120	22	melanoma	melanoma	NOUN
dpc-1025	120	23	in	in	ADP
dpc-1025	120	24	greece	greece	PROPN
dpc-1025	120	25	,	,	PUNCT
dpc-1025	120	26	and	and	CCONJ
dpc-1025	120	27	the	the	DET
dpc-1025	120	28	narrow	narrow	ADJ
dpc-1025	120	29	variations	variation	NOUN
dpc-1025	120	30	of	of	ADP
dpc-1025	120	31	the	the	DET
dpc-1025	120	32	median	median	NOUN
dpc-1025	120	33	(	(	PUNCT
dpc-1025	120	34	interquartile	interquartile	NOUN
dpc-1025	120	35	range	range	PROPN
dpc-1025	120	36	)	)	PUNCT
dpc-1025	120	37	serum	serum	VERB
dpc-1025	120	38	25	25	NUM
dpc-1025	120	39	-	-	PUNCT
dpc-1025	120	40	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	120	41	d	d	NOUN
dpc-1025	120	42	levels	level	NOUN
dpc-1025	120	43	between	between	ADP
dpc-1025	120	44	patients	patient	NOUN
dpc-1025	120	45	and	and	CCONJ
dpc-1025	120	46	healthy	healthy	ADJ
dpc-1025	120	47	controls	control	NOUN
dpc-1025	120	48	(	(	PUNCT
dpc-1025	120	49	table	table	NOUN
dpc-1025	120	50	1	1	NUM
dpc-1025	120	51	)	)	PUNCT
dpc-1025	120	52	,	,	PUNCT
dpc-1025	120	53	as	as	SCONJ
dpc-1025	120	54	both	both	DET
dpc-1025	120	55	groups	group	NOUN
dpc-1025	120	56	had	have	VERB
dpc-1025	120	57	median	median	ADJ
dpc-1025	120	58	values	value	NOUN
dpc-1025	120	59	of	of	ADP
dpc-1025	120	60	serum	serum	NOUN
dpc-1025	120	61	total	total	ADJ
dpc-1025	120	62	25	25	NUM
dpc-1025	120	63	-	-	PUNCT
dpc-1025	120	64	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	120	65	d	d	NOUN
dpc-1025	120	66	in	in	ADP
dpc-1025	120	67	the	the	DET
dpc-1025	120	68	range	range	NOUN
dpc-1025	120	69	of	of	ADP
dpc-1025	120	70	vitamin	vitamin	NOUN
dpc-1025	120	71	d	d	NOUN
dpc-1025	120	72	insufficiency	insufficiency	NOUN
dpc-1025	120	73	(	(	PUNCT
dpc-1025	120	74	20.62	20.62	NUM
dpc-1025	120	75	ng	ng	NOUN
dpc-1025	120	76	/	/	SYM
dpc-1025	120	77	ml	ml	X
dpc-1025	120	78	for	for	ADP
dpc-1025	120	79	the	the	DET
dpc-1025	120	80	melanoma	melanoma	NOUN
dpc-1025	120	81	patients	patient	NOUN
dpc-1025	120	82	and	and	CCONJ
dpc-1025	120	83	24.71	24.71	NUM
dpc-1025	120	84	ng	ng	NOUN
dpc-1025	120	85	/	/	SYM
dpc-1025	120	86	ml	ml	X
dpc-1025	120	87	for	for	ADP
dpc-1025	120	88	the	the	DET
dpc-1025	120	89	healthy	healthy	ADJ
dpc-1025	120	90	controls	control	NOUN
dpc-1025	120	91	.	.	PUNCT
dpc-1025	121	1	in	in	ADP
dpc-1025	121	2	contrast	contrast	NOUN
dpc-1025	121	3	,	,	PUNCT
dpc-1025	121	4	no	no	DET
dpc-1025	121	5	statistically	statistically	ADV
dpc-1025	121	6	significant	significant	ADJ
dpc-1025	121	7	associations	association	NOUN
dpc-1025	121	8	were	be	AUX
dpc-1025	121	9	documented	document	VERB
dpc-1025	121	10	between	between	ADP
dpc-1025	121	11	serum	serum	NOUN
dpc-1025	121	12	total	total	ADJ
dpc-1025	121	13	25	25	NUM
dpc-1025	121	14	-	-	PUNCT
dpc-1025	121	15	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	121	16	d	d	NOUN
dpc-1025	121	17	levels	level	NOUN
dpc-1025	121	18	at	at	ADP
dpc-1025	121	19	melanoma	melanoma	ADJ
dpc-1025	121	20	diagnosis	diagnosis	NOUN
dpc-1025	121	21	and	and	CCONJ
dpc-1025	121	22	demographic	demographic	ADJ
dpc-1025	121	23	characteristics	characteristic	NOUN
dpc-1025	121	24	,	,	PUNCT
dpc-1025	121	25	risk	risk	NOUN
dpc-1025	121	26	factors	factor	NOUN
dpc-1025	121	27	for	for	ADP
dpc-1025	121	28	cmm	cmm	NOUN
dpc-1025	121	29	,	,	PUNCT
dpc-1025	121	30	clinical	clinical	ADJ
dpc-1025	121	31	characteristics	characteristic	NOUN
dpc-1025	121	32	,	,	PUNCT
dpc-1025	121	33	and	and	CCONJ
dpc-1025	121	34	prognostic	prognostic	ADJ
dpc-1025	121	35	factors	factor	NOUN
dpc-1025	121	36	,	,	PUNCT
dpc-1025	121	37	such	such	ADJ
dpc-1025	121	38	as	as	ADP
dpc-1025	121	39	breslow	breslow	ADJ
dpc-1025	121	40	thickness	thickness	NOUN
dpc-1025	121	41	,	,	PUNCT
dpc-1025	121	42	ulceration	ulceration	NOUN
dpc-1025	121	43	,	,	PUNCT
dpc-1025	121	44	and	and	CCONJ
dpc-1025	121	45	melanoma	melanoma	NOUN
dpc-1025	121	46	stage	stage	NOUN
dpc-1025	121	47	.	.	PUNCT
dpc-1025	122	1	to	to	ADP
dpc-1025	122	2	our	our	PRON
dpc-1025	122	3	knowledge	knowledge	NOUN
dpc-1025	122	4	this	this	PRON
dpc-1025	122	5	is	be	AUX
dpc-1025	122	6	the	the	DET
dpc-1025	122	7	first	first	ADJ
dpc-1025	122	8	study	study	NOUN
dpc-1025	122	9	to	to	PART
dpc-1025	122	10	assess	assess	VERB
dpc-1025	122	11	serum	serum	NOUN
dpc-1025	122	12	total	total	ADJ
dpc-1025	122	13	25	25	NUM
dpc-1025	122	14	-	-	PUNCT
dpc-1025	122	15	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	122	16	d	d	NOUN
dpc-1025	122	17	at	at	ADP
dpc-1025	122	18	the	the	DET
dpc-1025	122	19	time	time	NOUN
dpc-1025	122	20	of	of	ADP
dpc-1025	122	21	melanoma	melanoma	ADJ
dpc-1025	122	22	diagnosis	diagnosis	NOUN
dpc-1025	122	23	and	and	CCONJ
dpc-1025	122	24	examine	examine	VERB
dpc-1025	122	25	its	its	PRON
dpc-1025	122	26	correlation	correlation	NOUN
dpc-1025	122	27	with	with	ADP
dpc-1025	122	28	clinical	clinical	ADJ
dpc-1025	122	29	and	and	CCONJ
dpc-1025	122	30	histological	histological	ADJ
dpc-1025	122	31	variables	variable	NOUN
dpc-1025	122	32	in	in	ADP
dpc-1025	122	33	a	a	DET
dpc-1025	122	34	low	low	ADJ
dpc-1025	122	35	-	-	PUNCT
dpc-1025	122	36	incidence	incidence	NOUN
dpc-1025	122	37	southern	southern	ADJ
dpc-1025	122	38	european	european	ADJ
dpc-1025	122	39	country	country	NOUN
dpc-1025	122	40	with	with	ADP
dpc-1025	122	41	high	high	ADJ
dpc-1025	122	42	year	year	NOUN
dpc-1025	122	43	-	-	PUNCT
dpc-1025	122	44	round	round	NOUN
dpc-1025	122	45	ambient	ambient	ADJ
dpc-1025	122	46	uvr	uvr	NOUN
dpc-1025	122	47	levels	level	NOUN
dpc-1025	122	48	.	.	PUNCT
dpc-1025	123	1	in	in	ADP
dpc-1025	123	2	recent	recent	ADJ
dpc-1025	123	3	years	year	NOUN
dpc-1025	123	4	,	,	PUNCT
dpc-1025	123	5	various	various	ADJ
dpc-1025	123	6	studies	study	NOUN
dpc-1025	123	7	have	have	AUX
dpc-1025	123	8	focused	focus	VERB
dpc-1025	123	9	on	on	ADP
dpc-1025	123	10	the	the	DET
dpc-1025	123	11	role	role	NOUN
dpc-1025	123	12	of	of	ADP
dpc-1025	123	13	vitamin	vitamin	NOUN
dpc-1025	123	14	d	d	NOUN
dpc-1025	123	15	status	status	NOUN
dpc-1025	123	16	in	in	ADP
dpc-1025	123	17	cmm	cmm	PROPN
dpc-1025	123	18	risk	risk	NOUN
dpc-1025	123	19	and	and	CCONJ
dpc-1025	123	20	progression	progression	NOUN
dpc-1025	123	21	.	.	PUNCT
dpc-1025	124	1	overall	overall	ADJ
dpc-1025	124	2	lower	low	ADJ
dpc-1025	124	3	serum	serum	NOUN
dpc-1025	124	4	vitamin	vitamin	NOUN
dpc-1025	124	5	d	d	NOUN
dpc-1025	124	6	levels	level	NOUN
dpc-1025	124	7	at	at	ADP
dpc-1025	124	8	melanoma	melanoma	ADJ
dpc-1025	124	9	diagnosis	diagnosis	NOUN
dpc-1025	124	10	have	have	AUX
dpc-1025	124	11	been	be	AUX
dpc-1025	124	12	associated	associate	VERB
dpc-1025	124	13	with	with	ADP
dpc-1025	124	14	an	an	DET
dpc-1025	124	15	increased	increase	VERB
dpc-1025	124	16	incidence	incidence	NOUN
dpc-1025	124	17	of	of	ADP
dpc-1025	124	18	cmm	cmm	NOUN
dpc-1025	124	19	and	and	CCONJ
dpc-1025	124	20	worse	bad	ADJ
dpc-1025	124	21	prognosis	prognosis	NOUN
dpc-1025	124	22	.	.	PUNCT
dpc-1025	125	1	in	in	ADP
dpc-1025	125	2	a	a	DET
dpc-1025	125	3	prospective	prospective	ADJ
dpc-1025	125	4	study	study	NOUN
dpc-1025	125	5	of	of	ADP
dpc-1025	125	6	271	271	NUM
dpc-1025	125	7	melanoma	melanoma	NOUN
dpc-1025	125	8	patients	patient	NOUN
dpc-1025	125	9	in	in	ADP
dpc-1025	125	10	uk	uk	PROPN
dpc-1025	125	11	,	,	PUNCT
dpc-1025	125	12	newton	newton	PROPN
dpc-1025	125	13	-	-	PUNCT
dpc-1025	125	14	bishop	bishop	PROPN
dpc-1025	125	15	et	et	PROPN
dpc-1025	125	16	al	al	PROPN
dpc-1025	125	17	found	find	VERB
dpc-1025	125	18	that	that	SCONJ
dpc-1025	125	19	higher	high	ADJ
dpc-1025	125	20	25	25	NUM
dpc-1025	125	21	-	-	PUNCT
dpc-1025	125	22	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	125	23	d3	d3	PROPN
dpc-1025	125	24	levels	level	NOUN
dpc-1025	125	25	were	be	AUX
dpc-1025	125	26	associated	associate	VERB
dpc-1025	125	27	with	with	ADP
dpc-1025	125	28	lower	low	ADJ
dpc-1025	125	29	breslow	breslow	ADJ
dpc-1025	125	30	thickness	thickness	NOUN
dpc-1025	125	31	table	table	NOUN
dpc-1025	125	32	3	3	NUM
dpc-1025	125	33	.	.	PUNCT
dpc-1025	125	34	descriptive	descriptive	ADJ
dpc-1025	125	35	statistics	statistic	NOUN
dpc-1025	125	36	of	of	ADP
dpc-1025	125	37	clinical	clinical	ADJ
dpc-1025	125	38	and	and	CCONJ
dpc-1025	125	39	histological	histological	ADJ
dpc-1025	125	40	characteristics	characteristic	NOUN
dpc-1025	125	41	and	and	CCONJ
dpc-1025	125	42	association	association	NOUN
dpc-1025	125	43	with	with	ADP
dpc-1025	125	44	serum	serum	NOUN
dpc-1025	125	45	25	25	NUM
dpc-1025	125	46	-	-	PUNCT
dpc-1025	125	47	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	125	48	d	d	NOUN
dpc-1025	125	49	levels	level	NOUN
dpc-1025	125	50	n	n	CCONJ
dpc-1025	125	51	(	(	PUNCT
dpc-1025	125	52	%	%	INTJ
dpc-1025	125	53	)	)	PUNCT
dpc-1025	125	54	p	p	NOUN
dpc-1025	125	55	valuea	valuea	ADJ
dpc-1025	125	56	melanoma	melanoma	NOUN
dpc-1025	125	57	location	location	NOUN
dpc-1025	125	58	0.139b	0.139b	PROPN
dpc-1025	125	59	trunk	trunk	NOUN
dpc-1025	125	60	45	45	NUM
dpc-1025	125	61	(	(	PUNCT
dpc-1025	125	62	45.45	45.45	NUM
dpc-1025	125	63	)	)	PUNCT
dpc-1025	125	64	extremities	extremity	NOUN
dpc-1025	125	65	43	43	NUM
dpc-1025	125	66	(	(	PUNCT
dpc-1025	125	67	43.43	43.43	NUM
dpc-1025	125	68	)	)	PUNCT
dpc-1025	125	69	face	face	NOUN
dpc-1025	125	70	and	and	CCONJ
dpc-1025	125	71	neck	neck	NOUN
dpc-1025	125	72	11	11	NUM
dpc-1025	125	73	(	(	PUNCT
dpc-1025	125	74	11.11	11.11	NUM
dpc-1025	125	75	)	)	PUNCT
dpc-1025	125	76	melanoma	melanoma	NOUN
dpc-1025	125	77	type	type	NOUN
dpc-1025	125	78	0.128b	0.128b	PROPN
dpc-1025	125	79	lmm	lmm	PROPN
dpc-1025	125	80	3	3	NUM
dpc-1025	125	81	(	(	PUNCT
dpc-1025	125	82	3.03	3.03	NUM
dpc-1025	125	83	)	)	PUNCT
dpc-1025	125	84	ssm	ssm	NOUN
dpc-1025	125	85	76	76	NUM
dpc-1025	125	86	(	(	PUNCT
dpc-1025	125	87	76.77	76.77	NUM
dpc-1025	125	88	)	)	PUNCT
dpc-1025	125	89	nm	nm	ADV
dpc-1025	125	90	16	16	NUM
dpc-1025	125	91	(	(	PUNCT
dpc-1025	125	92	16.16	16.16	NUM
dpc-1025	125	93	)	)	PUNCT
dpc-1025	125	94	alm	alm	NOUN
dpc-1025	125	95	2	2	NUM
dpc-1025	125	96	(	(	PUNCT
dpc-1025	125	97	2.02	2.02	NUM
dpc-1025	125	98	)	)	PUNCT
dpc-1025	125	99	other	other	ADJ
dpc-1025	125	100	2	2	NUM
dpc-1025	125	101	(	(	PUNCT
dpc-1025	125	102	2.02	2.02	NUM
dpc-1025	125	103	)	)	PUNCT
dpc-1025	125	104	stage	stage	NOUN
dpc-1025	125	105	0.602b	0.602b	NOUN
dpc-1025	125	106	in	in	ADP
dpc-1025	125	107	situ	situ	PROPN
dpc-1025	125	108	5	5	NUM
dpc-1025	125	109	(	(	PUNCT
dpc-1025	125	110	5.05	5.05	NUM
dpc-1025	125	111	)	)	PUNCT
dpc-1025	125	112	i	i	PRON
dpc-1025	125	113	63	63	NUM
dpc-1025	125	114	(	(	PUNCT
dpc-1025	125	115	63.64	63.64	NUM
dpc-1025	125	116	)	)	PUNCT
dpc-1025	125	117	ii	ii	NOUN
dpc-1025	125	118	19	19	NUM
dpc-1025	125	119	(	(	PUNCT
dpc-1025	125	120	19.19	19.19	NUM
dpc-1025	125	121	)	)	PUNCT
dpc-1025	125	122	iii	iii	X
dpc-1025	125	123	11	11	NUM
dpc-1025	125	124	(	(	PUNCT
dpc-1025	125	125	11.11	11.11	NUM
dpc-1025	125	126	)	)	PUNCT
dpc-1025	125	127	iv	iv	NUM
dpc-1025	125	128	1	1	NUM
dpc-1025	125	129	(	(	PUNCT
dpc-1025	125	130	1.01	1.01	NUM
dpc-1025	125	131	)	)	PUNCT
dpc-1025	125	132	deaths	death	NOUN
dpc-1025	125	133	0.566	0.566	NUM
dpc-1025	125	134	yes	yes	NOUN
dpc-1025	125	135	4	4	NUM
dpc-1025	125	136	(	(	PUNCT
dpc-1025	125	137	4.04	4.04	NUM
dpc-1025	125	138	)	)	PUNCT
dpc-1025	125	139	no	no	PRON
dpc-1025	125	140	95	95	NUM
dpc-1025	125	141	(	(	PUNCT
dpc-1025	125	142	95.96	95.96	NUM
dpc-1025	125	143	)	)	PUNCT
dpc-1025	125	144	recurrence	recurrence	NOUN
dpc-1025	125	145	0.359b	0.359b	ADJ
dpc-1025	125	146	yes	yes	PRON
dpc-1025	125	147	6	6	NUM
dpc-1025	125	148	(	(	PUNCT
dpc-1025	125	149	6.06	6.06	NUM
dpc-1025	125	150	)	)	PUNCT
dpc-1025	125	151	no	no	DET
dpc-1025	125	152	93	93	NUM
dpc-1025	125	153	(	(	PUNCT
dpc-1025	125	154	93.94	93.94	NUM
dpc-1025	125	155	)	)	PUNCT
dpc-1025	125	156	breslow	breslow	NOUN
dpc-1025	125	157	level	level	NOUN
dpc-1025	125	158	0.370	0.370	NUM
dpc-1025	125	159	<	<	X
dpc-1025	125	160	1	1	NUM
dpc-1025	125	161	mm	mm	NUM
dpc-1025	125	162	52	52	NUM
dpc-1025	125	163	(	(	PUNCT
dpc-1025	125	164	52.53	52.53	NUM
dpc-1025	125	165	)	)	PUNCT
dpc-1025	125	166	1	1	NUM
dpc-1025	125	167	-	-	SYM
dpc-1025	125	168	4	4	NUM
dpc-1025	125	169	mm	mm	NUM
dpc-1025	125	170	33	33	NUM
dpc-1025	125	171	(	(	PUNCT
dpc-1025	125	172	33.33	33.33	NUM
dpc-1025	125	173	)	)	PUNCT
dpc-1025	125	174	>	>	PUNCT
dpc-1025	125	175	4	4	NUM
dpc-1025	125	176	mm	mm	NUM
dpc-1025	125	177	14	14	NUM
dpc-1025	125	178	(	(	PUNCT
dpc-1025	125	179	14.14	14.14	NUM
dpc-1025	125	180	)	)	PUNCT
dpc-1025	125	181	ulceration	ulceration	NOUN
dpc-1025	125	182	0.494	0.494	NUM
dpc-1025	125	183	yes	yes	NOUN
dpc-1025	125	184	31	31	NUM
dpc-1025	125	185	(	(	PUNCT
dpc-1025	125	186	31.31	31.31	NUM
dpc-1025	125	187	)	)	PUNCT
dpc-1025	125	188	no	no	DET
dpc-1025	125	189	68	68	NUM
dpc-1025	125	190	(	(	PUNCT
dpc-1025	125	191	68.69	68.69	NUM
dpc-1025	125	192	)	)	PUNCT
dpc-1025	125	193	achi	achi	ADJ
dpc-1025	125	194	-	-	PUNCT
dpc-1025	125	195	square	square	ADJ
dpc-1025	125	196	test	test	NOUN
dpc-1025	125	197	(	(	PUNCT
dpc-1025	125	198	unless	unless	SCONJ
dpc-1025	125	199	specified	specify	VERB
dpc-1025	125	200	otherwise	otherwise	ADV
dpc-1025	125	201	)	)	PUNCT
dpc-1025	125	202	.	.	PUNCT
dpc-1025	126	1	bfisher	bfisher	PROPN
dpc-1025	126	2	exact	exact	ADJ
dpc-1025	126	3	test	test	NOUN
dpc-1025	126	4	.	.	PUNCT
dpc-1025	127	1	n	n	PROPN
dpc-1025	127	2	(	(	PUNCT
dpc-1025	127	3	%	%	INTJ
dpc-1025	127	4	)	)	PUNCT
dpc-1025	127	5	=	=	NOUN
dpc-1025	127	6	frequency	frequency	NOUN
dpc-1025	127	7	(	(	PUNCT
dpc-1025	127	8	percentage	percentage	NOUN
dpc-1025	127	9	)	)	PUNCT
dpc-1025	127	10	;	;	PUNCT
dpc-1025	127	11	lmm	lmm	PROPN
dpc-1025	127	12	=	=	SYM
dpc-1025	127	13	lentigo	lentigo	ADJ
dpc-1025	127	14	malignant	malignant	ADJ
dpc-1025	127	15	melanoma	melanoma	NOUN
dpc-1025	127	16	;	;	PUNCT
dpc-1025	128	1	ssm	ssm	NOUN
dpc-1025	128	2	=	=	PROPN
dpc-1025	128	3	superficial	superficial	ADJ
dpc-1025	128	4	spreading	spread	VERB
dpc-1025	128	5	melanoma	melanoma	NOUN
dpc-1025	128	6	;	;	PUNCT
dpc-1025	128	7	nm	nm	ADJ
dpc-1025	128	8	=	=	PUNCT
dpc-1025	128	9	nodular	nodular	ADJ
dpc-1025	128	10	melanoma	melanoma	NOUN
dpc-1025	128	11	;	;	PUNCT
dpc-1025	128	12	alm	alm	NOUN
dpc-1025	128	13	=	=	SYM
dpc-1025	128	14	acral	acral	ADJ
dpc-1025	128	15	lentiginous	lentiginous	ADJ
dpc-1025	128	16	melanoma	melanoma	NOUN
dpc-1025	128	17	.	.	PUNCT
dpc-1025	129	1	6	6	NUM
dpc-1025	129	2	research	research	NOUN
dpc-1025	129	3	|	|	ADV
dpc-1025	129	4	dermatol	dermatol	NOUN
dpc-1025	129	5	pract	pract	NOUN
dpc-1025	129	6	concept	concept	NOUN
dpc-1025	129	7	2020;10(1):e2020010	2020;10(1):e2020010	PRON
dpc-1025	129	8	found	find	VERB
dpc-1025	129	9	deficient	deficient	ADJ
dpc-1025	129	10	total	total	ADJ
dpc-1025	129	11	25	25	NUM
dpc-1025	129	12	-	-	PUNCT
dpc-1025	129	13	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	129	14	d	d	PROPN
dpc-1025	129	15	levels	level	NOUN
dpc-1025	129	16	among	among	ADP
dpc-1025	129	17	our	our	PRON
dpc-1025	129	18	healthy	healthy	ADJ
dpc-1025	129	19	controls	control	NOUN
dpc-1025	129	20	,	,	PUNCT
dpc-1025	129	21	in	in	ADP
dpc-1025	129	22	agreement	agreement	NOUN
dpc-1025	129	23	with	with	ADP
dpc-1025	129	24	previous	previous	ADJ
dpc-1025	129	25	greek	greek	ADJ
dpc-1025	129	26	experience	experience	NOUN
dpc-1025	129	27	in	in	ADP
dpc-1025	129	28	various	various	ADJ
dpc-1025	129	29	settings	setting	NOUN
dpc-1025	129	30	.	.	PUNCT
dpc-1025	130	1	this	this	PRON
dpc-1025	130	2	raises	raise	VERB
dpc-1025	130	3	the	the	DET
dpc-1025	130	4	discussion	discussion	NOUN
dpc-1025	130	5	on	on	ADP
dpc-1025	130	6	what	what	PRON
dpc-1025	130	7	is	be	AUX
dpc-1025	130	8	sufficient	sufficient	ADJ
dpc-1025	130	9	and	and	CCONJ
dpc-1025	130	10	necessary	necessary	ADJ
dpc-1025	130	11	for	for	ADP
dpc-1025	130	12	different	different	ADJ
dpc-1025	130	13	population	population	NOUN
dpc-1025	130	14	types	type	NOUN
dpc-1025	130	15	[	[	X
dpc-1025	130	16	31,32	31,32	NUM
dpc-1025	130	17	]	]	PUNCT
dpc-1025	130	18	.	.	PUNCT
dpc-1025	131	1	our	our	PRON
dpc-1025	131	2	findings	finding	NOUN
dpc-1025	131	3	are	be	AUX
dpc-1025	131	4	more	more	ADV
dpc-1025	131	5	consistent	consistent	ADJ
dpc-1025	131	6	with	with	ADP
dpc-1025	131	7	 	 	SPACE
dpc-1025	131	8	the	the	DET
dpc-1025	131	9	us	us	PROPN
dpc-1025	131	10	institute	institute	PROPN
dpc-1025	131	11	of	of	ADP
dpc-1025	131	12	medicine	medicine	PROPN
dpc-1025	131	13	cutoff	cutoff	NOUN
dpc-1025	131	14	levels	level	NOUN
dpc-1025	131	15	for	for	ADP
dpc-1025	131	16	serum	serum	NOUN
dpc-1025	131	17	25	25	NUM
dpc-1025	131	18	-	-	PUNCT
dpc-1025	131	19	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	131	20	d	d	NOUN
dpc-1025	131	21	sufficiency	sufficiency	NOUN
dpc-1025	131	22	in	in	ADP
dpc-1025	131	23	almost	almost	ADV
dpc-1025	131	24	the	the	DET
dpc-1025	131	25	entire	entire	ADJ
dpc-1025	131	26	(	(	PUNCT
dpc-1025	131	27	97.5	97.5	NUM
dpc-1025	131	28	%	%	NOUN
dpc-1025	131	29	)	)	PUNCT
dpc-1025	131	30	caucasian	caucasian	ADJ
dpc-1025	131	31	population	population	NOUN
dpc-1025	131	32	(	(	PUNCT
dpc-1025	131	33	>	>	SYM
dpc-1025	131	34	20	20	NUM
dpc-1025	131	35	ng	ng	PROPN
dpc-1025	131	36	/	/	SYM
dpc-1025	131	37	ml	ml	PROPN
dpc-1025	131	38	)	)	PUNCT
dpc-1025	131	39	and	and	CCONJ
dpc-1025	131	40	less	less	ADV
dpc-1025	131	41	consistent	consistent	ADJ
dpc-1025	131	42	with	with	ADP
dpc-1025	131	43	the	the	DET
dpc-1025	131	44	endocrine	endocrine	ADJ
dpc-1025	131	45	society	society	NOUN
dpc-1025	131	46	standards	standard	NOUN
dpc-1025	131	47	(	(	PUNCT
dpc-1025	131	48	>	>	SYM
dpc-1025	131	49	30	30	NUM
dpc-1025	131	50	ng	ng	NOUN
dpc-1025	131	51	/	/	SYM
dpc-1025	131	52	ml	ml	NOUN
dpc-1025	131	53	)	)	PUNCT
dpc-1025	132	1	[	[	X
dpc-1025	132	2	33,34	33,34	NOUN
dpc-1025	132	3	]	]	PUNCT
dpc-1025	132	4	.	.	PUNCT
dpc-1025	133	1	the	the	DET
dpc-1025	133	2	prognostic	prognostic	ADJ
dpc-1025	133	3	significance	significance	NOUN
dpc-1025	133	4	of	of	ADP
dpc-1025	133	5	serum	serum	NOUN
dpc-1025	133	6	25	25	NUM
dpc-1025	133	7	-	-	PUNCT
dpc-1025	133	8	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	133	9	d	d	NOUN
dpc-1025	133	10	levels	level	NOUN
dpc-1025	133	11	at	at	ADP
dpc-1025	133	12	melanoma	melanoma	ADJ
dpc-1025	133	13	diagnosis	diagnosis	NOUN
dpc-1025	133	14	remains	remain	VERB
dpc-1025	133	15	controversial	controversial	ADJ
dpc-1025	133	16	.	.	PUNCT
dpc-1025	134	1	in	in	ADP
dpc-1025	134	2	the	the	DET
dpc-1025	134	3	present	present	ADJ
dpc-1025	134	4	study	study	NOUN
dpc-1025	134	5	,	,	PUNCT
dpc-1025	134	6	no	no	DET
dpc-1025	134	7	significant	significant	ADJ
dpc-1025	134	8	association	association	NOUN
dpc-1025	134	9	with	with	ADP
dpc-1025	134	10	breslow	breslow	ADJ
dpc-1025	134	11	thickness	thickness	NOUN
dpc-1025	134	12	and	and	CCONJ
dpc-1025	134	13	melanoma	melanoma	NOUN
dpc-1025	134	14	stage	stage	NOUN
dpc-1025	134	15	was	be	AUX
dpc-1025	134	16	documented	document	VERB
dpc-1025	134	17	.	.	PUNCT
dpc-1025	135	1	a	a	DET
dpc-1025	135	2	possible	possible	ADJ
dpc-1025	135	3	explanation	explanation	NOUN
dpc-1025	135	4	for	for	ADP
dpc-1025	135	5	that	that	PRON
dpc-1025	135	6	could	could	AUX
dpc-1025	135	7	be	be	AUX
dpc-1025	135	8	that	that	SCONJ
dpc-1025	135	9	our	our	PRON
dpc-1025	135	10	sample	sample	NOUN
dpc-1025	135	11	consisted	consist	VERB
dpc-1025	135	12	mostly	mostly	ADV
dpc-1025	135	13	of	of	ADP
dpc-1025	135	14	thin	thin	ADJ
dpc-1025	135	15	melanomas	melanomas	NOUN
dpc-1025	135	16	(	(	PUNCT
dpc-1025	135	17	52.38	52.38	NUM
dpc-1025	135	18	%	%	NOUN
dpc-1025	135	19	of	of	ADP
dpc-1025	135	20	them	they	PRON
dpc-1025	135	21	had	have	AUX
dpc-1025	135	22	breslow	breslow	ADJ
dpc-1025	135	23	thickness	thickness	NOUN
dpc-1025	135	24	<	<	X
dpc-1025	135	25	1	1	NUM
dpc-1025	135	26	mm	mm	NOUN
dpc-1025	135	27	)	)	PUNCT
dpc-1025	135	28	and	and	CCONJ
dpc-1025	135	29	there	there	PRON
dpc-1025	135	30	was	be	VERB
dpc-1025	135	31	only	only	ADV
dpc-1025	135	32	1	1	NUM
dpc-1025	135	33	stage	stage	NOUN
dpc-1025	135	34	iv	iv	NUM
dpc-1025	135	35	case	case	NOUN
dpc-1025	135	36	.	.	PUNCT
dpc-1025	136	1	it	it	PRON
dpc-1025	136	2	is	be	AUX
dpc-1025	136	3	of	of	ADP
dpc-1025	136	4	note	note	NOUN
dpc-1025	136	5	that	that	SCONJ
dpc-1025	136	6	most	most	ADJ
dpc-1025	136	7	studies	study	NOUN
dpc-1025	136	8	showing	show	VERB
dpc-1025	136	9	significant	significant	ADJ
dpc-1025	136	10	association	association	NOUN
dpc-1025	136	11	between	between	ADP
dpc-1025	136	12	serum	serum	NOUN
dpc-1025	136	13	25	25	NUM
dpc-1025	136	14	-	-	PUNCT
dpc-1025	136	15	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	136	16	d	d	NOUN
dpc-1025	136	17	and	and	CCONJ
dpc-1025	136	18	breslow	breslow	ADJ
dpc-1025	136	19	thickness	thickness	NOUN
dpc-1025	136	20	and/or	and/or	CCONJ
dpc-1025	136	21	melanoma	melanoma	NOUN
dpc-1025	136	22	stage	stage	NOUN
dpc-1025	136	23	originate	originate	VERB
dpc-1025	136	24	from	from	ADP
dpc-1025	136	25	countries	country	NOUN
dpc-1025	136	26	with	with	ADP
dpc-1025	136	27	high	high	ADJ
dpc-1025	136	28	melanoma	melanoma	NOUN
dpc-1025	136	29	incidence	incidence	NOUN
dpc-1025	136	30	rates	rate	NOUN
dpc-1025	136	31	such	such	ADJ
dpc-1025	136	32	as	as	ADP
dpc-1025	136	33	australia	australia	PROPN
dpc-1025	136	34	,	,	PUNCT
dpc-1025	136	35	united	united	ADJ
dpc-1025	136	36	kingdom	kingdom	PROPN
dpc-1025	136	37	,	,	PUNCT
dpc-1025	136	38	germany	germany	PROPN
dpc-1025	136	39	,	,	PUNCT
dpc-1025	136	40	and	and	CCONJ
dpc-1025	136	41	italy	italy	PROPN
dpc-1025	137	1	[	[	X
dpc-1025	137	2	14,16	14,16	NUM
dpc-1025	137	3	-	-	SYM
dpc-1025	137	4	19	19	NUM
dpc-1025	137	5	]	]	PUNCT
dpc-1025	137	6	.	.	PUNCT
dpc-1025	138	1	in	in	ADP
dpc-1025	138	2	contrast	contrast	NOUN
dpc-1025	138	3	,	,	PUNCT
dpc-1025	138	4	the	the	DET
dpc-1025	138	5	incidence	incidence	NOUN
dpc-1025	138	6	in	in	ADP
dpc-1025	138	7	greece	greece	PROPN
dpc-1025	138	8	is	be	AUX
dpc-1025	138	9	low	low	ADJ
dpc-1025	138	10	and	and	CCONJ
dpc-1025	138	11	it	it	PRON
dpc-1025	138	12	is	be	AUX
dpc-1025	138	13	estimated	estimate	VERB
dpc-1025	138	14	to	to	PART
dpc-1025	138	15	be	be	AUX
dpc-1025	138	16	about	about	ADV
dpc-1025	138	17	4	4	NUM
dpc-1025	138	18	(	(	PUNCT
dpc-1025	138	19	4.01	4.01	NUM
dpc-1025	138	20	females	female	NOUN
dpc-1025	138	21	and	and	CCONJ
dpc-1025	138	22	4.05	4.05	NUM
dpc-1025	138	23	males	male	NOUN
dpc-1025	138	24	)	)	PUNCT
dpc-1025	138	25	cases/100,000	cases/100,000	PROPN
dpc-1025	138	26	/	/	SYM
dpc-1025	138	27	year	year	NOUN
dpc-1025	138	28	[	[	X
dpc-1025	138	29	35	35	NUM
dpc-1025	138	30	]	]	PUNCT
dpc-1025	138	31	.	.	PUNCT
dpc-1025	139	1	it	it	PRON
dpc-1025	139	2	can	can	AUX
dpc-1025	139	3	be	be	AUX
dpc-1025	139	4	speculated	speculate	VERB
dpc-1025	139	5	that	that	SCONJ
dpc-1025	139	6	in	in	ADP
dpc-1025	139	7	countries	country	NOUN
dpc-1025	139	8	with	with	ADP
dpc-1025	139	9	high	high	ADJ
dpc-1025	139	10	melanoma	melanoma	NOUN
dpc-1025	139	11	rates	rate	NOUN
dpc-1025	139	12	,	,	PUNCT
dpc-1025	139	13	the	the	DET
dpc-1025	139	14	prognostic	prognostic	ADJ
dpc-1025	139	15	significance	significance	NOUN
dpc-1025	139	16	of	of	ADP
dpc-1025	139	17	vitamin	vitamin	NOUN
dpc-1025	139	18	d	d	NOUN
dpc-1025	139	19	status	status	NOUN
dpc-1025	139	20	becomes	become	VERB
dpc-1025	139	21	more	more	ADV
dpc-1025	139	22	evident	evident	ADJ
dpc-1025	139	23	,	,	PUNCT
dpc-1025	139	24	possibly	possibly	ADV
dpc-1025	139	25	because	because	SCONJ
dpc-1025	139	26	of	of	ADP
dpc-1025	139	27	a	a	DET
dpc-1025	139	28	complex	complex	ADJ
dpc-1025	139	29	and	and	CCONJ
dpc-1025	139	30	yet	yet	ADV
dpc-1025	139	31	unknown	unknown	ADJ
dpc-1025	139	32	interplay	interplay	NOUN
dpc-1025	139	33	between	between	ADP
dpc-1025	139	34	genetic	genetic	ADJ
dpc-1025	139	35	and	and	CCONJ
dpc-1025	139	36	environmental	environmental	ADJ
dpc-1025	139	37	factors	factor	NOUN
dpc-1025	139	38	that	that	PRON
dpc-1025	139	39	affect	affect	VERB
dpc-1025	139	40	simultaneously	simultaneously	ADV
dpc-1025	139	41	both	both	CCONJ
dpc-1025	139	42	vitamin	vitamin	NOUN
dpc-1025	139	43	d	d	NOUN
dpc-1025	139	44	status	status	NOUN
dpc-1025	139	45	and	and	CCONJ
dpc-1025	139	46	melanoma	melanoma	NOUN
dpc-1025	139	47	development	development	NOUN
dpc-1025	139	48	and	and	CCONJ
dpc-1025	139	49	progression	progression	NOUN
dpc-1025	139	50	.	.	PUNCT
dpc-1025	140	1	the	the	DET
dpc-1025	140	2	question	question	NOUN
dpc-1025	140	3	remains	remain	VERB
dpc-1025	140	4	:	:	PUNCT
dpc-1025	140	5	should	should	AUX
dpc-1025	140	6	serum	serum	VERB
dpc-1025	140	7	vitamin	vitamin	NOUN
dpc-1025	140	8	d	d	NOUN
dpc-1025	140	9	levels	level	NOUN
dpc-1025	140	10	be	be	AUX
dpc-1025	140	11	determined	determine	VERB
dpc-1025	140	12	in	in	ADP
dpc-1025	140	13	any	any	DET
dpc-1025	140	14	newly	newly	ADV
dpc-1025	140	15	diagnosed	diagnose	VERB
dpc-1025	140	16	patient	patient	NOUN
dpc-1025	140	17	with	with	ADP
dpc-1025	140	18	melanoma	melanoma	NOUN
dpc-1025	140	19	?	?	PUNCT
dpc-1025	141	1	literature	literature	NOUN
dpc-1025	141	2	review	review	NOUN
dpc-1025	141	3	provides	provide	VERB
dpc-1025	141	4	contradicting	contradict	VERB
dpc-1025	141	5	evidence	evidence	NOUN
dpc-1025	141	6	.	.	PUNCT
dpc-1025	142	1	moreover	moreover	ADV
dpc-1025	142	2	,	,	PUNCT
dpc-1025	142	3	a	a	DET
dpc-1025	142	4	meta	meta	NOUN
dpc-1025	142	5	-	-	PUNCT
dpc-1025	142	6	analysis	analysis	NOUN
dpc-1025	142	7	of	of	ADP
dpc-1025	142	8	studies	study	NOUN
dpc-1025	142	9	that	that	PRON
dpc-1025	142	10	looked	look	VERB
dpc-1025	142	11	at	at	ADP
dpc-1025	142	12	serum	serum	NOUN
dpc-1025	142	13	vitamin	vitamin	NOUN
dpc-1025	142	14	d	d	NOUN
dpc-1025	142	15	levels	level	NOUN
dpc-1025	142	16	and	and	CCONJ
dpc-1025	142	17	the	the	DET
dpc-1025	142	18	incidence	incidence	NOUN
dpc-1025	142	19	of	of	ADP
dpc-1025	142	20	skin	skin	NOUN
dpc-1025	142	21	cancer	cancer	NOUN
dpc-1025	142	22	—	—	PUNCT
dpc-1025	142	23	cutaneous	cutaneous	ADJ
dpc-1025	142	24	melanoma	melanoma	NOUN
dpc-1025	142	25	and	and	CCONJ
dpc-1025	142	26	nonmelanoma	nonmelanoma	ADJ
dpc-1025	142	27	skin	skin	NOUN
dpc-1025	142	28	cancer	cancer	NOUN
dpc-1025	142	29	—	—	PUNCT
dpc-1025	142	30	found	find	VERB
dpc-1025	142	31	no	no	DET
dpc-1025	142	32	association	association	NOUN
dpc-1025	142	33	between	between	ADP
dpc-1025	142	34	vitamin	vitamin	NOUN
dpc-1025	142	35	d	d	NOUN
dpc-1025	142	36	level	level	NOUN
dpc-1025	142	37	and	and	CCONJ
dpc-1025	142	38	risk	risk	NOUN
dpc-1025	142	39	of	of	ADP
dpc-1025	142	40	melanoma	melanoma	NOUN
dpc-1025	142	41	development	development	NOUN
dpc-1025	142	42	,	,	PUNCT
dpc-1025	142	43	although	although	SCONJ
dpc-1025	142	44	there	there	PRON
dpc-1025	142	45	was	be	VERB
dpc-1025	142	46	a	a	DET
dpc-1025	142	47	clear	clear	ADJ
dpc-1025	142	48	association	association	NOUN
dpc-1025	142	49	with	with	ADP
dpc-1025	142	50	nonmelanoma	nonmelanoma	PROPN
dpc-1025	142	51	skin	skin	NOUN
dpc-1025	142	52	cancer	cancer	NOUN
dpc-1025	142	53	risk	risk	NOUN
dpc-1025	142	54	[	[	X
dpc-1025	142	55	36	36	NUM
dpc-1025	142	56	]	]	PUNCT
dpc-1025	142	57	.	.	PUNCT
dpc-1025	143	1	as	as	SCONJ
dpc-1025	143	2	mentioned	mention	VERB
dpc-1025	143	3	before	before	ADV
dpc-1025	143	4	,	,	PUNCT
dpc-1025	143	5	25	25	NUM
dpc-1025	143	6	-	-	PUNCT
dpc-1025	143	7	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	143	8	d	d	NOUN
dpc-1025	143	9	concentration	concentration	NOUN
dpc-1025	143	10	at	at	ADP
dpc-1025	143	11	melanoma	melanoma	ADJ
dpc-1025	143	12	diagnosis	diagnosis	NOUN
dpc-1025	143	13	is	be	AUX
dpc-1025	143	14	influenced	influence	VERB
dpc-1025	143	15	by	by	ADP
dpc-1025	143	16	many	many	ADJ
dpc-1025	143	17	factors	factor	NOUN
dpc-1025	143	18	,	,	PUNCT
dpc-1025	143	19	and	and	CCONJ
dpc-1025	143	20	it	it	PRON
dpc-1025	143	21	is	be	AUX
dpc-1025	143	22	not	not	PART
dpc-1025	143	23	by	by	ADP
dpc-1025	143	24	any	any	DET
dpc-1025	143	25	means	mean	NOUN
dpc-1025	143	26	representative	representative	NOUN
dpc-1025	143	27	of	of	ADP
dpc-1025	143	28	the	the	DET
dpc-1025	143	29	vitamin	vitamin	NOUN
dpc-1025	143	30	d	d	NOUN
dpc-1025	143	31	status	status	NOUN
dpc-1025	143	32	during	during	ADP
dpc-1025	143	33	the	the	DET
dpc-1025	143	34	whole	whole	ADJ
dpc-1025	143	35	process	process	NOUN
dpc-1025	143	36	of	of	ADP
dpc-1025	143	37	melanoma	melanoma	NOUN
dpc-1025	143	38	genesis	genesis	NOUN
dpc-1025	143	39	.	.	PUNCT
dpc-1025	144	1	the	the	DET
dpc-1025	144	2	use	use	NOUN
dpc-1025	144	3	of	of	ADP
dpc-1025	144	4	“	"	PUNCT
dpc-1025	144	5	snapshot	snapshot	ADJ
dpc-1025	144	6	”	"	PUNCT
dpc-1025	144	7	single	single	ADJ
dpc-1025	144	8	measurements	measurement	NOUN
dpc-1025	144	9	of	of	ADP
dpc-1025	144	10	25	25	NUM
dpc-1025	144	11	-	-	PUNCT
dpc-1025	144	12	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	144	13	d	d	NOUN
dpc-1025	144	14	when	when	SCONJ
dpc-1025	144	15	attempting	attempt	VERB
dpc-1025	144	16	to	to	PART
dpc-1025	144	17	demonstrate	demonstrate	VERB
dpc-1025	144	18	health	health	NOUN
dpc-1025	144	19	risks	risk	NOUN
dpc-1025	144	20	associated	associate	VERB
dpc-1025	144	21	with	with	ADP
dpc-1025	144	22	vitamin	vitamin	NOUN
dpc-1025	144	23	d	d	NOUN
dpc-1025	144	24	deficiency	deficiency	NOUN
dpc-1025	144	25	is	be	AUX
dpc-1025	144	26	in	in	ADP
dpc-1025	144	27	dispute	dispute	NOUN
dpc-1025	144	28	.	.	PUNCT
dpc-1025	145	1	in	in	ADP
dpc-1025	145	2	addition	addition	NOUN
dpc-1025	145	3	,	,	PUNCT
dpc-1025	145	4	serum	serum	NOUN
dpc-1025	145	5	25	25	NUM
dpc-1025	145	6	-	-	PUNCT
dpc-1025	145	7	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	145	8	d	d	NOUN
dpc-1025	145	9	level	level	NOUN
dpc-1025	145	10	is	be	AUX
dpc-1025	145	11	not	not	PART
dpc-1025	145	12	the	the	DET
dpc-1025	145	13	sole	sole	ADJ
dpc-1025	145	14	determinant	determinant	NOUN
dpc-1025	145	15	of	of	ADP
dpc-1025	145	16	vitamin	vitamin	NOUN
dpc-1025	145	17	d	d	NOUN
dpc-1025	145	18	activity	activity	NOUN
dpc-1025	145	19	.	.	PUNCT
dpc-1025	146	1	vitamin	vitamin	NOUN
dpc-1025	146	2	d	d	NOUN
dpc-1025	146	3	binding	bind	VERB
dpc-1025	146	4	protein	protein	NOUN
dpc-1025	146	5	,	,	PUNCT
dpc-1025	146	6	polymorphisms	polymorphism	NOUN
dpc-1025	146	7	in	in	ADP
dpc-1025	146	8	the	the	DET
dpc-1025	146	9	vitamin	vitamin	NOUN
dpc-1025	146	10	d	d	NOUN
dpc-1025	146	11	receptor	receptor	NOUN
dpc-1025	146	12	,	,	PUNCT
dpc-1025	146	13	calcium	calcium	NOUN
dpc-1025	146	14	ingestion	ingestion	NOUN
dpc-1025	146	15	,	,	PUNCT
dpc-1025	146	16	renal	renal	ADJ
dpc-1025	146	17	activation	activation	NOUN
dpc-1025	146	18	of	of	ADP
dpc-1025	146	19	vitamin	vitamin	NOUN
dpc-1025	146	20	d	d	PROPN
dpc-1025	146	21	,	,	PUNCT
dpc-1025	146	22	among	among	ADP
dpc-1025	146	23	others	other	NOUN
dpc-1025	146	24	,	,	PUNCT
dpc-1025	146	25	may	may	AUX
dpc-1025	146	26	also	also	ADV
dpc-1025	146	27	play	play	VERB
dpc-1025	146	28	an	an	DET
dpc-1025	146	29	important	important	ADJ
dpc-1025	146	30	part	part	NOUN
dpc-1025	146	31	[	[	X
dpc-1025	146	32	37,38	37,38	NOUN
dpc-1025	146	33	]	]	PUNCT
dpc-1025	146	34	.	.	PUNCT
dpc-1025	147	1	on	on	ADP
dpc-1025	147	2	the	the	DET
dpc-1025	147	3	other	other	ADJ
dpc-1025	147	4	hand	hand	NOUN
dpc-1025	147	5	,	,	PUNCT
dpc-1025	147	6	the	the	DET
dpc-1025	147	7	large	large	ADJ
dpc-1025	147	8	number	number	NOUN
dpc-1025	147	9	of	of	ADP
dpc-1025	147	10	melanoma	melanoma	NOUN
dpc-1025	147	11	patients	patient	NOUN
dpc-1025	147	12	who	who	PRON
dpc-1025	147	13	have	have	VERB
dpc-1025	147	14	low	low	ADJ
dpc-1025	147	15	or	or	CCONJ
dpc-1025	147	16	deficient	deficient	ADJ
dpc-1025	147	17	vitamin	vitamin	NOUN
dpc-1025	147	18	d	d	NOUN
dpc-1025	147	19	levels	level	NOUN
dpc-1025	147	20	at	at	ADP
dpc-1025	147	21	diagnosis	diagnosis	NOUN
dpc-1025	147	22	,	,	PUNCT
dpc-1025	147	23	combined	combine	VERB
dpc-1025	147	24	with	with	ADP
dpc-1025	147	25	the	the	DET
dpc-1025	147	26	routine	routine	ADJ
dpc-1025	147	27	recommendation	recommendation	NOUN
dpc-1025	147	28	for	for	ADP
dpc-1025	147	29	avoidance	avoidance	NOUN
dpc-1025	147	30	of	of	ADP
dpc-1025	147	31	unprotected	unprotected	ADJ
dpc-1025	147	32	sun	sun	NOUN
dpc-1025	147	33	exposure	exposure	NOUN
dpc-1025	147	34	thereafter	thereafter	ADV
dpc-1025	147	35	,	,	PUNCT
dpc-1025	147	36	and	and	CCONJ
dpc-1025	147	37	worse	bad	ADJ
dpc-1025	147	38	survival	survival	NOUN
dpc-1025	148	1	[	[	X
dpc-1025	148	2	16	16	NUM
dpc-1025	148	3	]	]	X
dpc-1025	148	4	;	;	PUNCT
dpc-1025	148	5	association	association	NOUN
dpc-1025	148	6	between	between	ADP
dpc-1025	148	7	lower	low	ADJ
dpc-1025	148	8	serum	serum	NOUN
dpc-1025	148	9	25	25	NUM
dpc-1025	148	10	-	-	PUNCT
dpc-1025	148	11	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	148	12	d	d	NOUN
dpc-1025	148	13	levels	level	NOUN
dpc-1025	148	14	,	,	PUNCT
dpc-1025	148	15	higher	high	ADJ
dpc-1025	148	16	breslow	breslow	NOUN
dpc-1025	148	17	thickness	thickness	NOUN
dpc-1025	148	18	,	,	PUNCT
dpc-1025	148	19	and	and	CCONJ
dpc-1025	148	20	higher	high	ADJ
dpc-1025	148	21	ajcc	ajcc	PROPN
dpc-1025	148	22	melanoma	melanoma	ADJ
dpc-1025	148	23	stage	stage	NOUN
dpc-1025	148	24	[	[	X
dpc-1025	148	25	17	17	NUM
dpc-1025	148	26	]	]	X
dpc-1025	148	27	;	;	PUNCT
dpc-1025	148	28	a	a	DET
dpc-1025	148	29	nearly	nearly	ADV
dpc-1025	148	30	4	4	NUM
dpc-1025	148	31	-	-	ADJ
dpc-1025	148	32	fold	fold	ADJ
dpc-1025	148	33	increase	increase	NOUN
dpc-1025	148	34	in	in	ADP
dpc-1025	148	35	risk	risk	NOUN
dpc-1025	148	36	of	of	ADP
dpc-1025	148	37	having	have	VERB
dpc-1025	148	38	a	a	DET
dpc-1025	148	39	thicker	thick	ADJ
dpc-1025	148	40	tumor	tumor	NOUN
dpc-1025	148	41	that	that	PRON
dpc-1025	148	42	was	be	AUX
dpc-1025	148	43	associated	associate	VERB
dpc-1025	148	44	with	with	ADP
dpc-1025	148	45	low	low	ADJ
dpc-1025	148	46	serum	serum	NOUN
dpc-1025	148	47	vitamin	vitamin	NOUN
dpc-1025	148	48	d	d	NOUN
dpc-1025	148	49	levels	level	NOUN
dpc-1025	148	50	(	(	PUNCT
dpc-1025	148	51	<	<	X
dpc-1025	148	52	50	50	NUM
dpc-1025	148	53	nmol	nmol	NOUN
dpc-1025	148	54	/	/	SYM
dpc-1025	148	55	l	l	NOUN
dpc-1025	148	56	)	)	PUNCT
dpc-1025	149	1	[	[	X
dpc-1025	149	2	18	18	NUM
dpc-1025	149	3	]	]	X
dpc-1025	149	4	;	;	PUNCT
dpc-1025	149	5	inversely	inversely	ADV
dpc-1025	149	6	associated	associate	VERB
dpc-1025	149	7	breslow	breslow	ADJ
dpc-1025	149	8	thickness	thickness	NOUN
dpc-1025	149	9	with	with	ADP
dpc-1025	149	10	vitamin	vitamin	NOUN
dpc-1025	149	11	d	d	NOUN
dpc-1025	149	12	levels	level	NOUN
dpc-1025	149	13	[	[	X
dpc-1025	149	14	19	19	NUM
dpc-1025	149	15	]	]	X
dpc-1025	149	16	;	;	PUNCT
dpc-1025	149	17	and	and	CCONJ
dpc-1025	149	18	higher	high	ADJ
dpc-1025	149	19	vitamin	vitamin	NOUN
dpc-1025	149	20	d	d	NOUN
dpc-1025	149	21	in	in	ADP
dpc-1025	149	22	nonulcerated	nonulcerated	ADJ
dpc-1025	149	23	tumors	tumor	NOUN
dpc-1025	149	24	and	and	CCONJ
dpc-1025	149	25	in	in	ADP
dpc-1025	149	26	tumors	tumor	NOUN
dpc-1025	149	27	within	within	ADP
dpc-1025	149	28	mitotic	mitotic	ADJ
dpc-1025	149	29	rate	rate	NOUN
dpc-1025	149	30	<	<	X
dpc-1025	149	31	1	1	NUM
dpc-1025	149	32	/	/	SYM
dpc-1025	149	33	mm2	mm2	NOUN
dpc-1025	150	1	[	[	X
dpc-1025	150	2	23	23	NUM
dpc-1025	150	3	]	]	PUNCT
dpc-1025	150	4	.	.	PUNCT
dpc-1025	151	1	other	other	ADJ
dpc-1025	151	2	studies	study	NOUN
dpc-1025	151	3	,	,	PUNCT
dpc-1025	151	4	however	however	ADV
dpc-1025	151	5	,	,	PUNCT
dpc-1025	151	6	have	have	AUX
dpc-1025	151	7	argued	argue	VERB
dpc-1025	151	8	against	against	ADP
dpc-1025	151	9	the	the	DET
dpc-1025	151	10	prognostic	prognostic	ADJ
dpc-1025	151	11	value	value	NOUN
dpc-1025	151	12	of	of	ADP
dpc-1025	151	13	serum	serum	NOUN
dpc-1025	151	14	25	25	NUM
dpc-1025	151	15	-	-	PUNCT
dpc-1025	151	16	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	151	17	d	d	NOUN
dpc-1025	151	18	in	in	ADP
dpc-1025	151	19	cmm	cmm	NOUN
dpc-1025	151	20	.	.	PUNCT
dpc-1025	152	1	in	in	ADP
dpc-1025	152	2	a	a	DET
dpc-1025	152	3	cohort	cohort	NOUN
dpc-1025	152	4	of	of	ADP
dpc-1025	152	5	1,171	1,171	NUM
dpc-1025	152	6	patients	patient	NOUN
dpc-1025	152	7	with	with	ADP
dpc-1025	152	8	invasive	invasive	ADJ
dpc-1025	152	9	melanoma	melanoma	NOUN
dpc-1025	152	10	,	,	PUNCT
dpc-1025	152	11	saiag	saiag	SCONJ
dpc-1025	152	12	et	et	PROPN
dpc-1025	152	13	al	al	PROPN
dpc-1025	152	14	tested	test	VERB
dpc-1025	152	15	the	the	DET
dpc-1025	152	16	prognostic	prognostic	ADJ
dpc-1025	152	17	value	value	NOUN
dpc-1025	152	18	of	of	ADP
dpc-1025	152	19	serum	serum	NOUN
dpc-1025	152	20	25	25	NUM
dpc-1025	152	21	-	-	PUNCT
dpc-1025	152	22	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	152	23	d3	d3	PROPN
dpc-1025	152	24	concentrations	concentration	NOUN
dpc-1025	152	25	and	and	CCONJ
dpc-1025	152	26	concluded	conclude	VERB
dpc-1025	152	27	that	that	SCONJ
dpc-1025	152	28	only	only	ADJ
dpc-1025	152	29	variation	variation	NOUN
dpc-1025	152	30	during	during	ADP
dpc-1025	152	31	follow	follow	NOUN
dpc-1025	152	32	-	-	PUNCT
dpc-1025	152	33	up	up	NOUN
dpc-1025	152	34	is	be	AUX
dpc-1025	152	35	an	an	DET
dpc-1025	152	36	independent	independent	ADJ
dpc-1025	152	37	melanoma	melanoma	NOUN
dpc-1025	152	38	prognostic	prognostic	ADJ
dpc-1025	152	39	marker	marker	NOUN
dpc-1025	152	40	,	,	PUNCT
dpc-1025	152	41	but	but	CCONJ
dpc-1025	152	42	not	not	PART
dpc-1025	152	43	levels	level	NOUN
dpc-1025	152	44	at	at	ADP
dpc-1025	152	45	diagnosis	diagnosis	NOUN
dpc-1025	152	46	[	[	X
dpc-1025	152	47	24	24	NUM
dpc-1025	152	48	]	]	PUNCT
dpc-1025	152	49	.	.	PUNCT
dpc-1025	153	1	previously	previously	ADV
dpc-1025	153	2	reported	report	VERB
dpc-1025	153	3	associations	association	NOUN
dpc-1025	153	4	between	between	ADP
dpc-1025	153	5	low	low	ADJ
dpc-1025	153	6	25	25	NUM
dpc-1025	153	7	-	-	PUNCT
dpc-1025	153	8	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	153	9	d3	d3	PROPN
dpc-1025	153	10	at	at	ADP
dpc-1025	153	11	diagnosis	diagnosis	NOUN
dpc-1025	153	12	and	and	CCONJ
dpc-1025	153	13	poor	poor	ADJ
dpc-1025	153	14	prognosis	prognosis	NOUN
dpc-1025	153	15	they	they	PRON
dpc-1025	153	16	believe	believe	VERB
dpc-1025	153	17	to	to	PART
dpc-1025	153	18	be	be	AUX
dpc-1025	153	19	due	due	ADJ
dpc-1025	153	20	to	to	ADP
dpc-1025	153	21	insufficient	insufficient	ADJ
dpc-1025	153	22	adjustment	adjustment	NOUN
dpc-1025	153	23	for	for	ADP
dpc-1025	153	24	prognostic	prognostic	ADJ
dpc-1025	153	25	factors	factor	NOUN
dpc-1025	153	26	[	[	X
dpc-1025	153	27	24	24	NUM
dpc-1025	153	28	]	]	PUNCT
dpc-1025	153	29	.	.	PUNCT
dpc-1025	154	1	other	other	ADJ
dpc-1025	154	2	authors	author	NOUN
dpc-1025	154	3	found	find	VERB
dpc-1025	154	4	significantly	significantly	ADV
dpc-1025	154	5	higher	high	ADJ
dpc-1025	154	6	levels	level	NOUN
dpc-1025	154	7	of	of	ADP
dpc-1025	154	8	vitamin	vitamin	NOUN
dpc-1025	154	9	d3	d3	PROPN
dpc-1025	154	10	in	in	ADP
dpc-1025	154	11	melanoma	melanoma	NOUN
dpc-1025	154	12	patients	patient	NOUN
dpc-1025	154	13	than	than	ADP
dpc-1025	154	14	in	in	ADP
dpc-1025	154	15	healthy	healthy	ADJ
dpc-1025	154	16	controls	control	NOUN
dpc-1025	154	17	,	,	PUNCT
dpc-1025	154	18	but	but	CCONJ
dpc-1025	154	19	both	both	DET
dpc-1025	154	20	inferior	inferior	ADJ
dpc-1025	154	21	of	of	ADP
dpc-1025	154	22	normal	normal	ADJ
dpc-1025	154	23	values	value	NOUN
dpc-1025	154	24	[	[	X
dpc-1025	154	25	25	25	NUM
dpc-1025	154	26	]	]	X
dpc-1025	154	27	;	;	PUNCT
dpc-1025	154	28	significantly	significantly	ADV
dpc-1025	154	29	reduced	reduce	VERB
dpc-1025	154	30	serum	serum	NOUN
dpc-1025	154	31	25	25	NUM
dpc-1025	154	32	-	-	PUNCT
dpc-1025	154	33	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	154	34	d	d	NOUN
dpc-1025	154	35	levels	level	NOUN
dpc-1025	154	36	only	only	ADV
dpc-1025	154	37	in	in	ADP
dpc-1025	154	38	the	the	DET
dpc-1025	154	39	stage	stage	NOUN
dpc-1025	154	40	iv	iv	NUM
dpc-1025	154	41	melanoma	melanoma	NOUN
dpc-1025	154	42	patients	patient	NOUN
dpc-1025	154	43	compared	compare	VERB
dpc-1025	154	44	with	with	ADP
dpc-1025	154	45	stage	stage	NOUN
dpc-1025	154	46	i	i	PRON
dpc-1025	154	47	patients	patient	NOUN
dpc-1025	154	48	,	,	PUNCT
dpc-1025	154	49	suggesting	suggest	VERB
dpc-1025	154	50	that	that	SCONJ
dpc-1025	154	51	patients	patient	NOUN
dpc-1025	154	52	with	with	ADP
dpc-1025	154	53	low	low	ADJ
dpc-1025	154	54	serum	serum	NOUN
dpc-1025	154	55	vitamin	vitamin	NOUN
dpc-1025	154	56	d	d	NOUN
dpc-1025	154	57	levels	level	NOUN
dpc-1025	154	58	may	may	AUX
dpc-1025	154	59	develop	develop	VERB
dpc-1025	154	60	earlier	early	ADV
dpc-1025	154	61	distant	distant	ADJ
dpc-1025	154	62	metastatic	metastatic	ADJ
dpc-1025	154	63	disease	disease	NOUN
dpc-1025	154	64	[	[	X
dpc-1025	154	65	26	26	NUM
dpc-1025	154	66	]	]	X
dpc-1025	154	67	;	;	PUNCT
dpc-1025	154	68	and	and	CCONJ
dpc-1025	154	69	significantly	significantly	ADV
dpc-1025	154	70	lower	low	ADJ
dpc-1025	154	71	serum	serum	NOUN
dpc-1025	154	72	vitamin	vitamin	NOUN
dpc-1025	154	73	d	d	NOUN
dpc-1025	154	74	binding	bind	VERB
dpc-1025	154	75	protein	protein	NOUN
dpc-1025	154	76	levels	level	NOUN
dpc-1025	154	77	in	in	ADP
dpc-1025	154	78	melanoma	melanoma	NOUN
dpc-1025	154	79	patients	patient	NOUN
dpc-1025	154	80	compared	compare	VERB
dpc-1025	154	81	with	with	ADP
dpc-1025	154	82	healthy	healthy	ADJ
dpc-1025	154	83	controls	control	NOUN
dpc-1025	154	84	,	,	PUNCT
dpc-1025	154	85	emphasizing	emphasize	VERB
dpc-1025	154	86	the	the	DET
dpc-1025	154	87	prognostic	prognostic	ADJ
dpc-1025	154	88	significance	significance	NOUN
dpc-1025	154	89	of	of	ADP
dpc-1025	154	90	vitamin	vitamin	NOUN
dpc-1025	154	91	d	d	NOUN
dpc-1025	154	92	binding	bind	VERB
dpc-1025	154	93	protein	protein	NOUN
dpc-1025	154	94	rather	rather	ADV
dpc-1025	154	95	than	than	ADP
dpc-1025	154	96	of	of	ADP
dpc-1025	154	97	25	25	NUM
dpc-1025	154	98	-	-	PUNCT
dpc-1025	154	99	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	154	100	d	d	NOUN
dpc-1025	154	101	levels	level	NOUN
dpc-1025	154	102	[	[	X
dpc-1025	154	103	27	27	NUM
dpc-1025	154	104	]	]	PUNCT
dpc-1025	154	105	.	.	PUNCT
dpc-1025	155	1	in	in	ADP
dpc-1025	155	2	contrast	contrast	NOUN
dpc-1025	155	3	to	to	ADP
dpc-1025	155	4	what	what	PRON
dpc-1025	155	5	one	one	PRON
dpc-1025	155	6	might	might	AUX
dpc-1025	155	7	expect	expect	VERB
dpc-1025	155	8	,	,	PUNCT
dpc-1025	155	9	ie	ie	X
dpc-1025	155	10	,	,	PUNCT
dpc-1025	155	11	the	the	DET
dpc-1025	155	12	typical	typical	ADJ
dpc-1025	155	13	fair	fair	ADJ
dpc-1025	155	14	-	-	PUNCT
dpc-1025	155	15	skinned	skinned	ADJ
dpc-1025	155	16	patient	patient	NOUN
dpc-1025	155	17	with	with	ADP
dpc-1025	155	18	melanoma	melanoma	NOUN
dpc-1025	155	19	with	with	ADP
dpc-1025	155	20	a	a	DET
dpc-1025	155	21	history	history	NOUN
dpc-1025	155	22	of	of	ADP
dpc-1025	155	23	excessive	excessive	ADJ
dpc-1025	155	24	sun	sun	NOUN
dpc-1025	155	25	exposure	exposure	NOUN
dpc-1025	155	26	would	would	AUX
dpc-1025	155	27	have	have	VERB
dpc-1025	155	28	normal	normal	ADJ
dpc-1025	155	29	vitamin	vitamin	NOUN
dpc-1025	155	30	d	d	NOUN
dpc-1025	155	31	levels	level	NOUN
dpc-1025	155	32	at	at	ADP
dpc-1025	155	33	diagnosis	diagnosis	NOUN
dpc-1025	155	34	,	,	PUNCT
dpc-1025	155	35	a	a	DET
dpc-1025	155	36	significant	significant	ADJ
dpc-1025	155	37	number	number	NOUN
dpc-1025	155	38	of	of	ADP
dpc-1025	155	39	melanoma	melanoma	NOUN
dpc-1025	155	40	patients	patient	NOUN
dpc-1025	155	41	in	in	ADP
dpc-1025	155	42	the	the	DET
dpc-1025	155	43	cohorts	cohort	NOUN
dpc-1025	155	44	studied	study	VERB
dpc-1025	155	45	were	be	AUX
dpc-1025	155	46	serologically	serologically	ADV
dpc-1025	155	47	vitamin	vitamin	ADJ
dpc-1025	156	1	d	d	ADJ
dpc-1025	156	2	-	-	ADJ
dpc-1025	156	3	deficient	deficient	ADJ
dpc-1025	157	1	[	[	X
dpc-1025	157	2	21	21	NUM
dpc-1025	157	3	]	]	PUNCT
dpc-1025	157	4	.	.	PUNCT
dpc-1025	158	1	τhis	τhis	PRON
dpc-1025	158	2	observation	observation	NOUN
dpc-1025	158	3	is	be	AUX
dpc-1025	158	4	difficult	difficult	ADJ
dpc-1025	158	5	to	to	PART
dpc-1025	158	6	interpret	interpret	VERB
dpc-1025	158	7	.	.	PUNCT
dpc-1025	159	1	although	although	SCONJ
dpc-1025	159	2	serum	serum	NOUN
dpc-1025	159	3	25	25	NUM
dpc-1025	159	4	-	-	PUNCT
dpc-1025	159	5	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	159	6	d	d	NOUN
dpc-1025	159	7	concentration	concentration	NOUN
dpc-1025	159	8	is	be	AUX
dpc-1025	159	9	the	the	DET
dpc-1025	159	10	best	good	ADJ
dpc-1025	159	11	determinant	determinant	ADJ
dpc-1025	159	12	of	of	ADP
dpc-1025	159	13	vitamin	vitamin	NOUN
dpc-1025	159	14	d	d	NOUN
dpc-1025	159	15	status	status	NOUN
dpc-1025	159	16	because	because	SCONJ
dpc-1025	159	17	of	of	ADP
dpc-1025	159	18	its	its	PRON
dpc-1025	159	19	long	long	ADJ
dpc-1025	159	20	half	half	ADJ
dpc-1025	159	21	-	-	PUNCT
dpc-1025	159	22	life	life	NOUN
dpc-1025	159	23	(	(	PUNCT
dpc-1025	159	24	more	more	ADJ
dpc-1025	159	25	than	than	ADP
dpc-1025	159	26	250	250	NUM
dpc-1025	159	27	hours	hour	NOUN
dpc-1025	159	28	)	)	PUNCT
dpc-1025	159	29	,	,	PUNCT
dpc-1025	159	30	its	its	PRON
dpc-1025	159	31	value	value	NOUN
dpc-1025	159	32	is	be	AUX
dpc-1025	159	33	influenced	influence	VERB
dpc-1025	159	34	by	by	ADP
dpc-1025	159	35	several	several	ADJ
dpc-1025	159	36	factors	factor	NOUN
dpc-1025	159	37	,	,	PUNCT
dpc-1025	159	38	such	such	ADJ
dpc-1025	159	39	as	as	ADP
dpc-1025	159	40	variation	variation	NOUN
dpc-1025	159	41	in	in	ADP
dpc-1025	159	42	sun	sun	NOUN
dpc-1025	159	43	exposure	exposure	NOUN
dpc-1025	159	44	due	due	ADP
dpc-1025	159	45	to	to	ADP
dpc-1025	159	46	latitude	latitude	NOUN
dpc-1025	159	47	,	,	PUNCT
dpc-1025	159	48	season	season	NOUN
dpc-1025	159	49	,	,	PUNCT
dpc-1025	159	50	or	or	CCONJ
dpc-1025	159	51	time	time	NOUN
dpc-1025	159	52	of	of	ADP
dpc-1025	159	53	day	day	NOUN
dpc-1025	159	54	,	,	PUNCT
dpc-1025	159	55	clothing	clothing	NOUN
dpc-1025	159	56	,	,	PUNCT
dpc-1025	159	57	sunscreen	sunscreen	NOUN
dpc-1025	159	58	use	use	NOUN
dpc-1025	159	59	,	,	PUNCT
dpc-1025	159	60	skin	skin	NOUN
dpc-1025	159	61	pigmentation	pigmentation	NOUN
dpc-1025	159	62	,	,	PUNCT
dpc-1025	159	63	age	age	NOUN
dpc-1025	159	64	,	,	PUNCT
dpc-1025	159	65	and	and	CCONJ
dpc-1025	159	66	obesity	obesity	NOUN
dpc-1025	159	67	[	[	X
dpc-1025	159	68	28	28	NUM
dpc-1025	159	69	]	]	PUNCT
dpc-1025	159	70	.	.	PUNCT
dpc-1025	160	1	in	in	ADP
dpc-1025	160	2	addition	addition	NOUN
dpc-1025	160	3	,	,	PUNCT
dpc-1025	160	4	suboptimal	suboptimal	ADJ
dpc-1025	160	5	serum	serum	NOUN
dpc-1025	160	6	25	25	NUM
dpc-1025	160	7	-	-	PUNCT
dpc-1025	160	8	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	160	9	d	d	NOUN
dpc-1025	160	10	levels	level	NOUN
dpc-1025	160	11	are	be	AUX
dpc-1025	160	12	common	common	ADJ
dpc-1025	160	13	in	in	ADP
dpc-1025	160	14	adults	adult	NOUN
dpc-1025	160	15	in	in	ADP
dpc-1025	160	16	many	many	ADJ
dpc-1025	160	17	countries	country	NOUN
dpc-1025	160	18	and	and	CCONJ
dpc-1025	160	19	are	be	AUX
dpc-1025	160	20	highly	highly	ADV
dpc-1025	160	21	prevalent	prevalent	ADJ
dpc-1025	160	22	in	in	ADP
dpc-1025	160	23	the	the	DET
dpc-1025	160	24	middle	middle	PROPN
dpc-1025	160	25	east	east	PROPN
dpc-1025	160	26	and	and	CCONJ
dpc-1025	160	27	asia	asia	PROPN
dpc-1025	161	1	[	[	X
dpc-1025	161	2	29	29	NUM
dpc-1025	161	3	]	]	PUNCT
dpc-1025	161	4	.	.	PUNCT
dpc-1025	162	1	serum	serum	PROPN
dpc-1025	162	2	25	25	NUM
dpc-1025	162	3	-	-	PUNCT
dpc-1025	162	4	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	162	5	d	d	NOUN
dpc-1025	162	6	levels	level	NOUN
dpc-1025	162	7	are	be	AUX
dpc-1025	162	8	higher	high	ADJ
dpc-1025	162	9	in	in	ADP
dpc-1025	162	10	northern	northern	ADJ
dpc-1025	162	11	than	than	ADP
dpc-1025	162	12	in	in	ADP
dpc-1025	162	13	southern	southern	ADJ
dpc-1025	162	14	europe	europe	PROPN
dpc-1025	162	15	,	,	PUNCT
dpc-1025	162	16	and	and	CCONJ
dpc-1025	162	17	in	in	ADP
dpc-1025	162	18	western	western	ADJ
dpc-1025	162	19	than	than	ADP
dpc-1025	162	20	in	in	ADP
dpc-1025	162	21	eastern	eastern	PROPN
dpc-1025	162	22	europe	europe	PROPN
dpc-1025	162	23	,	,	PUNCT
dpc-1025	162	24	presumably	presumably	ADV
dpc-1025	162	25	owing	owe	VERB
dpc-1025	162	26	to	to	ADP
dpc-1025	162	27	differences	difference	NOUN
dpc-1025	162	28	in	in	ADP
dpc-1025	162	29	skin	skin	NOUN
dpc-1025	162	30	phototypes	phototype	NOUN
dpc-1025	162	31	among	among	ADP
dpc-1025	162	32	european	european	ADJ
dpc-1025	162	33	populations	population	NOUN
dpc-1025	162	34	[	[	X
dpc-1025	162	35	30	30	NUM
dpc-1025	162	36	]	]	PUNCT
dpc-1025	162	37	.	.	PUNCT
dpc-1025	163	1	in	in	ADP
dpc-1025	163	2	mediterranean	mediterranean	PROPN
dpc-1025	163	3	countries	country	NOUN
dpc-1025	163	4	such	such	ADJ
dpc-1025	163	5	as	as	ADP
dpc-1025	163	6	spain	spain	PROPN
dpc-1025	163	7	,	,	PUNCT
dpc-1025	163	8	italy	italy	PROPN
dpc-1025	163	9	,	,	PUNCT
dpc-1025	163	10	and	and	CCONJ
dpc-1025	163	11	greece	greece	PROPN
dpc-1025	163	12	,	,	PUNCT
dpc-1025	163	13	low	low	ADJ
dpc-1025	163	14	serum	serum	NOUN
dpc-1025	163	15	25	25	NUM
dpc-1025	163	16	-	-	PUNCT
dpc-1025	163	17	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	163	18	d	d	NOUN
dpc-1025	163	19	may	may	AUX
dpc-1025	163	20	be	be	AUX
dpc-1025	163	21	attributed	attribute	VERB
dpc-1025	163	22	to	to	ADP
dpc-1025	163	23	darker	dark	ADJ
dpc-1025	163	24	skin	skin	NOUN
dpc-1025	163	25	pigmentation	pigmentation	NOUN
dpc-1025	163	26	and	and	CCONJ
dpc-1025	163	27	reduced	reduce	VERB
dpc-1025	163	28	sun	sun	NOUN
dpc-1025	163	29	exposure	exposure	NOUN
dpc-1025	163	30	resulting	result	VERB
dpc-1025	163	31	from	from	ADP
dpc-1025	163	32	urbanization	urbanization	NOUN
dpc-1025	163	33	[	[	X
dpc-1025	163	34	29	29	NUM
dpc-1025	163	35	]	]	PUNCT
dpc-1025	163	36	.	.	PUNCT
dpc-1025	164	1	also	also	ADV
dpc-1025	164	2	in	in	ADP
dpc-1025	164	3	greece	greece	PROPN
dpc-1025	164	4	dairy	dairy	NOUN
dpc-1025	164	5	product	product	NOUN
dpc-1025	164	6	fortification	fortification	NOUN
dpc-1025	164	7	and	and	CCONJ
dpc-1025	164	8	vitamin	vitamin	NOUN
dpc-1025	164	9	d	d	PROPN
dpc-1025	164	10	supplementation	supplementation	NOUN
dpc-1025	164	11	is	be	AUX
dpc-1025	164	12	not	not	PART
dpc-1025	164	13	a	a	DET
dpc-1025	164	14	usual	usual	ADJ
dpc-1025	164	15	practice	practice	NOUN
dpc-1025	164	16	,	,	PUNCT
dpc-1025	164	17	especially	especially	ADV
dpc-1025	164	18	for	for	ADP
dpc-1025	164	19	younger	young	ADJ
dpc-1025	164	20	age	age	NOUN
dpc-1025	164	21	groups	group	NOUN
dpc-1025	164	22	(	(	PUNCT
dpc-1025	164	23	median	median	ADJ
dpc-1025	164	24	age	age	NOUN
dpc-1025	164	25	of	of	ADP
dpc-1025	164	26	our	our	PRON
dpc-1025	164	27	melanoma	melanoma	NOUN
dpc-1025	164	28	patients	patient	NOUN
dpc-1025	164	29	was	be	AUX
dpc-1025	164	30	50	50	NUM
dpc-1025	164	31	years	year	NOUN
dpc-1025	164	32	)	)	PUNCT
dpc-1025	164	33	.	.	PUNCT
dpc-1025	165	1	we	we	PRON
dpc-1025	165	2	research	research	VERB
dpc-1025	165	3	|	|	ADV
dpc-1025	165	4	dermatol	dermatol	ADJ
dpc-1025	165	5	pract	pract	NOUN
dpc-1025	165	6	concept	concept	NOUN
dpc-1025	165	7	2020;10(1):e2020010	2020;10(1):e2020010	NUM
dpc-1025	165	8	7	7	NUM
dpc-1025	165	9	4	4	NUM
dpc-1025	165	10	.	.	PUNCT
dpc-1025	166	1	guillot	guillot	NOUN
dpc-1025	166	2	 	 	SPACE
dpc-1025	166	3	x	x	NOUN
dpc-1025	166	4	,	,	PUNCT
dpc-1025	166	5	semerano	semerano	ADJ
dpc-1025	166	6	l	l	NOUN
dpc-1025	166	7	,	,	PUNCT
dpc-1025	166	8	saidenberg	saidenberg	NOUN
dpc-1025	166	9	-	-	PUNCT
dpc-1025	166	10	kermanach	kermanach	NOUN
dpc-1025	166	11	n	n	NOUN
dpc-1025	166	12	,	,	PUNCT
dpc-1025	166	13	falgarone	falgarone	NOUN
dpc-1025	166	14	g	g	NOUN
dpc-1025	166	15	,	,	PUNCT
dpc-1025	166	16	boissier	boissier	PROPN
dpc-1025	166	17	mc	mc	PROPN
dpc-1025	166	18	.	.	PROPN
dpc-1025	167	1	vitamin	vitamin	PROPN
dpc-1025	168	1	d	d	NOUN
dpc-1025	168	2	 	 	SPACE
dpc-1025	168	3	and	and	CCONJ
dpc-1025	168	4	inflammation	inflammation	NOUN
dpc-1025	168	5	.	.	PUNCT
dpc-1025	169	1	joint	joint	ADJ
dpc-1025	169	2	bone	bone	NOUN
dpc-1025	169	3	spine	spine	NOUN
dpc-1025	169	4	.	.	PUNCT
dpc-1025	170	1	2010;77(6):552	2010;77(6):552	NUM
dpc-1025	170	2	-	-	SYM
dpc-1025	170	3	557	557	NUM
dpc-1025	170	4	.	.	PUNCT
dpc-1025	171	1	5	5	NUM
dpc-1025	171	2	.	.	X
dpc-1025	171	3	scaglione	scaglione	NOUN
dpc-1025	171	4	-	-	PUNCT
dpc-1025	171	5	sewell	sewell	PROPN
dpc-1025	171	6	ba	ba	PROPN
dpc-1025	171	7	,	,	PUNCT
dpc-1025	171	8	bissonnette	bissonnette	PROPN
dpc-1025	171	9	m	m	PROPN
dpc-1025	171	10	,	,	PUNCT
dpc-1025	171	11	skarosi	skarosi	NOUN
dpc-1025	171	12	s	s	PROPN
dpc-1025	171	13	,	,	PUNCT
dpc-1025	171	14	abraham	abraham	PROPN
dpc-1025	171	15	c	c	PROPN
dpc-1025	171	16	,	,	PUNCT
dpc-1025	171	17	brasitus	brasitus	PROPN
dpc-1025	171	18	ta	ta	PROPN
dpc-1025	171	19	.	.	PUNCT
dpc-1025	172	1	a	a	DET
dpc-1025	172	2	vitamin	vitamin	NOUN
dpc-1025	172	3	d3	d3	PROPN
dpc-1025	172	4	analog	analog	NOUN
dpc-1025	172	5	induces	induce	VERB
dpc-1025	172	6	a	a	DET
dpc-1025	172	7	g1	g1	ADJ
dpc-1025	172	8	-	-	PUNCT
dpc-1025	172	9	phase	phase	NOUN
dpc-1025	172	10	arrest	arrest	NOUN
dpc-1025	172	11	in	in	ADP
dpc-1025	172	12	caco-2	caco-2	NUM
dpc-1025	172	13	cells	cell	NOUN
dpc-1025	172	14	by	by	ADP
dpc-1025	172	15	inhibiting	inhibit	VERB
dpc-1025	172	16	cdk2	cdk2	NOUN
dpc-1025	172	17	and	and	CCONJ
dpc-1025	172	18	cdk6	cdk6	PROPN
dpc-1025	172	19	:	:	PUNCT
dpc-1025	172	20	roles	role	NOUN
dpc-1025	172	21	of	of	ADP
dpc-1025	172	22	cyclin	cyclin	PROPN
dpc-1025	172	23	e	e	PROPN
dpc-1025	172	24	,	,	PUNCT
dpc-1025	172	25	p21waf1	p21waf1	NOUN
dpc-1025	172	26	,	,	PUNCT
dpc-1025	172	27	and	and	CCONJ
dpc-1025	172	28	p27kip1	p27kip1	PROPN
dpc-1025	172	29	.	.	PUNCT
dpc-1025	173	1	endocrinology	endocrinology	NOUN
dpc-1025	173	2	.	.	PUNCT
dpc-1025	174	1	2000;141(11):3931	2000;141(11):3931	NUM
dpc-1025	174	2	-	-	SYM
dpc-1025	174	3	3939	3939	NUM
dpc-1025	174	4	.	.	PUNCT
dpc-1025	175	1	6	6	NUM
dpc-1025	175	2	.	.	X
dpc-1025	175	3	lamprecht	lamprecht	PROPN
dpc-1025	175	4	sa	sa	PROPN
dpc-1025	175	5	,	,	PUNCT
dpc-1025	175	6	lipkin	lipkin	PROPN
dpc-1025	175	7	m.	m.	NOUN
dpc-1025	175	8	cellular	cellular	ADJ
dpc-1025	175	9	mechanisms	mechanism	NOUN
dpc-1025	175	10	of	of	ADP
dpc-1025	175	11	calcium	calcium	NOUN
dpc-1025	175	12	and	and	CCONJ
dpc-1025	175	13	vitamin	vitamin	NOUN
dpc-1025	175	14	d	d	NOUN
dpc-1025	175	15	in	in	ADP
dpc-1025	175	16	the	the	DET
dpc-1025	175	17	inhibition	inhibition	NOUN
dpc-1025	175	18	of	of	ADP
dpc-1025	175	19	colorectal	colorectal	ADJ
dpc-1025	175	20	carcinogenesis	carcinogenesis	NOUN
dpc-1025	175	21	.	.	PUNCT
dpc-1025	176	1	ann	ann	PROPN
dpc-1025	176	2	n	n	PROPN
dpc-1025	176	3	y	y	PROPN
dpc-1025	176	4	acad	acad	PROPN
dpc-1025	176	5	sci	sci	PROPN
dpc-1025	176	6	.	.	PUNCT
dpc-1025	177	1	2001;952(1):73	2001;952(1):73	NUM
dpc-1025	177	2	-	-	SYM
dpc-1025	177	3	87	87	NUM
dpc-1025	177	4	.	.	PUNCT
dpc-1025	178	1	7	7	X
dpc-1025	178	2	.	.	X
dpc-1025	178	3	evans	evans	PROPN
dpc-1025	178	4	sr	sr	PROPN
dpc-1025	178	5	,	,	PUNCT
dpc-1025	178	6	shchepotin	shchepotin	PROPN
dpc-1025	178	7	ei	ei	PROPN
dpc-1025	178	8	,	,	PUNCT
dpc-1025	178	9	young	young	ADJ
dpc-1025	178	10	h	h	NOUN
dpc-1025	178	11	,	,	PUNCT
dpc-1025	178	12	rochon	rochon	PROPN
dpc-1025	178	13	j	j	PROPN
dpc-1025	178	14	,	,	PUNCT
dpc-1025	178	15	uskokovic	uskokovic	PROPN
dpc-1025	178	16	m	m	PROPN
dpc-1025	178	17	,	,	PUNCT
dpc-1025	178	18	shchepotin	shchepotin	PROPN
dpc-1025	178	19	ib	ib	PROPN
dpc-1025	178	20	.	.	PUNCT
dpc-1025	178	21	25	25	NUM
dpc-1025	178	22	-	-	PUNCT
dpc-1025	178	23	dihydroxyvitamin	dihydroxyvitamin	NOUN
dpc-1025	178	24	d3	d3	PROPN
dpc-1025	178	25	synthetic	synthetic	ADJ
dpc-1025	178	26	analogs	analog	NOUN
dpc-1025	178	27	inhibit	inhibit	VERB
dpc-1025	178	28	spontaneous	spontaneous	ADJ
dpc-1025	178	29	metastases	metastasis	NOUN
dpc-1025	178	30	in	in	ADP
dpc-1025	178	31	a	a	DET
dpc-1025	178	32	1,2	1,2	NUM
dpc-1025	178	33	-	-	PUNCT
dpc-1025	178	34	dimethylhydrazine	dimethylhydrazine	ADV
dpc-1025	178	35	-	-	PUNCT
dpc-1025	178	36	induced	induce	VERB
dpc-1025	178	37	colon	colon	NOUN
dpc-1025	178	38	carcinogenesis	carcinogenesis	NOUN
dpc-1025	178	39	model	model	NOUN
dpc-1025	178	40	.	.	PUNCT
dpc-1025	179	1	int	int	PROPN
dpc-1025	179	2	j	j	PROPN
dpc-1025	179	3	oncol	oncol	ADJ
dpc-1025	179	4	.	.	PUNCT
dpc-1025	180	1	2000;16(6):1249	2000;16(6):1249	NUM
dpc-1025	180	2	-	-	SYM
dpc-1025	180	3	1254	1254	NUM
dpc-1025	180	4	.	.	PUNCT
dpc-1025	181	1	8	8	NUM
dpc-1025	181	2	.	.	PUNCT
dpc-1025	181	3	aranow	aranow	PROPN
dpc-1025	181	4	 	 	SPACE
dpc-1025	181	5	c.	c.	PROPN
dpc-1025	181	6	vitamin	vitamin	PROPN
dpc-1025	181	7	d	d	PROPN
dpc-1025	181	8	and	and	CCONJ
dpc-1025	181	9	the	the	DET
dpc-1025	181	10	immune	immune	ADJ
dpc-1025	181	11	system	system	NOUN
dpc-1025	181	12	.	.	PUNCT
dpc-1025	182	1	j	j	PROPN
dpc-1025	182	2	investig	investig	NOUN
dpc-1025	182	3	med	med	PROPN
dpc-1025	182	4	.	.	PUNCT
dpc-1025	183	1	2011;59(6):881	2011;59(6):881	NUM
dpc-1025	183	2	-	-	PUNCT
dpc-1025	183	3	886	886	NUM
dpc-1025	183	4	.	.	PUNCT
dpc-1025	184	1	9	9	NUM
dpc-1025	184	2	.	.	X
dpc-1025	184	3	atoum	atoum	PROPN
dpc-1025	184	4	m	m	PROPN
dpc-1025	184	5	,	,	PUNCT
dpc-1025	184	6	alzoughool	alzoughool	PROPN
dpc-1025	184	7	f.	f.	PROPN
dpc-1025	184	8	vitamin	vitamin	PROPN
dpc-1025	184	9	d	d	PROPN
dpc-1025	184	10	and	and	CCONJ
dpc-1025	184	11	breast	breast	NOUN
dpc-1025	184	12	cancer	cancer	NOUN
dpc-1025	184	13	:	:	PUNCT
dpc-1025	184	14	latest	late	ADJ
dpc-1025	184	15	evidence	evidence	NOUN
dpc-1025	184	16	and	and	CCONJ
dpc-1025	184	17	future	future	ADJ
dpc-1025	184	18	steps	step	NOUN
dpc-1025	184	19	.	.	PUNCT
dpc-1025	185	1	breast	breast	NOUN
dpc-1025	185	2	cancer	cancer	NOUN
dpc-1025	185	3	(	(	PUNCT
dpc-1025	185	4	auckl	auckl	NOUN
dpc-1025	185	5	)	)	PUNCT
dpc-1025	185	6	.	.	PUNCT
dpc-1025	186	1	2017;11	2017;11	NUM
dpc-1025	186	2	:	:	PUNCT
dpc-1025	186	3	1178223417749816	1178223417749816	NUM
dpc-1025	186	4	.	.	PUNCT
dpc-1025	187	1	10	10	NUM
dpc-1025	187	2	.	.	PUNCT
dpc-1025	188	1	liu	liu	PROPN
dpc-1025	188	2	y	y	PROPN
dpc-1025	188	3	,	,	PUNCT
dpc-1025	188	4	wang	wang	PROPN
dpc-1025	188	5	x	x	PROPN
dpc-1025	188	6	,	,	PUNCT
dpc-1025	188	7	sun	sun	PROPN
dpc-1025	188	8	x	x	AUX
dpc-1025	188	9	,	,	PUNCT
dpc-1025	188	10	lu	lu	PROPN
dpc-1025	188	11	s	s	PROPN
dpc-1025	188	12	,	,	PUNCT
dpc-1025	188	13	liu	liu	PROPN
dpc-1025	188	14	s.	s.	PROPN
dpc-1025	188	15	vitamin	vitamin	PROPN
dpc-1025	188	16	intake	intake	PROPN
dpc-1025	188	17	and	and	CCONJ
dpc-1025	188	18	pancreatic	pancreatic	ADJ
dpc-1025	188	19	cancer	cancer	NOUN
dpc-1025	188	20	risk	risk	NOUN
dpc-1025	188	21	reduction	reduction	NOUN
dpc-1025	188	22	:	:	PUNCT
dpc-1025	188	23	a	a	DET
dpc-1025	188	24	meta	meta	ADJ
dpc-1025	188	25	-	-	PUNCT
dpc-1025	188	26	analysis	analysis	NOUN
dpc-1025	188	27	of	of	ADP
dpc-1025	188	28	observational	observational	ADJ
dpc-1025	188	29	studies	study	NOUN
dpc-1025	188	30	.	.	PUNCT
dpc-1025	189	1	medicine	medicine	NOUN
dpc-1025	189	2	(	(	PUNCT
dpc-1025	189	3	baltimore	baltimore	PROPN
dpc-1025	189	4	)	)	PUNCT
dpc-1025	189	5	.	.	PUNCT
dpc-1025	190	1	2018;97(13):e0114	2018;97(13):e0114	X
dpc-1025	190	2	.	.	PUNCT
dpc-1025	191	1	11	11	NUM
dpc-1025	191	2	.	.	PUNCT
dpc-1025	192	1	egan	egan	PROPN
dpc-1025	192	2	km	km	PROPN
dpc-1025	192	3	.	.	PUNCT
dpc-1025	193	1	vitamin	vitamin	NOUN
dpc-1025	193	2	d	d	NOUN
dpc-1025	193	3	and	and	CCONJ
dpc-1025	193	4	melanoma	melanoma	NOUN
dpc-1025	193	5	.	.	PUNCT
dpc-1025	194	1	ann	ann	PROPN
dpc-1025	194	2	epidemiol	epidemiol	PROPN
dpc-1025	194	3	.	.	PUNCT
dpc-1025	195	1	2009;19(7):455	2009;19(7):455	NUM
dpc-1025	195	2	-	-	PUNCT
dpc-1025	195	3	461	461	NUM
dpc-1025	195	4	.	.	PUNCT
dpc-1025	196	1	12	12	NUM
dpc-1025	196	2	.	.	PUNCT
dpc-1025	196	3	reichrath	reichrath	PROPN
dpc-1025	196	4	 	 	SPACE
dpc-1025	196	5	j	j	PROPN
dpc-1025	196	6	,	,	PUNCT
dpc-1025	196	7	rech	rech	PROPN
dpc-1025	196	8	m	m	PROPN
dpc-1025	196	9	,	,	PUNCT
dpc-1025	196	10	moeini	moeini	PROPN
dpc-1025	196	11	m	m	PROPN
dpc-1025	196	12	,	,	PUNCT
dpc-1025	196	13	meese	meese	PROPN
dpc-1025	196	14	e	e	PROPN
dpc-1025	196	15	,	,	PUNCT
dpc-1025	196	16	tilgen	tilgen	PROPN
dpc-1025	196	17	w	w	PROPN
dpc-1025	196	18	,	,	PUNCT
dpc-1025	196	19	seifert	seifert	PROPN
dpc-1025	196	20	m.	m.	NOUN
dpc-1025	196	21	in	in	ADP
dpc-1025	196	22	vitro	vitro	X
dpc-1025	196	23	comparison	comparison	NOUN
dpc-1025	196	24	of	of	ADP
dpc-1025	196	25	the	the	DET
dpc-1025	196	26	vitamin	vitamin	NOUN
dpc-1025	196	27	d	d	NOUN
dpc-1025	196	28	endocrine	endocrine	NOUN
dpc-1025	196	29	system	system	NOUN
dpc-1025	196	30	in	in	ADP
dpc-1025	196	31	1,25(oh)2d3	1,25(oh)2d3	ADJ
dpc-1025	196	32	-	-	PUNCT
dpc-1025	196	33	responsive	responsive	ADJ
dpc-1025	196	34	and	and	CCONJ
dpc-1025	196	35	-resistant	-resistant	ADJ
dpc-1025	196	36	melanoma	melanoma	NOUN
dpc-1025	196	37	cells	cell	NOUN
dpc-1025	196	38	.	.	PUNCT
dpc-1025	197	1	cancer	cancer	NOUN
dpc-1025	197	2	biol	biol	PROPN
dpc-1025	197	3	ther	ther	ADV
dpc-1025	197	4	.	.	PUNCT
dpc-1025	197	5	 	 	SPACE
dpc-1025	198	1	2007;6(1):48	2007;6(1):48	PROPN
dpc-1025	198	2	-	-	SYM
dpc-1025	198	3	55	55	NUM
dpc-1025	198	4	.	.	PUNCT
dpc-1025	199	1	13	13	NUM
dpc-1025	199	2	.	.	PUNCT
dpc-1025	200	1	piotrowska	piotrowska	PROPN
dpc-1025	200	2	a	a	PRON
dpc-1025	200	3	,	,	PUNCT
dpc-1025	200	4	wierzbicka	wierzbicka	PROPN
dpc-1025	200	5	j	j	PROPN
dpc-1025	200	6	,	,	PUNCT
dpc-1025	200	7	nadkarni	nadkarni	PROPN
dpc-1025	200	8	s	s	PROPN
dpc-1025	200	9	,	,	PUNCT
dpc-1025	200	10	brown	brown	ADJ
dpc-1025	200	11	g	g	PROPN
dpc-1025	200	12	,	,	PUNCT
dpc-1025	200	13	kutner	kutner	PROPN
dpc-1025	200	14	a	a	PROPN
dpc-1025	200	15	,	,	PUNCT
dpc-1025	200	16	żmijewski	żmijewski	PROPN
dpc-1025	200	17	ma	ma	PROPN
dpc-1025	200	18	.	.	PROPN
dpc-1025	200	19	antiproliferative	antiproliferative	ADJ
dpc-1025	200	20	activity	activity	NOUN
dpc-1025	200	21	of	of	ADP
dpc-1025	200	22	double	double	ADJ
dpc-1025	200	23	point	point	NOUN
dpc-1025	200	24	modified	modify	VERB
dpc-1025	200	25	analogs	analog	NOUN
dpc-1025	200	26	of	of	ADP
dpc-1025	200	27	1,25	1,25	NUM
dpc-1025	200	28	-	-	PUNCT
dpc-1025	200	29	dihydroxyvitamin	dihydroxyvitamin	ADJ
dpc-1025	200	30	d	d	NOUN
dpc-1025	200	31	against	against	ADP
dpc-1025	200	32	human	human	ADJ
dpc-1025	200	33	malignant	malignant	ADJ
dpc-1025	200	34	melanoma	melanoma	NOUN
dpc-1025	200	35	cell	cell	NOUN
dpc-1025	200	36	lines	line	NOUN
dpc-1025	200	37	.	.	PUNCT
dpc-1025	201	1	int	int	PROPN
dpc-1025	201	2	j	j	PROPN
dpc-1025	201	3	mol	mol	ADP
dpc-1025	201	4	sci	sci	PROPN
dpc-1025	201	5	.	.	PUNCT
dpc-1025	202	1	2016;17(1):e76	2016;17(1):e76	NUM
dpc-1025	202	2	.	.	PUNCT
dpc-1025	203	1	14	14	NUM
dpc-1025	203	2	.	.	PUNCT
dpc-1025	204	1	newton	newton	PROPN
dpc-1025	204	2	-	-	PUNCT
dpc-1025	204	3	bishop	bishop	PROPN
dpc-1025	204	4	ja	ja	PROPN
dpc-1025	204	5	,	,	PUNCT
dpc-1025	204	6	beswick	beswick	PROPN
dpc-1025	204	7	s	s	PROPN
dpc-1025	204	8	,	,	PUNCT
dpc-1025	204	9	randerson	randerson	NOUN
dpc-1025	204	10	-	-	PUNCT
dpc-1025	204	11	moor	moor	PROPN
dpc-1025	204	12	j	j	PROPN
dpc-1025	204	13	,	,	PUNCT
dpc-1025	204	14	et	et	PROPN
dpc-1025	204	15	al	al	PROPN
dpc-1025	204	16	.	.	PROPN
dpc-1025	205	1	serum	serum	PROPN
dpc-1025	205	2	25	25	NUM
dpc-1025	205	3	-	-	PUNCT
dpc-1025	205	4	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	205	5	d3	d3	PROPN
dpc-1025	205	6	levels	level	NOUN
dpc-1025	205	7	are	be	AUX
dpc-1025	205	8	associated	associate	VERB
dpc-1025	205	9	with	with	ADP
dpc-1025	205	10	breslow	breslow	ADJ
dpc-1025	205	11	thickness	thickness	NOUN
dpc-1025	205	12	at	at	ADP
dpc-1025	205	13	presentation	presentation	NOUN
dpc-1025	205	14	and	and	CCONJ
dpc-1025	205	15	survival	survival	NOUN
dpc-1025	205	16	from	from	ADP
dpc-1025	205	17	melanoma	melanoma	NOUN
dpc-1025	205	18	.	.	PUNCT
dpc-1025	206	1	j	j	PROPN
dpc-1025	206	2	clin	clin	PROPN
dpc-1025	206	3	oncol	oncol	PROPN
dpc-1025	206	4	.	.	PUNCT
dpc-1025	207	1	2009;27(32):5439	2009;27(32):5439	NUM
dpc-1025	207	2	-	-	NOUN
dpc-1025	207	3	5444	5444	NUM
dpc-1025	207	4	.	.	PUNCT
dpc-1025	208	1	15	15	NUM
dpc-1025	208	2	.	.	PUNCT
dpc-1025	208	3	newton	newton	PROPN
dpc-1025	208	4	-	-	PUNCT
dpc-1025	208	5	bishop	bishop	PROPN
dpc-1025	208	6	ja	ja	PROPN
dpc-1025	208	7	,	,	PUNCT
dpc-1025	208	8	davies	davies	PROPN
dpc-1025	208	9	jr	jr	PROPN
dpc-1025	208	10	,	,	PUNCT
dpc-1025	208	11	latheef	latheef	PROPN
dpc-1025	208	12	f	f	NUM
dpc-1025	208	13	,	,	PUNCT
dpc-1025	208	14	et	et	PROPN
dpc-1025	208	15	al	al	PROPN
dpc-1025	208	16	.	.	PROPN
dpc-1025	209	1	25	25	NUM
dpc-1025	209	2	-	-	PUNCT
dpc-1025	209	3	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	209	4	d2	d2	PROPN
dpc-1025	209	5	/	/	SYM
dpc-1025	209	6	d3	d3	PROPN
dpc-1025	209	7	levels	level	NOUN
dpc-1025	209	8	and	and	CCONJ
dpc-1025	209	9	factors	factor	NOUN
dpc-1025	209	10	associated	associate	VERB
dpc-1025	209	11	with	with	ADP
dpc-1025	209	12	systemic	systemic	ADJ
dpc-1025	209	13	inflammation	inflammation	NOUN
dpc-1025	209	14	and	and	CCONJ
dpc-1025	209	15	melanoma	melanoma	NOUN
dpc-1025	209	16	survival	survival	NOUN
dpc-1025	209	17	in	in	ADP
dpc-1025	209	18	the	the	DET
dpc-1025	209	19	leeds	leeds	PROPN
dpc-1025	209	20	melanoma	melanoma	PROPN
dpc-1025	209	21	cohort	cohort	NOUN
dpc-1025	209	22	.	.	PUNCT
dpc-1025	210	1	int	int	NOUN
dpc-1025	210	2	j	j	PROPN
dpc-1025	210	3	cancer	cancer	NOUN
dpc-1025	210	4	.	.	PUNCT
dpc-1025	211	1	2015;136(12):2890	2015;136(12):2890	NOUN
dpc-1025	211	2	-	-	NOUN
dpc-1025	211	3	2899	2899	NUM
dpc-1025	211	4	.	.	PUNCT
dpc-1025	212	1	16	16	NUM
dpc-1025	212	2	.	.	PUNCT
dpc-1025	213	1	gambichler	gambichler	PROPN
dpc-1025	213	2	t	t	PROPN
dpc-1025	213	3	,	,	PUNCT
dpc-1025	213	4	bindsteiner	bindsteiner	PROPN
dpc-1025	213	5	m	m	PROPN
dpc-1025	213	6	,	,	PUNCT
dpc-1025	213	7	hoxtermann	hoxtermann	PROPN
dpc-1025	213	8	s	s	PART
dpc-1025	213	9	,	,	PUNCT
dpc-1025	213	10	kreuter	kreuter	NOUN
dpc-1025	213	11	a.	a.	NOUN
dpc-1025	213	12	serum	serum	PROPN
dpc-1025	213	13	25	25	NUM
dpc-1025	213	14	-	-	PUNCT
dpc-1025	213	15	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	213	16	d	d	NOUN
dpc-1025	213	17	serum	serum	NOUN
dpc-1025	213	18	levels	level	NOUN
dpc-1025	213	19	in	in	ADP
dpc-1025	213	20	a	a	DET
dpc-1025	213	21	large	large	ADJ
dpc-1025	213	22	german	german	ADJ
dpc-1025	213	23	cohort	cohort	NOUN
dpc-1025	213	24	of	of	ADP
dpc-1025	213	25	patients	patient	NOUN
dpc-1025	213	26	with	with	ADP
dpc-1025	213	27	melanoma	melanoma	NOUN
dpc-1025	213	28	.	.	PUNCT
dpc-1025	214	1	br	br	PROPN
dpc-1025	214	2	j	j	PROPN
dpc-1025	214	3	dermatol	dermatol	NOUN
dpc-1025	214	4	.	.	PUNCT
dpc-1025	215	1	2013;168(3):625	2013;168(3):625	NUM
dpc-1025	215	2	-	-	SYM
dpc-1025	215	3	628	628	NUM
dpc-1025	215	4	.	.	PUNCT
dpc-1025	216	1	17	17	NUM
dpc-1025	216	2	.	.	PUNCT
dpc-1025	216	3	bade	bade	PROPN
dpc-1025	216	4	b	b	PROPN
dpc-1025	216	5	,	,	PUNCT
dpc-1025	216	6	zdebik	zdebik	X
dpc-1025	217	1	a	a	PRON
dpc-1025	217	2	,	,	PUNCT
dpc-1025	217	3	wagenpfeil	wagenpfeil	NOUN
dpc-1025	217	4	s	s	PROPN
dpc-1025	217	5	,	,	PUNCT
dpc-1025	217	6	et	et	PROPN
dpc-1025	217	7	al	al	PROPN
dpc-1025	217	8	.	.	PROPN
dpc-1025	218	1	low	low	PROPN
dpc-1025	218	2	serum	serum	PROPN
dpc-1025	218	3	25	25	NUM
dpc-1025	218	4	-	-	PUNCT
dpc-1025	218	5	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	218	6	d	d	NOUN
dpc-1025	218	7	concentrations	concentration	NOUN
dpc-1025	218	8	are	be	AUX
dpc-1025	218	9	associated	associate	VERB
dpc-1025	218	10	with	with	ADP
dpc-1025	218	11	increased	increase	VERB
dpc-1025	218	12	risk	risk	NOUN
dpc-1025	218	13	for	for	ADP
dpc-1025	218	14	melanoma	melanoma	NOUN
dpc-1025	218	15	and	and	CCONJ
dpc-1025	218	16	unfavourable	unfavourable	ADJ
dpc-1025	218	17	prognosis	prognosis	NOUN
dpc-1025	218	18	.	.	PUNCT
dpc-1025	219	1	plos	plos	PROPN
dpc-1025	219	2	one	one	NUM
dpc-1025	219	3	.	.	PUNCT
dpc-1025	220	1	2014;9(12):e112863	2014;9(12):e112863	NUM
dpc-1025	220	2	.	.	PROPN
dpc-1025	220	3	18	18	NUM
dpc-1025	220	4	.	.	PUNCT
dpc-1025	221	1	wyatt	wyatt	PROPN
dpc-1025	221	2	c	c	PROPN
dpc-1025	221	3	,	,	PUNCT
dpc-1025	221	4	lucas	lucas	PROPN
dpc-1025	221	5	rm	rm	PROPN
dpc-1025	221	6	,	,	PUNCT
dpc-1025	221	7	hurst	hurst	PROPN
dpc-1025	221	8	c	c	PROPN
dpc-1025	221	9	,	,	PUNCT
dpc-1025	221	10	kimlin	kimlin	PROPN
dpc-1025	221	11	mg	mg	PROPN
dpc-1025	221	12	.	.	PUNCT
dpc-1025	222	1	vitamin	vitamin	NOUN
dpc-1025	222	2	d	d	NOUN
dpc-1025	222	3	deficiency	deficiency	NOUN
dpc-1025	222	4	at	at	ADP
dpc-1025	222	5	melanoma	melanoma	ADJ
dpc-1025	222	6	diagnosis	diagnosis	NOUN
dpc-1025	222	7	is	be	AUX
dpc-1025	222	8	associated	associate	VERB
dpc-1025	222	9	with	with	ADP
dpc-1025	222	10	higher	high	ADJ
dpc-1025	222	11	breslow	breslow	NOUN
dpc-1025	222	12	thickness	thickness	NOUN
dpc-1025	222	13	.	.	PUNCT
dpc-1025	223	1	plos	plos	PROPN
dpc-1025	223	2	one	one	NUM
dpc-1025	223	3	.	.	PUNCT
dpc-1025	224	1	2015;10(5):e0126394	2015;10(5):e0126394	NUM
dpc-1025	224	2	.	.	NOUN
dpc-1025	224	3	19	19	NUM
dpc-1025	225	1	.	.	X
dpc-1025	225	2	cattaruzza	cattaruzza	PROPN
dpc-1025	225	3	ms	ms	PROPN
dpc-1025	225	4	,	,	PUNCT
dpc-1025	225	5	pisani	pisani	PROPN
dpc-1025	225	6	d	d	NOUN
dpc-1025	225	7	,	,	PUNCT
dpc-1025	225	8	fidanza	fidanza	PRON
dpc-1025	225	9	l	l	NOUN
dpc-1025	225	10	,	,	PUNCT
dpc-1025	225	11	et	et	PROPN
dpc-1025	225	12	al	al	PROPN
dpc-1025	225	13	.	.	PROPN
dpc-1025	226	1	25	25	NUM
dpc-1025	226	2	-	-	PUNCT
dpc-1025	226	3	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	226	4	d	d	NOUN
dpc-1025	226	5	serum	serum	NOUN
dpc-1025	226	6	levels	level	NOUN
dpc-1025	226	7	and	and	CCONJ
dpc-1025	226	8	melanoma	melanoma	NOUN
dpc-1025	226	9	risk	risk	NOUN
dpc-1025	226	10	:	:	PUNCT
dpc-1025	226	11	a	a	DET
dpc-1025	226	12	case	case	NOUN
dpc-1025	226	13	-	-	PUNCT
dpc-1025	226	14	control	control	NOUN
dpc-1025	226	15	study	study	NOUN
dpc-1025	226	16	and	and	CCONJ
dpc-1025	226	17	evidence	evidence	NOUN
dpc-1025	226	18	synthesis	synthesis	NOUN
dpc-1025	226	19	of	of	ADP
dpc-1025	226	20	clinical	clinical	ADJ
dpc-1025	226	21	epidemiological	epidemiological	ADJ
dpc-1025	226	22	studies	study	NOUN
dpc-1025	226	23	.	.	PUNCT
dpc-1025	227	1	eur	eur	PROPN
dpc-1025	227	2	j	j	PROPN
dpc-1025	227	3	cancer	cancer	NOUN
dpc-1025	227	4	prev	prev	X
dpc-1025	227	5	.	.	PUNCT
dpc-1025	227	6	2019;28(3):203	2019;28(3):203	NUM
dpc-1025	227	7	-	-	PUNCT
dpc-1025	227	8	211	211	NUM
dpc-1025	227	9	.	.	PUNCT
dpc-1025	228	1	20	20	NUM
dpc-1025	228	2	.	.	PUNCT
dpc-1025	229	1	bianconi	bianconi	PROPN
dpc-1025	229	2	f	f	PROPN
dpc-1025	229	3	,	,	PUNCT
dpc-1025	229	4	masanotti	masanotti	PROPN
dpc-1025	229	5	gm	gm	PROPN
dpc-1025	229	6	,	,	PUNCT
dpc-1025	229	7	liso	liso	VERB
dpc-1025	229	8	a	a	PRON
dpc-1025	229	9	,	,	PUNCT
dpc-1025	229	10	la	la	PROPN
dpc-1025	229	11	rosa	rosa	PROPN
dpc-1025	229	12	f	f	PROPN
dpc-1025	229	13	,	,	PUNCT
dpc-1025	229	14	duca	duca	PROPN
dpc-1025	229	15	e	e	PROPN
dpc-1025	229	16	,	,	PUNCT
dpc-1025	229	17	stracci	stracci	PROPN
dpc-1025	229	18	f.	f.	PROPN
dpc-1025	229	19	seasonal	seasonal	PROPN
dpc-1025	229	20	variation	variation	NOUN
dpc-1025	229	21	in	in	ADP
dpc-1025	229	22	skin	skin	NOUN
dpc-1025	229	23	cancer	cancer	NOUN
dpc-1025	229	24	diagnosis	diagnosis	NOUN
dpc-1025	229	25	.	.	PUNCT
dpc-1025	230	1	front	front	ADJ
dpc-1025	230	2	public	public	ADJ
dpc-1025	230	3	health	health	NOUN
dpc-1025	230	4	.	.	PUNCT
dpc-1025	231	1	2016;4:78	2016;4:78	NOUN
dpc-1025	231	2	.	.	PUNCT
dpc-1025	232	1	21	21	NUM
dpc-1025	232	2	.	.	PUNCT
dpc-1025	233	1	sondak	sondak	PROPN
dpc-1025	233	2	vk	vk	PROPN
dpc-1025	233	3	,	,	PUNCT
dpc-1025	233	4	mciver	mciver	NOUN
dpc-1025	233	5	b	b	NOUN
dpc-1025	233	6	,	,	PUNCT
dpc-1025	233	7	kanetsky	kanetsky	PROPN
dpc-1025	233	8	pa	pa	PROPN
dpc-1025	233	9	.	.	PROPN
dpc-1025	234	1	vitamin	vitamin	PROPN
dpc-1025	234	2	d	d	NOUN
dpc-1025	234	3	and	and	CCONJ
dpc-1025	234	4	melanoma	melanoma	NOUN
dpc-1025	234	5	:	:	PUNCT
dpc-1025	234	6	what	what	PRON
dpc-1025	234	7	do	do	AUX
dpc-1025	234	8	we	we	PRON
dpc-1025	234	9	tell	tell	VERB
dpc-1025	234	10	our	our	PRON
dpc-1025	234	11	patients	patient	NOUN
dpc-1025	234	12	?	?	PUNCT
dpc-1025	235	1	j	j	PROPN
dpc-1025	235	2	clin	clin	PROPN
dpc-1025	235	3	oncol	oncol	PROPN
dpc-1025	235	4	.	.	PUNCT
dpc-1025	236	1	2016;34(15):17131714	2016;34(15):17131714	NUM
dpc-1025	236	2	.	.	NOUN
dpc-1025	236	3	along	along	ADP
dpc-1025	236	4	with	with	ADP
dpc-1025	236	5	the	the	DET
dpc-1025	236	6	real	real	ADJ
dpc-1025	236	7	possibility	possibility	NOUN
dpc-1025	236	8	that	that	SCONJ
dpc-1025	236	9	patients	patient	NOUN
dpc-1025	236	10	with	with	ADP
dpc-1025	236	11	lower	low	ADJ
dpc-1025	236	12	vitamin	vitamin	NOUN
dpc-1025	236	13	d	d	NOUN
dpc-1025	236	14	levels	level	NOUN
dpc-1025	236	15	may	may	AUX
dpc-1025	236	16	fare	fare	VERB
dpc-1025	236	17	worse	bad	ADJ
dpc-1025	236	18	than	than	ADP
dpc-1025	236	19	those	those	PRON
dpc-1025	236	20	with	with	ADP
dpc-1025	236	21	higher	high	ADJ
dpc-1025	236	22	levels	level	NOUN
dpc-1025	236	23	,	,	PUNCT
dpc-1025	236	24	seems	seem	VERB
dpc-1025	236	25	to	to	PART
dpc-1025	236	26	provide	provide	VERB
dpc-1025	236	27	strong	strong	ADJ
dpc-1025	236	28	rationale	rationale	NOUN
dpc-1025	236	29	for	for	ADP
dpc-1025	236	30	routine	routine	ADJ
dpc-1025	236	31	determination	determination	NOUN
dpc-1025	236	32	of	of	ADP
dpc-1025	236	33	the	the	DET
dpc-1025	236	34	25	25	NUM
dpc-1025	236	35	-	-	PUNCT
dpc-1025	236	36	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	236	37	d	d	NOUN
dpc-1025	236	38	level	level	NOUN
dpc-1025	236	39	at	at	ADP
dpc-1025	236	40	initial	initial	ADJ
dpc-1025	236	41	diagnosis	diagnosis	NOUN
dpc-1025	236	42	,	,	PUNCT
dpc-1025	236	43	followed	follow	VERB
dpc-1025	236	44	by	by	ADP
dpc-1025	236	45	oral	oral	ADJ
dpc-1025	236	46	supplementation	supplementation	NOUN
dpc-1025	236	47	and	and	CCONJ
dpc-1025	236	48	monitoring	monitoring	NOUN
dpc-1025	236	49	for	for	ADP
dpc-1025	236	50	patients	patient	NOUN
dpc-1025	236	51	with	with	ADP
dpc-1025	236	52	low	low	ADJ
dpc-1025	236	53	or	or	CCONJ
dpc-1025	236	54	deficient	deficient	ADJ
dpc-1025	236	55	levels	level	NOUN
dpc-1025	236	56	[	[	X
dpc-1025	236	57	21	21	NUM
dpc-1025	236	58	]	]	PUNCT
dpc-1025	236	59	.	.	PUNCT
dpc-1025	237	1	in	in	ADP
dpc-1025	237	2	view	view	NOUN
dpc-1025	237	3	of	of	ADP
dpc-1025	237	4	the	the	DET
dpc-1025	237	5	well	well	ADV
dpc-1025	237	6	-	-	PUNCT
dpc-1025	237	7	established	establish	VERB
dpc-1025	237	8	pathogenetic	pathogenetic	ADJ
dpc-1025	237	9	role	role	NOUN
dpc-1025	237	10	of	of	ADP
dpc-1025	237	11	uvr	uvr	NOUN
dpc-1025	237	12	in	in	ADP
dpc-1025	237	13	skin	skin	NOUN
dpc-1025	237	14	carcinogenesis	carcinogenesis	NOUN
dpc-1025	237	15	and	and	CCONJ
dpc-1025	237	16	the	the	DET
dpc-1025	237	17	controversy	controversy	NOUN
dpc-1025	237	18	over	over	ADP
dpc-1025	237	19	vitamin	vitamin	PROPN
dpc-1025	237	20	d	d	PROPN
dpc-1025	237	21	,	,	PUNCT
dpc-1025	237	22	changes	change	NOUN
dpc-1025	237	23	in	in	ADP
dpc-1025	237	24	current	current	ADJ
dpc-1025	237	25	recommendations	recommendation	NOUN
dpc-1025	237	26	for	for	ADP
dpc-1025	237	27	strict	strict	ADJ
dpc-1025	237	28	photo	photo	NOUN
dpc-1025	237	29	-	-	PUNCT
dpc-1025	237	30	protection	protection	NOUN
dpc-1025	237	31	as	as	ADP
dpc-1025	237	32	a	a	DET
dpc-1025	237	33	major	major	ADJ
dpc-1025	237	34	target	target	NOUN
dpc-1025	237	35	of	of	ADP
dpc-1025	237	36	skin	skin	NOUN
dpc-1025	237	37	cancer	cancer	NOUN
dpc-1025	237	38	prevention	prevention	NOUN
dpc-1025	237	39	are	be	AUX
dpc-1025	237	40	not	not	PART
dpc-1025	237	41	warranted	warrant	VERB
dpc-1025	237	42	[	[	PUNCT
dpc-1025	237	43	21	21	NUM
dpc-1025	237	44	]	]	PUNCT
dpc-1025	237	45	.	.	PUNCT
dpc-1025	238	1	most	most	ADV
dpc-1025	238	2	importantly	importantly	ADV
dpc-1025	238	3	,	,	PUNCT
dpc-1025	238	4	sun	sun	NOUN
dpc-1025	238	5	exposure	exposure	NOUN
dpc-1025	238	6	alone	alone	ADV
dpc-1025	238	7	does	do	AUX
dpc-1025	238	8	not	not	PART
dpc-1025	238	9	guarantee	guarantee	VERB
dpc-1025	238	10	vitamin	vitamin	NOUN
dpc-1025	238	11	d	d	X
dpc-1025	238	12	sufficiency	sufficiency	NOUN
dpc-1025	239	1	[	[	X
dpc-1025	239	2	15,22,39	15,22,39	NUM
dpc-1025	239	3	]	]	PUNCT
dpc-1025	239	4	.	.	PUNCT
dpc-1025	240	1	nevertheless	nevertheless	ADV
dpc-1025	240	2	,	,	PUNCT
dpc-1025	240	3	an	an	DET
dpc-1025	240	4	optimum	optimum	ADJ
dpc-1025	240	5	balance	balance	NOUN
dpc-1025	240	6	between	between	ADP
dpc-1025	240	7	sun	sun	NOUN
dpc-1025	240	8	protection	protection	NOUN
dpc-1025	240	9	and	and	CCONJ
dpc-1025	240	10	exposure	exposure	NOUN
dpc-1025	240	11	is	be	AUX
dpc-1025	240	12	advocated	advocate	VERB
dpc-1025	240	13	[	[	PUNCT
dpc-1025	240	14	1	1	NUM
dpc-1025	240	15	]	]	PUNCT
dpc-1025	240	16	.	.	PUNCT
dpc-1025	241	1	the	the	DET
dpc-1025	241	2	present	present	ADJ
dpc-1025	241	3	study	study	NOUN
dpc-1025	241	4	has	have	VERB
dpc-1025	241	5	some	some	DET
dpc-1025	241	6	limitations	limitation	NOUN
dpc-1025	241	7	.	.	PUNCT
dpc-1025	242	1	the	the	DET
dpc-1025	242	2	sample	sample	NOUN
dpc-1025	242	3	size	size	NOUN
dpc-1025	242	4	of	of	ADP
dpc-1025	242	5	melanoma	melanoma	NOUN
dpc-1025	242	6	patients	patient	NOUN
dpc-1025	242	7	was	be	AUX
dpc-1025	242	8	relatively	relatively	ADV
dpc-1025	242	9	small	small	ADJ
dpc-1025	242	10	and	and	CCONJ
dpc-1025	242	11	monocentric	monocentric	ADJ
dpc-1025	242	12	compared	compare	VERB
dpc-1025	242	13	to	to	ADP
dpc-1025	242	14	other	other	ADJ
dpc-1025	242	15	studies	study	NOUN
dpc-1025	242	16	,	,	PUNCT
dpc-1025	242	17	although	although	SCONJ
dpc-1025	242	18	it	it	PRON
dpc-1025	242	19	originated	originate	VERB
dpc-1025	242	20	from	from	ADP
dpc-1025	242	21	the	the	DET
dpc-1025	242	22	largest	large	ADJ
dpc-1025	242	23	referral	referral	ADJ
dpc-1025	242	24	center	center	NOUN
dpc-1025	242	25	of	of	ADP
dpc-1025	242	26	melanoma	melanoma	NOUN
dpc-1025	242	27	patients	patient	NOUN
dpc-1025	242	28	in	in	ADP
dpc-1025	242	29	central	central	PROPN
dpc-1025	242	30	greece	greece	PROPN
dpc-1025	242	31	.	.	PUNCT
dpc-1025	243	1	in	in	ADP
dpc-1025	243	2	addition	addition	NOUN
dpc-1025	243	3	,	,	PUNCT
dpc-1025	243	4	most	most	ADJ
dpc-1025	243	5	cases	case	NOUN
dpc-1025	243	6	were	be	AUX
dpc-1025	243	7	early	early	ADJ
dpc-1025	243	8	-	-	PUNCT
dpc-1025	243	9	stage	stage	NOUN
dpc-1025	243	10	melanomas	melanomas	NOUN
dpc-1025	243	11	.	.	PUNCT
dpc-1025	244	1	it	it	PRON
dpc-1025	244	2	is	be	AUX
dpc-1025	244	3	known	know	VERB
dpc-1025	244	4	that	that	SCONJ
dpc-1025	244	5	serum	serum	NOUN
dpc-1025	244	6	total	total	ADJ
dpc-1025	244	7	25	25	NUM
dpc-1025	244	8	-	-	PUNCT
dpc-1025	244	9	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	244	10	d	d	NOUN
dpc-1025	244	11	levels	level	NOUN
dpc-1025	244	12	are	be	AUX
dpc-1025	244	13	usually	usually	ADV
dpc-1025	244	14	not	not	PART
dpc-1025	244	15	affected	affect	VERB
dpc-1025	244	16	until	until	SCONJ
dpc-1025	244	17	the	the	DET
dpc-1025	244	18	bmi	bmi	NOUN
dpc-1025	244	19	is	be	AUX
dpc-1025	244	20	>	>	X
dpc-1025	244	21	30	30	NUM
dpc-1025	244	22	ng	ng	NOUN
dpc-1025	244	23	/	/	SYM
dpc-1025	244	24	ml	ml	PROPN
dpc-1025	244	25	.	.	PUNCT
dpc-1025	245	1	in	in	ADP
dpc-1025	245	2	our	our	PRON
dpc-1025	245	3	melanoma	melanoma	NOUN
dpc-1025	245	4	group	group	NOUN
dpc-1025	245	5	no	no	DET
dpc-1025	245	6	patient	patient	NOUN
dpc-1025	245	7	had	have	VERB
dpc-1025	245	8	bmi	bmi	NOUN
dpc-1025	245	9	>	>	PUNCT
dpc-1025	245	10	30	30	NUM
dpc-1025	245	11	so	so	SCONJ
dpc-1025	245	12	we	we	PRON
dpc-1025	245	13	divided	divide	VERB
dpc-1025	245	14	our	our	PRON
dpc-1025	245	15	patients	patient	NOUN
dpc-1025	245	16	into	into	ADP
dpc-1025	245	17	2	2	NUM
dpc-1025	245	18	groups	group	NOUN
dpc-1025	245	19	,	,	PUNCT
dpc-1025	245	20	one	one	NUM
dpc-1025	245	21	with	with	ADP
dpc-1025	245	22	bmi	bmi	PROPN
dpc-1025	245	23	≤25	≤25	PROPN
dpc-1025	245	24	and	and	CCONJ
dpc-1025	245	25	the	the	DET
dpc-1025	245	26	other	other	ADJ
dpc-1025	245	27	with	with	ADP
dpc-1025	245	28	overweight	overweight	ADJ
dpc-1025	245	29	patients	patient	NOUN
dpc-1025	245	30	and	and	CCONJ
dpc-1025	245	31	bmi	bmi	X
dpc-1025	245	32	>	>	PROPN
dpc-1025	245	33	25	25	NUM
dpc-1025	245	34	.	.	PUNCT
dpc-1025	246	1	another	another	DET
dpc-1025	246	2	limitation	limitation	NOUN
dpc-1025	246	3	of	of	ADP
dpc-1025	246	4	studies	study	NOUN
dpc-1025	246	5	including	include	VERB
dpc-1025	246	6	ours	our	NOUN
dpc-1025	246	7	,	,	PUNCT
dpc-1025	246	8	assessing	assess	VERB
dpc-1025	246	9	serum	serum	NOUN
dpc-1025	246	10	25	25	NUM
dpc-1025	246	11	-	-	PUNCT
dpc-1025	246	12	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	246	13	d	d	NOUN
dpc-1025	246	14	levels	level	NOUN
dpc-1025	246	15	,	,	PUNCT
dpc-1025	246	16	is	be	AUX
dpc-1025	246	17	that	that	SCONJ
dpc-1025	246	18	the	the	DET
dpc-1025	246	19	ideal	ideal	ADJ
dpc-1025	246	20	levels	level	NOUN
dpc-1025	246	21	are	be	AUX
dpc-1025	246	22	a	a	DET
dpc-1025	246	23	matter	matter	NOUN
dpc-1025	246	24	of	of	ADP
dpc-1025	246	25	controversy	controversy	NOUN
dpc-1025	246	26	and	and	CCONJ
dpc-1025	246	27	concentrations	concentration	NOUN
dpc-1025	246	28	that	that	PRON
dpc-1025	246	29	would	would	AUX
dpc-1025	246	30	be	be	AUX
dpc-1025	246	31	beneficial	beneficial	ADJ
dpc-1025	246	32	for	for	SCONJ
dpc-1025	246	33	patients	patient	NOUN
dpc-1025	246	34	with	with	ADP
dpc-1025	246	35	melanoma	melanoma	NOUN
dpc-1025	246	36	are	be	AUX
dpc-1025	246	37	not	not	PART
dpc-1025	246	38	adequately	adequately	ADV
dpc-1025	246	39	documented	document	VERB
dpc-1025	246	40	.	.	PUNCT
dpc-1025	247	1	conclusions	conclusion	NOUN
dpc-1025	247	2	we	we	PRON
dpc-1025	247	3	found	find	VERB
dpc-1025	247	4	lower	low	ADJ
dpc-1025	247	5	serum	serum	NOUN
dpc-1025	247	6	total	total	ADJ
dpc-1025	247	7	25	25	NUM
dpc-1025	247	8	-	-	PUNCT
dpc-1025	247	9	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	247	10	d	d	PROPN
dpc-1025	247	11	levels	level	NOUN
dpc-1025	247	12	among	among	ADP
dpc-1025	247	13	our	our	PRON
dpc-1025	247	14	melanoma	melanoma	NOUN
dpc-1025	247	15	patients	patient	NOUN
dpc-1025	247	16	in	in	ADP
dpc-1025	247	17	a	a	DET
dpc-1025	247	18	case	case	NOUN
dpc-1025	247	19	-	-	PUNCT
dpc-1025	247	20	control	control	NOUN
dpc-1025	247	21	study	study	NOUN
dpc-1025	247	22	performed	perform	VERB
dpc-1025	247	23	in	in	ADP
dpc-1025	247	24	a	a	DET
dpc-1025	247	25	low	low	ADJ
dpc-1025	247	26	-	-	PUNCT
dpc-1025	247	27	risk	risk	NOUN
dpc-1025	247	28	southern	southern	ADJ
dpc-1025	247	29	european	european	ADJ
dpc-1025	247	30	population	population	NOUN
dpc-1025	247	31	.	.	PUNCT
dpc-1025	248	1	however	however	ADV
dpc-1025	248	2	,	,	PUNCT
dpc-1025	248	3	no	no	DET
dpc-1025	248	4	statistically	statistically	ADV
dpc-1025	248	5	significant	significant	ADJ
dpc-1025	248	6	difference	difference	NOUN
dpc-1025	248	7	was	be	AUX
dpc-1025	248	8	documented	document	VERB
dpc-1025	248	9	,	,	PUNCT
dpc-1025	248	10	and	and	CCONJ
dpc-1025	248	11	these	these	DET
dpc-1025	248	12	levels	level	NOUN
dpc-1025	248	13	were	be	AUX
dpc-1025	248	14	not	not	PART
dpc-1025	248	15	associated	associate	VERB
dpc-1025	248	16	with	with	ADP
dpc-1025	248	17	established	establish	VERB
dpc-1025	248	18	risk	risk	NOUN
dpc-1025	248	19	factors	factor	NOUN
dpc-1025	248	20	and	and	CCONJ
dpc-1025	248	21	prognostic	prognostic	ADJ
dpc-1025	248	22	variables	variable	NOUN
dpc-1025	248	23	for	for	ADP
dpc-1025	248	24	cmm	cmm	NOUN
dpc-1025	248	25	.	.	PUNCT
dpc-1025	249	1	more	more	ADJ
dpc-1025	249	2	studies	study	NOUN
dpc-1025	249	3	are	be	AUX
dpc-1025	249	4	needed	need	VERB
dpc-1025	249	5	to	to	PART
dpc-1025	249	6	elucidate	elucidate	VERB
dpc-1025	249	7	the	the	DET
dpc-1025	249	8	complex	complex	ADJ
dpc-1025	249	9	effect	effect	NOUN
dpc-1025	249	10	of	of	ADP
dpc-1025	249	11	vitamin	vitamin	NOUN
dpc-1025	249	12	d	d	NOUN
dpc-1025	249	13	in	in	ADP
dpc-1025	249	14	the	the	DET
dpc-1025	249	15	development	development	NOUN
dpc-1025	249	16	and	and	CCONJ
dpc-1025	249	17	progression	progression	NOUN
dpc-1025	249	18	of	of	ADP
dpc-1025	249	19	cmm	cmm	NOUN
dpc-1025	249	20	.	.	PUNCT
dpc-1025	250	1	better	well	ADJ
dpc-1025	250	2	understanding	understanding	NOUN
dpc-1025	250	3	of	of	ADP
dpc-1025	250	4	the	the	DET
dpc-1025	250	5	role	role	NOUN
dpc-1025	250	6	of	of	ADP
dpc-1025	250	7	vitamin	vitamin	NOUN
dpc-1025	250	8	d	d	NOUN
dpc-1025	250	9	may	may	AUX
dpc-1025	250	10	provide	provide	VERB
dpc-1025	250	11	new	new	ADJ
dpc-1025	250	12	insights	insight	NOUN
dpc-1025	250	13	applicable	applicable	ADJ
dpc-1025	250	14	to	to	ADP
dpc-1025	250	15	melanoma	melanoma	NOUN
dpc-1025	250	16	prevention	prevention	NOUN
dpc-1025	250	17	and	and	CCONJ
dpc-1025	250	18	treatment	treatment	NOUN
dpc-1025	250	19	.	.	PUNCT
dpc-1025	251	1	references	reference	NOUN
dpc-1025	251	2	1	1	NUM
dpc-1025	251	3	.	.	PUNCT
dpc-1025	251	4	ombra	ombra	PROPN
dpc-1025	251	5	mn	mn	PROPN
dpc-1025	251	6	,	,	PUNCT
dpc-1025	251	7	paliogiannis	paliogiannis	PROPN
dpc-1025	251	8	p	p	X
dpc-1025	251	9	,	,	PUNCT
dpc-1025	251	10	doneddu	doneddu	ADJ
dpc-1025	251	11	v	v	ADP
dpc-1025	251	12	,	,	PUNCT
dpc-1025	251	13	et	et	PROPN
dpc-1025	251	14	al	al	PROPN
dpc-1025	251	15	.	.	PUNCT
dpc-1025	251	16	vitamin	vitamin	NOUN
dpc-1025	251	17	d	d	NOUN
dpc-1025	251	18	status	status	NOUN
dpc-1025	251	19	and	and	CCONJ
dpc-1025	251	20	risk	risk	NOUN
dpc-1025	251	21	for	for	ADP
dpc-1025	251	22	malignant	malignant	ADJ
dpc-1025	251	23	cutaneous	cutaneous	ADJ
dpc-1025	251	24	melanoma	melanoma	NOUN
dpc-1025	251	25	:	:	PUNCT
dpc-1025	251	26	recent	recent	ADJ
dpc-1025	251	27	advances	advance	NOUN
dpc-1025	251	28	.	.	PUNCT
dpc-1025	252	1	eur	eur	PROPN
dpc-1025	252	2	j	j	PROPN
dpc-1025	252	3	cancer	cancer	NOUN
dpc-1025	252	4	prev	prev	X
dpc-1025	252	5	.	.	PUNCT
dpc-1025	253	1	2017;26(6):532	2017;26(6):532	NUM
dpc-1025	253	2	-	-	SYM
dpc-1025	253	3	541	541	NUM
dpc-1025	253	4	.	.	PUNCT
dpc-1025	254	1	2	2	X
dpc-1025	254	2	.	.	X
dpc-1025	254	3	savoye	savoye	VERB
dpc-1025	254	4	i	i	PRON
dpc-1025	254	5	,	,	PUNCT
dpc-1025	254	6	olsen	olsen	NOUN
dpc-1025	254	7	cm	cm	PROPN
dpc-1025	254	8	,	,	PUNCT
dpc-1025	254	9	whiteman	whiteman	PROPN
dpc-1025	254	10	dc	dc	PROPN
dpc-1025	254	11	,	,	PUNCT
dpc-1025	254	12	et	et	PROPN
dpc-1025	254	13	al	al	PROPN
dpc-1025	254	14	.	.	PUNCT
dpc-1025	255	1	patterns	pattern	NOUN
dpc-1025	255	2	of	of	ADP
dpc-1025	255	3	ultraviolet	ultraviolet	ADJ
dpc-1025	255	4	radiation	radiation	NOUN
dpc-1025	255	5	exposure	exposure	NOUN
dpc-1025	255	6	and	and	CCONJ
dpc-1025	255	7	skin	skin	NOUN
dpc-1025	255	8	cancer	cancer	NOUN
dpc-1025	255	9	risk	risk	NOUN
dpc-1025	255	10	:	:	PUNCT
dpc-1025	255	11	the	the	DET
dpc-1025	255	12	e3n	e3n	ADJ
dpc-1025	255	13	-	-	PUNCT
dpc-1025	255	14	sunexp	sunexp	NOUN
dpc-1025	255	15	study	study	NOUN
dpc-1025	255	16	.	.	PUNCT
dpc-1025	256	1	j	j	PROPN
dpc-1025	256	2	epidemiol	epidemiol	PROPN
dpc-1025	256	3	.	.	PUNCT
dpc-1025	257	1	2018;28(1):27	2018;28(1):27	NUM
dpc-1025	257	2	-	-	SYM
dpc-1025	257	3	33	33	NUM
dpc-1025	257	4	.	.	PUNCT
dpc-1025	258	1	3	3	X
dpc-1025	258	2	.	.	X
dpc-1025	258	3	pilz	pilz	PROPN
dpc-1025	258	4	s	s	PART
dpc-1025	258	5	,	,	PUNCT
dpc-1025	258	6	trummer	trummer	PROPN
dpc-1025	258	7	c	c	NOUN
dpc-1025	258	8	,	,	PUNCT
dpc-1025	258	9	pandis	pandis	NOUN
dpc-1025	258	10	m	m	PROPN
dpc-1025	258	11	,	,	PUNCT
dpc-1025	258	12	et	et	PROPN
dpc-1025	258	13	al	al	PROPN
dpc-1025	258	14	.	.	PUNCT
dpc-1025	259	1	vitamin	vitamin	PROPN
dpc-1025	259	2	d	d	NOUN
dpc-1025	259	3	:	:	PUNCT
dpc-1025	259	4	current	current	ADJ
dpc-1025	259	5	guidelines	guideline	NOUN
dpc-1025	259	6	and	and	CCONJ
dpc-1025	259	7	future	future	ADJ
dpc-1025	259	8	outlook	outlook	NOUN
dpc-1025	259	9	.	.	PUNCT
dpc-1025	260	1	anticancer	anticancer	NOUN
dpc-1025	260	2	res	re	NOUN
dpc-1025	260	3	.	.	PUNCT
dpc-1025	261	1	2018;38(2):1145	2018;38(2):1145	NUM
dpc-1025	261	2	-	-	SYM
dpc-1025	261	3	1151	1151	NUM
dpc-1025	261	4	.	.	PUNCT
dpc-1025	262	1	8	8	NUM
dpc-1025	262	2	research	research	NOUN
dpc-1025	262	3	|	|	ADV
dpc-1025	262	4	dermatol	dermatol	NOUN
dpc-1025	262	5	pract	pract	NOUN
dpc-1025	262	6	concept	concept	NOUN
dpc-1025	262	7	2020;10(1):e2020010	2020;10(1):e2020010	PROPN
dpc-1025	262	8	32	32	NUM
dpc-1025	262	9	.	.	PUNCT
dpc-1025	263	1	katrinaki	katrinaki	PROPN
dpc-1025	263	2	m	m	PROPN
dpc-1025	263	3	,	,	PUNCT
dpc-1025	263	4	kampa	kampa	VERB
dpc-1025	263	5	m	m	PROPN
dpc-1025	263	6	,	,	PUNCT
dpc-1025	263	7	margioris	margioris	VERB
dpc-1025	263	8	a	a	PRON
dpc-1025	263	9	,	,	PUNCT
dpc-1025	263	10	castanas	castanas	PROPN
dpc-1025	263	11	e	e	NOUN
dpc-1025	263	12	,	,	PUNCT
dpc-1025	263	13	malliaraki	malliaraki	PROPN
dpc-1025	263	14	n.	n.	PROPN
dpc-1025	263	15	vitamin	vitamin	NOUN
dpc-1025	263	16	d	d	PROPN
dpc-1025	263	17	levels	level	NOUN
dpc-1025	263	18	in	in	ADP
dpc-1025	263	19	a	a	DET
dpc-1025	263	20	large	large	ADJ
dpc-1025	263	21	mediterranean	mediterranean	ADJ
dpc-1025	263	22	cohort	cohort	NOUN
dpc-1025	263	23	:	:	PUNCT
dpc-1025	263	24	reconsidering	reconsider	VERB
dpc-1025	263	25	normal	normal	ADJ
dpc-1025	263	26	cut	cut	NOUN
dpc-1025	263	27	-	-	PUNCT
dpc-1025	263	28	off	off	ADP
dpc-1025	263	29	values	value	NOUN
dpc-1025	263	30	.	.	PUNCT
dpc-1025	264	1	hormones	hormone	NOUN
dpc-1025	264	2	.	.	PUNCT
dpc-1025	265	1	2016;15(2):205	2016;15(2):205	NUM
dpc-1025	265	2	-	-	SYM
dpc-1025	265	3	223	223	NUM
dpc-1025	265	4	.	.	PUNCT
dpc-1025	266	1	33	33	NUM
dpc-1025	266	2	.	.	PUNCT
dpc-1025	267	1	ross	ross	PROPN
dpc-1025	267	2	ac	ac	PROPN
dpc-1025	267	3	,	,	PUNCT
dpc-1025	267	4	manson	manson	PROPN
dpc-1025	267	5	je	je	PROPN
dpc-1025	267	6	,	,	PUNCT
dpc-1025	267	7	abrams	abrams	PROPN
dpc-1025	267	8	sa	sa	PROPN
dpc-1025	267	9	,	,	PUNCT
dpc-1025	267	10	et	et	PROPN
dpc-1025	267	11	al	al	PROPN
dpc-1025	267	12	.	.	PUNCT
dpc-1025	268	1	the	the	DET
dpc-1025	268	2	2011	2011	NUM
dpc-1025	268	3	report	report	NOUN
dpc-1025	268	4	on	on	ADP
dpc-1025	268	5	dietary	dietary	ADJ
dpc-1025	268	6	reference	reference	NOUN
dpc-1025	268	7	intakes	intake	NOUN
dpc-1025	268	8	for	for	ADP
dpc-1025	268	9	calcium	calcium	NOUN
dpc-1025	268	10	and	and	CCONJ
dpc-1025	268	11	vitamin	vitamin	NOUN
dpc-1025	268	12	d	d	NOUN
dpc-1025	268	13	from	from	ADP
dpc-1025	268	14	the	the	DET
dpc-1025	268	15	institute	institute	NOUN
dpc-1025	268	16	of	of	ADP
dpc-1025	268	17	medicine	medicine	NOUN
dpc-1025	268	18	:	:	PUNCT
dpc-1025	268	19	what	what	DET
dpc-1025	268	20	clinicians	clinician	NOUN
dpc-1025	268	21	need	need	VERB
dpc-1025	268	22	to	to	PART
dpc-1025	268	23	know	know	VERB
dpc-1025	268	24	.	.	PUNCT
dpc-1025	269	1	j	j	PROPN
dpc-1025	269	2	clin	clin	PROPN
dpc-1025	269	3	endocrinol	endocrinol	PROPN
dpc-1025	269	4	metab	metab	NOUN
dpc-1025	269	5	.	.	PUNCT
dpc-1025	270	1	2011;111(4):524	2011;111(4):524	NUM
dpc-1025	270	2	-	-	SYM
dpc-1025	270	3	527	527	NUM
dpc-1025	270	4	.	.	PUNCT
dpc-1025	271	1	34	34	NUM
dpc-1025	271	2	.	.	PUNCT
dpc-1025	272	1	holick	holick	NOUN
dpc-1025	272	2	mf	mf	PROPN
dpc-1025	272	3	,	,	PUNCT
dpc-1025	272	4	binkley	binkley	PROPN
dpc-1025	272	5	nc	nc	PROPN
dpc-1025	272	6	,	,	PUNCT
dpc-1025	272	7	bischoff	bischoff	PROPN
dpc-1025	272	8	-	-	PUNCT
dpc-1025	272	9	ferrari	ferrari	PROPN
dpc-1025	272	10	ha	ha	INTJ
dpc-1025	272	11	,	,	PUNCT
dpc-1025	272	12	et	et	PROPN
dpc-1025	272	13	al	al	PROPN
dpc-1025	272	14	.	.	PROPN
dpc-1025	272	15	evaluation	evaluation	NOUN
dpc-1025	272	16	,	,	PUNCT
dpc-1025	272	17	treatment	treatment	NOUN
dpc-1025	272	18	,	,	PUNCT
dpc-1025	272	19	and	and	CCONJ
dpc-1025	272	20	prevention	prevention	NOUN
dpc-1025	272	21	of	of	ADP
dpc-1025	272	22	vitamin	vitamin	NOUN
dpc-1025	272	23	d	d	NOUN
dpc-1025	272	24	deficiency	deficiency	NOUN
dpc-1025	272	25	:	:	PUNCT
dpc-1025	272	26	an	an	DET
dpc-1025	272	27	endocrine	endocrine	ADJ
dpc-1025	272	28	society	society	NOUN
dpc-1025	272	29	clinical	clinical	ADJ
dpc-1025	272	30	practice	practice	NOUN
dpc-1025	272	31	guideline	guideline	NOUN
dpc-1025	272	32	.	.	PUNCT
dpc-1025	273	1	j	j	PROPN
dpc-1025	273	2	clin	clin	PROPN
dpc-1025	273	3	endocrinol	endocrinol	PROPN
dpc-1025	273	4	metab	metab	NOUN
dpc-1025	273	5	.	.	PUNCT
dpc-1025	274	1	2011;96(7):1911–1930	2011;96(7):1911–1930	NUM
dpc-1025	274	2	.	.	PUNCT
dpc-1025	275	1	35	35	NUM
dpc-1025	275	2	.	.	PUNCT
dpc-1025	276	1	lasithiotakis	lasithiotakis	PROPN
dpc-1025	276	2	k	k	PROPN
dpc-1025	276	3	,	,	PUNCT
dpc-1025	276	4	leiter	leiter	PROPN
dpc-1025	276	5	u	u	NOUN
dpc-1025	276	6	,	,	PUNCT
dpc-1025	276	7	krüger	krüger	NOUN
dpc-1025	276	8	-	-	PUNCT
dpc-1025	276	9	krasagakis	krasagakis	PROPN
dpc-1025	276	10	s	s	PROPN
dpc-1025	276	11	,	,	PUNCT
dpc-1025	276	12	tosca	tosca	PROPN
dpc-1025	276	13	a	a	PRON
dpc-1025	276	14	,	,	PUNCT
dpc-1025	276	15	garbe	garbe	PROPN
dpc-1025	276	16	c.	c.	PROPN
dpc-1025	276	17	comparative	comparative	ADJ
dpc-1025	276	18	analysis	analysis	NOUN
dpc-1025	276	19	of	of	ADP
dpc-1025	276	20	incidence	incidence	NOUN
dpc-1025	276	21	and	and	CCONJ
dpc-1025	276	22	clinical	clinical	ADJ
dpc-1025	276	23	features	feature	NOUN
dpc-1025	276	24	of	of	ADP
dpc-1025	276	25	cutaneous	cutaneous	ADJ
dpc-1025	276	26	malignant	malignant	ADJ
dpc-1025	276	27	melanoma	melanoma	NOUN
dpc-1025	276	28	in	in	ADP
dpc-1025	276	29	crete	crete	PROPN
dpc-1025	276	30	(	(	PUNCT
dpc-1025	276	31	greece	greece	PROPN
dpc-1025	276	32	)	)	PUNCT
dpc-1025	276	33	and	and	CCONJ
dpc-1025	276	34	southern	southern	PROPN
dpc-1025	276	35	germany	germany	PROPN
dpc-1025	276	36	(	(	PUNCT
dpc-1025	276	37	central	central	PROPN
dpc-1025	276	38	baden	baden	PROPN
dpc-1025	276	39	-	-	PUNCT
dpc-1025	276	40	württemberg	württemberg	PROPN
dpc-1025	276	41	)	)	PUNCT
dpc-1025	276	42	.	.	PUNCT
dpc-1025	277	1	br	br	PROPN
dpc-1025	277	2	j	j	PROPN
dpc-1025	277	3	dermatol	dermatol	NOUN
dpc-1025	277	4	.	.	PUNCT
dpc-1025	278	1	2006;154(6):1123	2006;154(6):1123	NUM
dpc-1025	278	2	-	-	SYM
dpc-1025	278	3	1127	1127	NUM
dpc-1025	278	4	.	.	PUNCT
dpc-1025	279	1	36	36	NUM
dpc-1025	279	2	.	.	PUNCT
dpc-1025	279	3	caini	caini	PROPN
dpc-1025	279	4	s	s	PROPN
dpc-1025	279	5	,	,	PUNCT
dpc-1025	279	6	boniol	boniol	PROPN
dpc-1025	279	7	m	m	PROPN
dpc-1025	279	8	,	,	PUNCT
dpc-1025	279	9	tosti	tosti	PROPN
dpc-1025	279	10	g	g	PROPN
dpc-1025	279	11	,	,	PUNCT
dpc-1025	279	12	et	et	PROPN
dpc-1025	279	13	al	al	PROPN
dpc-1025	279	14	.	.	PUNCT
dpc-1025	279	15	vitamin	vitamin	PROPN
dpc-1025	279	16	d	d	NOUN
dpc-1025	279	17	and	and	CCONJ
dpc-1025	279	18	melanoma	melanoma	NOUN
dpc-1025	279	19	and	and	CCONJ
dpc-1025	279	20	non	non	ADJ
dpc-1025	279	21	-	-	ADJ
dpc-1025	279	22	melanoma	melanoma	ADJ
dpc-1025	279	23	skin	skin	NOUN
dpc-1025	279	24	cancer	cancer	NOUN
dpc-1025	279	25	risk	risk	NOUN
dpc-1025	279	26	and	and	CCONJ
dpc-1025	279	27	prognosis	prognosis	NOUN
dpc-1025	279	28	:	:	PUNCT
dpc-1025	279	29	a	a	DET
dpc-1025	279	30	comprehensive	comprehensive	ADJ
dpc-1025	279	31	review	review	NOUN
dpc-1025	279	32	and	and	CCONJ
dpc-1025	279	33	meta	meta	ADJ
dpc-1025	279	34	-	-	PUNCT
dpc-1025	279	35	analysis	analysis	NOUN
dpc-1025	279	36	.	.	PUNCT
dpc-1025	280	1	eur	eur	PROPN
dpc-1025	280	2	j	j	PROPN
dpc-1025	280	3	cancer	cancer	NOUN
dpc-1025	280	4	.	.	PUNCT
dpc-1025	281	1	2014;50(15):2649	2014;50(15):2649	NUM
dpc-1025	281	2	-	-	SYM
dpc-1025	281	3	2658	2658	NUM
dpc-1025	281	4	.	.	PUNCT
dpc-1025	282	1	37	37	NUM
dpc-1025	282	2	.	.	PUNCT
dpc-1025	283	1	tagliabue	tagliabue	PROPN
dpc-1025	283	2	e	e	PROPN
dpc-1025	283	3	,	,	PUNCT
dpc-1025	283	4	raimondi	raimondi	PROPN
dpc-1025	283	5	s	s	PROPN
dpc-1025	283	6	,	,	PUNCT
dpc-1025	283	7	gandini	gandini	VERB
dpc-1025	283	8	s.	s.	PROPN
dpc-1025	283	9	meta	meta	PROPN
dpc-1025	283	10	-	-	PUNCT
dpc-1025	283	11	analysis	analysis	NOUN
dpc-1025	283	12	of	of	ADP
dpc-1025	283	13	vitamin	vitamin	NOUN
dpc-1025	283	14	d	d	NOUN
dpc-1025	283	15	-	-	ADJ
dpc-1025	283	16	binding	bind	VERB
dpc-1025	283	17	protein	protein	NOUN
dpc-1025	283	18	and	and	CCONJ
dpc-1025	283	19	cancer	cancer	NOUN
dpc-1025	283	20	risk	risk	NOUN
dpc-1025	283	21	.	.	PUNCT
dpc-1025	284	1	cancer	cancer	NOUN
dpc-1025	284	2	epidemiol	epidemiol	PROPN
dpc-1025	284	3	biomarkers	biomarkers	PROPN
dpc-1025	284	4	prev	prev	X
dpc-1025	284	5	.	.	PUNCT
dpc-1025	285	1	2015;24(11):1758	2015;24(11):1758	NUM
dpc-1025	285	2	-	-	SYM
dpc-1025	285	3	1765	1765	NUM
dpc-1025	285	4	.	.	PUNCT
dpc-1025	286	1	38	38	NUM
dpc-1025	286	2	.	.	PUNCT
dpc-1025	287	1	orlow	orlow	PROPN
dpc-1025	287	2	i	i	PROPN
dpc-1025	287	3	,	,	PUNCT
dpc-1025	287	4	reiner	reiner	NOUN
dpc-1025	287	5	as	as	ADP
dpc-1025	287	6	,	,	PUNCT
dpc-1025	287	7	thomas	thomas	PROPN
dpc-1025	287	8	ne	ne	PROPN
dpc-1025	287	9	,	,	PUNCT
dpc-1025	287	10	et	et	PROPN
dpc-1025	287	11	al	al	PROPN
dpc-1025	287	12	.	.	PUNCT
dpc-1025	288	1	vitamin	vitamin	NOUN
dpc-1025	288	2	d	d	NOUN
dpc-1025	288	3	receptor	receptor	NOUN
dpc-1025	288	4	polymorphisms	polymorphism	NOUN
dpc-1025	288	5	and	and	CCONJ
dpc-1025	288	6	survival	survival	NOUN
dpc-1025	288	7	in	in	ADP
dpc-1025	288	8	patients	patient	NOUN
dpc-1025	288	9	with	with	ADP
dpc-1025	288	10	cutaneous	cutaneous	ADJ
dpc-1025	288	11	melanoma	melanoma	NOUN
dpc-1025	288	12	:	:	PUNCT
dpc-1025	288	13	a	a	DET
dpc-1025	288	14	population	population	NOUN
dpc-1025	288	15	-	-	PUNCT
dpc-1025	288	16	based	base	VERB
dpc-1025	288	17	study	study	NOUN
dpc-1025	288	18	.	.	PUNCT
dpc-1025	289	1	carcinogenesis	carcinogenesis	NOUN
dpc-1025	289	2	.	.	PUNCT
dpc-1025	290	1	2016;37(1):30	2016;37(1):30	NUM
dpc-1025	290	2	-	-	SYM
dpc-1025	290	3	38	38	NUM
dpc-1025	290	4	.	.	NOUN
dpc-1025	290	5	39	39	NUM
dpc-1025	290	6	.	.	PUNCT
dpc-1025	291	1	binkley	binkley	PROPN
dpc-1025	291	2	n	n	PROPN
dpc-1025	291	3	,	,	PUNCT
dpc-1025	291	4	novotny	novotny	PROPN
dpc-1025	291	5	r	r	PROPN
dpc-1025	291	6	,	,	PUNCT
dpc-1025	291	7	krueger	krueger	PROPN
dpc-1025	291	8	d	d	PROPN
dpc-1025	291	9	,	,	PUNCT
dpc-1025	291	10	et	et	PROPN
dpc-1025	291	11	al	al	PROPN
dpc-1025	291	12	.	.	PUNCT
dpc-1025	291	13	low	low	ADJ
dpc-1025	291	14	vitamin	vitamin	NOUN
dpc-1025	291	15	d	d	NOUN
dpc-1025	291	16	status	status	NOUN
dpc-1025	291	17	despite	despite	SCONJ
dpc-1025	291	18	abundant	abundant	ADJ
dpc-1025	291	19	sun	sun	NOUN
dpc-1025	291	20	exposure	exposure	NOUN
dpc-1025	291	21	.	.	PUNCT
dpc-1025	292	1	j	j	PROPN
dpc-1025	292	2	clin	clin	PROPN
dpc-1025	292	3	endocrinol	endocrinol	PROPN
dpc-1025	292	4	metab	metab	NOUN
dpc-1025	292	5	.	.	PUNCT
dpc-1025	293	1	2007;92(6):2130	2007;92(6):2130	NUM
dpc-1025	293	2	-	-	SYM
dpc-1025	293	3	2135	2135	NUM
dpc-1025	293	4	.	.	PUNCT
dpc-1025	294	1	22	22	NUM
dpc-1025	294	2	.	.	X
dpc-1025	294	3	fang	fang	PROPN
dpc-1025	294	4	s	s	PROPN
dpc-1025	294	5	,	,	PUNCT
dpc-1025	294	6	sui	sui	PROPN
dpc-1025	294	7	d	d	PROPN
dpc-1025	294	8	,	,	PUNCT
dpc-1025	294	9	wang	wang	PROPN
dpc-1025	294	10	y	y	PROPN
dpc-1025	294	11	,	,	PUNCT
dpc-1025	294	12	et	et	PROPN
dpc-1025	294	13	al	al	PROPN
dpc-1025	294	14	.	.	PROPN
dpc-1025	294	15	association	association	PROPN
dpc-1025	294	16	of	of	ADP
dpc-1025	294	17	vitamin	vitamin	NOUN
dpc-1025	294	18	d	d	PROPN
dpc-1025	294	19	levels	level	NOUN
dpc-1025	294	20	with	with	ADP
dpc-1025	294	21	outcome	outcome	NOUN
dpc-1025	294	22	in	in	ADP
dpc-1025	294	23	patients	patient	NOUN
dpc-1025	294	24	with	with	ADP
dpc-1025	294	25	melanoma	melanoma	NOUN
dpc-1025	294	26	after	after	ADP
dpc-1025	294	27	adjustment	adjustment	NOUN
dpc-1025	294	28	for	for	ADP
dpc-1025	294	29	c	c	NOUN
dpc-1025	294	30	-	-	PUNCT
dpc-1025	294	31	reactive	reactive	ADJ
dpc-1025	294	32	protein	protein	NOUN
dpc-1025	294	33	.	.	PUNCT
dpc-1025	295	1	j	j	PROPN
dpc-1025	295	2	clin	clin	PROPN
dpc-1025	295	3	oncol	oncol	PROPN
dpc-1025	295	4	.	.	PUNCT
dpc-1025	296	1	2016;34(15):1741	2016;34(15):1741	NUM
dpc-1025	296	2	-	-	SYM
dpc-1025	296	3	1747	1747	NUM
dpc-1025	296	4	.	.	PUNCT
dpc-1025	297	1	23	23	NUM
dpc-1025	297	2	.	.	PUNCT
dpc-1025	298	1	lim	lim	PROPN
dpc-1025	298	2	a	a	PROPN
dpc-1025	298	3	,	,	PUNCT
dpc-1025	298	4	shayan	shayan	PROPN
dpc-1025	298	5	r	r	PROPN
dpc-1025	298	6	,	,	PUNCT
dpc-1025	298	7	varigos	varigo	NOUN
dpc-1025	298	8	g.	g.	PROPN
dpc-1025	298	9	high	high	PROPN
dpc-1025	298	10	serum	serum	NOUN
dpc-1025	298	11	vitamin	vitamin	NOUN
dpc-1025	298	12	d	d	NOUN
dpc-1025	298	13	level	level	NOUN
dpc-1025	298	14	correlates	correlate	VERB
dpc-1025	298	15	with	with	ADP
dpc-1025	298	16	better	well	ADJ
dpc-1025	298	17	prognostic	prognostic	ADJ
dpc-1025	298	18	indicators	indicator	NOUN
dpc-1025	298	19	in	in	ADP
dpc-1025	298	20	primary	primary	ADJ
dpc-1025	298	21	melanoma	melanoma	NOUN
dpc-1025	298	22	:	:	PUNCT
dpc-1025	298	23	a	a	DET
dpc-1025	298	24	pilot	pilot	NOUN
dpc-1025	298	25	study	study	NOUN
dpc-1025	298	26	.	.	PUNCT
dpc-1025	299	1	australas	australas	PROPN
dpc-1025	299	2	j	j	PROPN
dpc-1025	299	3	dermatol	dermatol	NOUN
dpc-1025	299	4	.	.	PUNCT
dpc-1025	300	1	2018;59(3):182	2018;59(3):182	NUM
dpc-1025	300	2	-	-	SYM
dpc-1025	300	3	187	187	NUM
dpc-1025	300	4	.	.	PUNCT
dpc-1025	300	5	24	24	NUM
dpc-1025	300	6	.	.	PUNCT
dpc-1025	301	1	saiag	saiag	ADP
dpc-1025	301	2	p	p	X
dpc-1025	301	3	,	,	PUNCT
dpc-1025	301	4	aegerter	aegerter	ADP
dpc-1025	301	5	p	p	PRON
dpc-1025	301	6	,	,	PUNCT
dpc-1025	301	7	vitoux	vitoux	NOUN
dpc-1025	301	8	d	d	NOUN
dpc-1025	301	9	,	,	PUNCT
dpc-1025	301	10	et	et	PROPN
dpc-1025	301	11	al	al	PROPN
dpc-1025	301	12	.	.	PROPN
dpc-1025	302	1	prognostic	prognostic	ADJ
dpc-1025	302	2	value	value	NOUN
dpc-1025	302	3	of	of	ADP
dpc-1025	302	4	25	25	NUM
dpc-1025	302	5	-	-	PUNCT
dpc-1025	302	6	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	302	7	d3	d3	PROPN
dpc-1025	302	8	levels	level	NOUN
dpc-1025	302	9	at	at	ADP
dpc-1025	302	10	diagnosis	diagnosis	NOUN
dpc-1025	302	11	and	and	CCONJ
dpc-1025	302	12	during	during	ADP
dpc-1025	302	13	follow	follow	NOUN
dpc-1025	302	14	-	-	PUNCT
dpc-1025	302	15	up	up	NOUN
dpc-1025	302	16	in	in	ADP
dpc-1025	302	17	melanoma	melanoma	NOUN
dpc-1025	302	18	patients	patient	NOUN
dpc-1025	302	19	.	.	PUNCT
dpc-1025	303	1	j	j	PROPN
dpc-1025	303	2	natl	natl	PROPN
dpc-1025	303	3	cancer	cancer	PROPN
dpc-1025	303	4	inst	inst	PROPN
dpc-1025	303	5	.	.	PUNCT
dpc-1025	304	1	2015;107(12):djv264	2015;107(12):djv264	NUM
dpc-1025	304	2	.	.	PUNCT
dpc-1025	305	1	25	25	NUM
dpc-1025	305	2	.	.	PUNCT
dpc-1025	306	1	oliveira	oliveira	PROPN
dpc-1025	306	2	filho	filho	PROPN
dpc-1025	306	3	rs	rs	PROPN
dpc-1025	306	4	,	,	PUNCT
dpc-1025	306	5	oliveira	oliveira	PROPN
dpc-1025	306	6	da	da	PROPN
dpc-1025	306	7	,	,	PUNCT
dpc-1025	306	8	martinho	martinho	PROPN
dpc-1025	306	9	va	va	PROPN
dpc-1025	306	10	,	,	PUNCT
dpc-1025	306	11	antoneli	antoneli	PROPN
dpc-1025	306	12	cb	cb	PROPN
dpc-1025	306	13	,	,	PUNCT
dpc-1025	306	14	marcussi	marcussi	PROPN
dpc-1025	306	15	la	la	PROPN
dpc-1025	306	16	,	,	PUNCT
dpc-1025	306	17	ferreira	ferreira	PROPN
dpc-1025	306	18	ce	ce	PROPN
dpc-1025	306	19	.	.	PROPN
dpc-1025	306	20	serum	serum	PROPN
dpc-1025	306	21	level	level	NOUN
dpc-1025	306	22	of	of	ADP
dpc-1025	306	23	vitamin	vitamin	NOUN
dpc-1025	306	24	d3	d3	PROPN
dpc-1025	306	25	in	in	ADP
dpc-1025	306	26	cutaneous	cutaneous	ADJ
dpc-1025	306	27	melanoma	melanoma	NOUN
dpc-1025	306	28	.	.	PUNCT
dpc-1025	307	1	einstein	einstein	PROPN
dpc-1025	307	2	(	(	PUNCT
dpc-1025	307	3	sao	sao	PROPN
dpc-1025	307	4	paulo	paulo	PROPN
dpc-1025	307	5	)	)	PUNCT
dpc-1025	307	6	.	.	PUNCT
dpc-1025	308	1	2014;12(4):473	2014;12(4):473	X
dpc-1025	308	2	-	-	SYM
dpc-1025	308	3	476	476	NUM
dpc-1025	308	4	.	.	PUNCT
dpc-1025	309	1	26	26	NUM
dpc-1025	309	2	.	.	PUNCT
dpc-1025	310	1	nürnberg	nürnberg	PROPN
dpc-1025	310	2	b	b	PROPN
dpc-1025	310	3	,	,	PUNCT
dpc-1025	310	4	gräber	gräber	PROPN
dpc-1025	310	5	s	s	PROPN
dpc-1025	310	6	,	,	PUNCT
dpc-1025	310	7	gärtner	gärtner	PROPN
dpc-1025	310	8	b	b	PROPN
dpc-1025	310	9	,	,	PUNCT
dpc-1025	310	10	et	et	PROPN
dpc-1025	310	11	al	al	PROPN
dpc-1025	310	12	.	.	PROPN
dpc-1025	310	13	reduced	reduce	VERB
dpc-1025	310	14	serum	serum	NOUN
dpc-1025	310	15	25	25	NUM
dpc-1025	310	16	-	-	PUNCT
dpc-1025	310	17	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	310	18	d	d	NOUN
dpc-1025	310	19	levels	level	NOUN
dpc-1025	310	20	in	in	ADP
dpc-1025	310	21	stage	stage	NOUN
dpc-1025	310	22	iv	iv	NUM
dpc-1025	310	23	melanoma	melanoma	NOUN
dpc-1025	310	24	patients	patient	NOUN
dpc-1025	310	25	.	.	PUNCT
dpc-1025	311	1	anticancer	anticancer	NOUN
dpc-1025	311	2	res	re	NOUN
dpc-1025	311	3	.	.	PUNCT
dpc-1025	312	1	2009;29(9):3669	2009;29(9):3669	NOUN
dpc-1025	312	2	-	-	SYM
dpc-1025	312	3	7364	7364	NUM
dpc-1025	312	4	.	.	PUNCT
dpc-1025	313	1	27	27	NUM
dpc-1025	313	2	.	.	PUNCT
dpc-1025	314	1	navarrete	navarrete	ADJ
dpc-1025	314	2	-	-	PUNCT
dpc-1025	314	3	dechent	dechent	NOUN
dpc-1025	314	4	c	c	NOUN
dpc-1025	314	5	,	,	PUNCT
dpc-1025	314	6	del	del	PROPN
dpc-1025	314	7	puerto	puerto	PROPN
dpc-1025	314	8	c	c	PROPN
dpc-1025	314	9	,	,	PUNCT
dpc-1025	314	10	molgó	molgó	NOUN
dpc-1025	314	11	m	m	PROPN
dpc-1025	314	12	,	,	PUNCT
dpc-1025	314	13	et	et	PROPN
dpc-1025	314	14	al	al	PROPN
dpc-1025	314	15	.	.	PUNCT
dpc-1025	315	1	circulating	circulate	VERB
dpc-1025	315	2	vitamin	vitamin	NOUN
dpc-1025	315	3	d	d	NOUN
dpc-1025	315	4	-	-	ADJ
dpc-1025	315	5	binding	bind	VERB
dpc-1025	315	6	protein	protein	NOUN
dpc-1025	315	7	and	and	CCONJ
dpc-1025	315	8	free	free	ADJ
dpc-1025	315	9	25	25	NUM
dpc-1025	315	10	-	-	PUNCT
dpc-1025	315	11	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	315	12	d	d	NOUN
dpc-1025	315	13	concentrations	concentration	NOUN
dpc-1025	315	14	in	in	ADP
dpc-1025	315	15	patients	patient	NOUN
dpc-1025	315	16	with	with	ADP
dpc-1025	315	17	melanoma	melanoma	NOUN
dpc-1025	315	18	:	:	PUNCT
dpc-1025	315	19	a	a	DET
dpc-1025	315	20	case	case	NOUN
dpc-1025	315	21	-	-	PUNCT
dpc-1025	315	22	control	control	NOUN
dpc-1025	315	23	study	study	NOUN
dpc-1025	315	24	.	.	PUNCT
dpc-1025	316	1	j	j	PROPN
dpc-1025	316	2	am	be	AUX
dpc-1025	316	3	acad	acad	ADJ
dpc-1025	316	4	dermatol	dermatol	NOUN
dpc-1025	316	5	.	.	PUNCT
dpc-1025	317	1	2017;77(3):575	2017;77(3):575	NUM
dpc-1025	317	2	-	-	PUNCT
dpc-1025	317	3	577	577	NUM
dpc-1025	317	4	.	.	PUNCT
dpc-1025	318	1	28	28	NUM
dpc-1025	318	2	.	.	PUNCT
dpc-1025	319	1	tsiaras	tsiaras	PROPN
dpc-1025	319	2	wg	wg	PROPN
dpc-1025	319	3	,	,	PUNCT
dpc-1025	319	4	weinstock	weinstock	PROPN
dpc-1025	319	5	ma	ma	PROPN
dpc-1025	319	6	.	.	PROPN
dpc-1025	319	7	factors	factor	NOUN
dpc-1025	319	8	influencing	influence	VERB
dpc-1025	319	9	vitamin	vitamin	NOUN
dpc-1025	319	10	d	d	NOUN
dpc-1025	319	11	status	status	NOUN
dpc-1025	319	12	.	.	PUNCT
dpc-1025	320	1	acta	acta	PROPN
dpc-1025	320	2	derm	derm	PROPN
dpc-1025	320	3	venereol	venereol	NOUN
dpc-1025	320	4	.	.	PUNCT
dpc-1025	321	1	2011;91(2):115	2011;91(2):115	NUM
dpc-1025	321	2	-	-	SYM
dpc-1025	321	3	124	124	NUM
dpc-1025	321	4	.	.	PUNCT
dpc-1025	321	5	29	29	NUM
dpc-1025	321	6	.	.	PUNCT
dpc-1025	322	1	van	van	PROPN
dpc-1025	322	2	schoor	schoor	PROPN
dpc-1025	322	3	nm	nm	PROPN
dpc-1025	322	4	,	,	PUNCT
dpc-1025	322	5	lips	lip	NOUN
dpc-1025	322	6	p.	p.	NOUN
dpc-1025	322	7	worldwide	worldwide	ADJ
dpc-1025	322	8	vitamin	vitamin	NOUN
dpc-1025	322	9	d	d	NOUN
dpc-1025	322	10	status	status	NOUN
dpc-1025	322	11	.	.	PUNCT
dpc-1025	323	1	best	good	ADJ
dpc-1025	323	2	pract	pract	PROPN
dpc-1025	323	3	res	re	NOUN
dpc-1025	323	4	clin	clin	PROPN
dpc-1025	323	5	endocrinol	endocrinol	NOUN
dpc-1025	323	6	metab	metab	NOUN
dpc-1025	323	7	.	.	PUNCT
dpc-1025	324	1	2011;25(4):671	2011;25(4):671	NUM
dpc-1025	324	2	-	-	PUNCT
dpc-1025	324	3	680	680	NUM
dpc-1025	324	4	.	.	PUNCT
dpc-1025	324	5	30	30	NUM
dpc-1025	324	6	.	.	PUNCT
dpc-1025	325	1	van	van	PROPN
dpc-1025	325	2	der	der	PROPN
dpc-1025	325	3	wielen	wielen	VERB
dpc-1025	325	4	rp	rp	NOUN
dpc-1025	325	5	,	,	PUNCT
dpc-1025	325	6	lowik	lowik	PROPN
dpc-1025	325	7	mr	mr	PROPN
dpc-1025	325	8	,	,	PUNCT
dpc-1025	325	9	van	van	PROPN
dpc-1025	325	10	den	den	PROPN
dpc-1025	325	11	berg	berg	PROPN
dpc-1025	325	12	h	h	PROPN
dpc-1025	325	13	,	,	PUNCT
dpc-1025	325	14	et	et	PROPN
dpc-1025	325	15	al	al	PROPN
dpc-1025	325	16	.	.	PROPN
dpc-1025	325	17	serum	serum	PROPN
dpc-1025	325	18	vitamin	vitamin	PROPN
dpc-1025	325	19	d	d	NOUN
dpc-1025	325	20	concentrations	concentration	NOUN
dpc-1025	325	21	among	among	ADP
dpc-1025	325	22	elderly	elderly	ADJ
dpc-1025	325	23	people	people	NOUN
dpc-1025	325	24	in	in	ADP
dpc-1025	325	25	europe	europe	PROPN
dpc-1025	325	26	.	.	PUNCT
dpc-1025	326	1	lancet	lancet	PROPN
dpc-1025	326	2	.	.	PUNCT
dpc-1025	327	1	1995;346(8969):p207	1995;346(8969):p207	NOUN
dpc-1025	327	2	-	-	PUNCT
dpc-1025	327	3	p210	p210	PROPN
dpc-1025	327	4	.	.	PUNCT
dpc-1025	328	1	31	31	NUM
dpc-1025	328	2	.	.	PUNCT
dpc-1025	329	1	manios	manios	PROPN
dpc-1025	329	2	y	y	PROPN
dpc-1025	329	3	,	,	PUNCT
dpc-1025	329	4	moschonis	moschonis	PROPN
dpc-1025	329	5	g	g	NOUN
dpc-1025	329	6	,	,	PUNCT
dpc-1025	329	7	hulshof	hulshof	PROPN
dpc-1025	329	8	t	t	PROPN
dpc-1025	329	9	,	,	PUNCT
dpc-1025	329	10	et	et	PROPN
dpc-1025	329	11	al	al	PROPN
dpc-1025	329	12	.	.	PUNCT
dpc-1025	329	13	prevalence	prevalence	NOUN
dpc-1025	329	14	of	of	ADP
dpc-1025	329	15	vitamin	vitamin	NOUN
dpc-1025	329	16	d	d	NOUN
dpc-1025	329	17	deficiency	deficiency	NOUN
dpc-1025	329	18	among	among	ADP
dpc-1025	329	19	school	school	NOUN
dpc-1025	329	20	children	child	NOUN
dpc-1025	329	21	in	in	ADP
dpc-1025	329	22	greece	greece	PROPN
dpc-1025	329	23	:	:	PUNCT
dpc-1025	329	24	the	the	DET
dpc-1025	329	25	role	role	NOUN
dpc-1025	329	26	of	of	ADP
dpc-1025	329	27	sex	sex	NOUN
dpc-1025	329	28	,	,	PUNCT
dpc-1025	329	29	degree	degree	NOUN
dpc-1025	329	30	of	of	ADP
dpc-1025	329	31	urbanisation	urbanisation	NOUN
dpc-1025	329	32	and	and	CCONJ
dpc-1025	329	33	seasonality	seasonality	NOUN
dpc-1025	329	34	.	.	PUNCT
dpc-1025	330	1	br	br	PROPN
dpc-1025	330	2	j	j	PROPN
dpc-1025	330	3	nutr	nutr	PROPN
dpc-1025	330	4	.	.	PUNCT
dpc-1025	331	1	2017;118(7):550	2017;118(7):550	NUM
dpc-1025	331	2	-	-	SYM
dpc-1025	331	3	558	558	NUM
dpc-1025	331	4	.	.	PUNCT
dpc-1025	332	1	research	research	NOUN
dpc-1025	332	2	|	|	ADV
dpc-1025	332	3	dermatol	dermatol	NOUN
dpc-1025	332	4	pract	pract	NOUN
dpc-1025	332	5	concept	concept	NOUN
dpc-1025	332	6	2020;10(1):e2020010	2020;10(1):e2020010	NUM
dpc-1025	332	7	9	9	NUM
dpc-1025	332	8	table	table	NOUN
dpc-1025	332	9	e1	e1	PROPN
dpc-1025	332	10	.	.	PUNCT
dpc-1025	333	1	association	association	NOUN
dpc-1025	333	2	of	of	ADP
dpc-1025	333	3	serum	serum	NOUN
dpc-1025	333	4	25(oh)d	25(oh)d	NUM
dpc-1025	333	5	levels	level	NOUN
dpc-1025	333	6	with	with	ADP
dpc-1025	333	7	clinical	clinical	ADJ
dpc-1025	333	8	and	and	CCONJ
dpc-1025	333	9	histopathological	histopathological	ADJ
dpc-1025	333	10	characteristics	characteristic	NOUN
dpc-1025	333	11	in	in	ADP
dpc-1025	333	12	different	different	ADJ
dpc-1025	333	13	levels	level	NOUN
dpc-1025	333	14	of	of	ADP
dpc-1025	333	15	bmi	bmi	PROPN
dpc-1025	333	16	serum	serum	NOUN
dpc-1025	333	17	25(oh)d	25(oh)d	PROPN
dpc-1025	333	18	,	,	PUNCT
dpc-1025	333	19	n	n	CCONJ
dpc-1025	333	20	(	(	PUNCT
dpc-1025	333	21	%	%	INTJ
dpc-1025	333	22	)	)	PUNCT
dpc-1025	333	23	total	total	NOUN
dpc-1025	333	24	p	p	NOUN
dpc-1025	333	25	value	value	NOUN
dpc-1025	333	26	<	<	X
dpc-1025	333	27	20	20	NUM
dpc-1025	333	28	ng	ng	PROPN
dpc-1025	333	29	/	/	SYM
dpc-1025	333	30	ml	ml	PROPN
dpc-1025	333	31	21	21	NUM
dpc-1025	333	32	-	-	SYM
dpc-1025	333	33	29	29	NUM
dpc-1025	333	34	ng	ng	PROPN
dpc-1025	333	35	/	/	SYM
dpc-1025	333	36	ml	ml	PROPN
dpc-1025	333	37	>	>	SYM
dpc-1025	333	38	30	30	NUM
dpc-1025	333	39	ng	ng	NOUN
dpc-1025	333	40	/	/	SYM
dpc-1025	333	41	ml	ml	PROPN
dpc-1025	333	42	patients	patient	NOUN
dpc-1025	333	43	with	with	ADP
dpc-1025	333	44	bmi	bmi	PROPN
dpc-1025	333	45	≤25	≤25	CCONJ
dpc-1025	333	46	breslow	breslow	VERB
dpc-1025	333	47	0.473a	0.473a	ADJ
dpc-1025	333	48	<	<	NOUN
dpc-1025	333	49	1	1	NUM
dpc-1025	333	50	mm	mm	NUM
dpc-1025	333	51	8	8	NUM
dpc-1025	333	52	(	(	PUNCT
dpc-1025	333	53	40	40	NUM
dpc-1025	333	54	)	)	PUNCT
dpc-1025	333	55	8	8	NUM
dpc-1025	333	56	(	(	PUNCT
dpc-1025	333	57	40	40	NUM
dpc-1025	333	58	)	)	SYM
dpc-1025	333	59	4	4	NUM
dpc-1025	333	60	(	(	PUNCT
dpc-1025	333	61	20	20	NUM
dpc-1025	333	62	)	)	SYM
dpc-1025	333	63	20	20	NUM
dpc-1025	333	64	(	(	PUNCT
dpc-1025	333	65	100	100	NUM
dpc-1025	333	66	)	)	PUNCT
dpc-1025	333	67	1	1	NUM
dpc-1025	333	68	-	-	SYM
dpc-1025	333	69	4	4	NUM
dpc-1025	333	70	mm	mm	NOUN
dpc-1025	333	71	9	9	NUM
dpc-1025	333	72	(	(	PUNCT
dpc-1025	333	73	60	60	NUM
dpc-1025	333	74	)	)	SYM
dpc-1025	333	75	2	2	NUM
dpc-1025	333	76	(	(	PUNCT
dpc-1025	333	77	13.33	13.33	NUM
dpc-1025	333	78	)	)	PUNCT
dpc-1025	333	79	4	4	NUM
dpc-1025	333	80	(	(	PUNCT
dpc-1025	333	81	26.67	26.67	NUM
dpc-1025	333	82	)	)	PUNCT
dpc-1025	333	83	15	15	NUM
dpc-1025	333	84	(	(	PUNCT
dpc-1025	333	85	100	100	NUM
dpc-1025	333	86	)	)	PUNCT
dpc-1025	333	87	>	>	PUNCT
dpc-1025	333	88	4	4	NUM
dpc-1025	333	89	mm	mm	NUM
dpc-1025	333	90	3	3	NUM
dpc-1025	333	91	(	(	PUNCT
dpc-1025	333	92	42.86	42.86	NUM
dpc-1025	333	93	)	)	PUNCT
dpc-1025	333	94	3	3	NUM
dpc-1025	333	95	(	(	PUNCT
dpc-1025	333	96	42.86	42.86	NUM
dpc-1025	333	97	)	)	PUNCT
dpc-1025	333	98	1	1	NUM
dpc-1025	333	99	(	(	PUNCT
dpc-1025	333	100	14.29	14.29	NUM
dpc-1025	333	101	)	)	PUNCT
dpc-1025	333	102	7	7	NUM
dpc-1025	333	103	(	(	PUNCT
dpc-1025	333	104	100	100	NUM
dpc-1025	333	105	)	)	PUNCT
dpc-1025	333	106	total	total	ADJ
dpc-1025	333	107	20(47.62	20(47.62	NUM
dpc-1025	333	108	)	)	PUNCT
dpc-1025	333	109	13(30.95	13(30.95	NUM
dpc-1025	333	110	)	)	PUNCT
dpc-1025	333	111	9	9	NUM
dpc-1025	333	112	(	(	PUNCT
dpc-1025	333	113	21.43	21.43	NUM
dpc-1025	333	114	)	)	SYM
dpc-1025	333	115	42	42	NUM
dpc-1025	333	116	(	(	PUNCT
dpc-1025	333	117	100	100	NUM
dpc-1025	333	118	)	)	PUNCT
dpc-1025	333	119	patients	patient	NOUN
dpc-1025	333	120	with	with	ADP
dpc-1025	333	121	bmi	bmi	PROPN
dpc-1025	333	122	>	>	X
dpc-1025	333	123	25	25	NUM
dpc-1025	333	124	breslow	breslow	NOUN
dpc-1025	333	125	0.338a	0.338a	PROPN
dpc-1025	333	126	<	<	X
dpc-1025	333	127	1	1	NUM
dpc-1025	333	128	mm	mm	NUM
dpc-1025	333	129	14	14	NUM
dpc-1025	333	130	(	(	PUNCT
dpc-1025	333	131	43.75	43.75	NUM
dpc-1025	333	132	)	)	PUNCT
dpc-1025	333	133	9	9	NUM
dpc-1025	333	134	(	(	PUNCT
dpc-1025	333	135	28.13	28.13	NUM
dpc-1025	333	136	)	)	PUNCT
dpc-1025	333	137	9(28.13	9(28.13	NUM
dpc-1025	333	138	)	)	PUNCT
dpc-1025	333	139	32	32	NUM
dpc-1025	333	140	(	(	PUNCT
dpc-1025	333	141	100	100	NUM
dpc-1025	333	142	)	)	PUNCT
dpc-1025	333	143	1	1	NUM
dpc-1025	333	144	-	-	SYM
dpc-1025	333	145	4	4	NUM
dpc-1025	333	146	mm	mm	NUM
dpc-1025	333	147	7	7	NUM
dpc-1025	333	148	(	(	PUNCT
dpc-1025	333	149	38.89	38.89	NUM
dpc-1025	333	150	)	)	PUNCT
dpc-1025	333	151	5	5	NUM
dpc-1025	333	152	(	(	PUNCT
dpc-1025	333	153	27.78	27.78	NUM
dpc-1025	333	154	)	)	PUNCT
dpc-1025	333	155	6	6	NUM
dpc-1025	333	156	(	(	PUNCT
dpc-1025	333	157	33.33	33.33	NUM
dpc-1025	333	158	)	)	PUNCT
dpc-1025	333	159	18	18	NUM
dpc-1025	333	160	(	(	PUNCT
dpc-1025	333	161	100	100	NUM
dpc-1025	333	162	)	)	PUNCT
dpc-1025	333	163	>	>	PUNCT
dpc-1025	333	164	4	4	NUM
dpc-1025	333	165	mm	mm	NUM
dpc-1025	333	166	6	6	NUM
dpc-1025	333	167	(	(	PUNCT
dpc-1025	333	168	85.71	85.71	NUM
dpc-1025	333	169	)	)	PUNCT
dpc-1025	333	170	1	1	NUM
dpc-1025	333	171	(	(	PUNCT
dpc-1025	333	172	14.29	14.29	NUM
dpc-1025	333	173	)	)	PUNCT
dpc-1025	333	174	0	0	NUM
dpc-1025	333	175	7	7	NUM
dpc-1025	333	176	(	(	PUNCT
dpc-1025	333	177	100	100	NUM
dpc-1025	333	178	)	)	PUNCT
dpc-1025	333	179	total	total	NOUN
dpc-1025	333	180	27	27	NUM
dpc-1025	333	181	(	(	PUNCT
dpc-1025	333	182	47.37	47.37	NUM
dpc-1025	333	183	)	)	PUNCT
dpc-1025	333	184	15	15	NUM
dpc-1025	333	185	(	(	PUNCT
dpc-1025	333	186	26.32	26.32	NUM
dpc-1025	333	187	)	)	PUNCT
dpc-1025	333	188	15	15	NUM
dpc-1025	333	189	(	(	PUNCT
dpc-1025	333	190	26.32	26.32	NUM
dpc-1025	333	191	)	)	PUNCT
dpc-1025	333	192	57	57	NUM
dpc-1025	333	193	(	(	PUNCT
dpc-1025	333	194	100	100	NUM
dpc-1025	333	195	)	)	PUNCT
dpc-1025	333	196	patients	patient	NOUN
dpc-1025	333	197	with	with	ADP
dpc-1025	333	198	bmi	bmi	PROPN
dpc-1025	333	199	≤25	≤25	PROPN
dpc-1025	333	200	ulceration	ulceration	NOUN
dpc-1025	333	201	0.423	0.423	NUM
dpc-1025	333	202	yes	yes	NOUN
dpc-1025	333	203	6	6	NUM
dpc-1025	333	204	(	(	PUNCT
dpc-1025	333	205	37.50	37.50	NUM
dpc-1025	333	206	)	)	PUNCT
dpc-1025	333	207	5	5	NUM
dpc-1025	333	208	(	(	PUNCT
dpc-1025	333	209	31.25	31.25	NUM
dpc-1025	333	210	)	)	PUNCT
dpc-1025	333	211	5	5	NUM
dpc-1025	333	212	(	(	PUNCT
dpc-1025	333	213	31.25	31.25	NUM
dpc-1025	333	214	)	)	PUNCT
dpc-1025	333	215	16	16	NUM
dpc-1025	333	216	(	(	PUNCT
dpc-1025	333	217	100	100	NUM
dpc-1025	333	218	)	)	PUNCT
dpc-1025	333	219	no	no	DET
dpc-1025	333	220	14	14	NUM
dpc-1025	333	221	(	(	PUNCT
dpc-1025	333	222	53.85	53.85	NUM
dpc-1025	333	223	)	)	PUNCT
dpc-1025	333	224	8	8	NUM
dpc-1025	333	225	(	(	PUNCT
dpc-1025	333	226	30.77	30.77	NUM
dpc-1025	333	227	)	)	PUNCT
dpc-1025	333	228	4	4	NUM
dpc-1025	333	229	(	(	PUNCT
dpc-1025	333	230	15.38	15.38	NUM
dpc-1025	333	231	)	)	PUNCT
dpc-1025	333	232	26	26	NUM
dpc-1025	333	233	(	(	PUNCT
dpc-1025	333	234	100	100	NUM
dpc-1025	333	235	)	)	PUNCT
dpc-1025	333	236	total	total	ADJ
dpc-1025	333	237	20(47.62	20(47.62	NUM
dpc-1025	333	238	)	)	PUNCT
dpc-1025	333	239	13	13	NUM
dpc-1025	333	240	(	(	PUNCT
dpc-1025	333	241	30.95	30.95	NUM
dpc-1025	333	242	)	)	PUNCT
dpc-1025	333	243	9	9	NUM
dpc-1025	333	244	(	(	PUNCT
dpc-1025	333	245	21.43	21.43	NUM
dpc-1025	333	246	)	)	SYM
dpc-1025	333	247	42	42	NUM
dpc-1025	333	248	(	(	PUNCT
dpc-1025	333	249	100	100	NUM
dpc-1025	333	250	)	)	PUNCT
dpc-1025	333	251	patients	patient	NOUN
dpc-1025	333	252	with	with	ADP
dpc-1025	333	253	bmi	bmi	PROPN
dpc-1025	333	254	>	>	X
dpc-1025	333	255	25	25	NUM
dpc-1025	333	256	ulceration	ulceration	NOUN
dpc-1025	333	257	0.735	0.735	NUM
dpc-1025	333	258	yes	yes	NOUN
dpc-1025	333	259	6	6	NUM
dpc-1025	333	260	(	(	PUNCT
dpc-1025	333	261	40	40	NUM
dpc-1025	333	262	)	)	SYM
dpc-1025	333	263	5	5	NUM
dpc-1025	333	264	(	(	PUNCT
dpc-1025	333	265	33.33	33.33	NUM
dpc-1025	333	266	)	)	PUNCT
dpc-1025	333	267	4	4	NUM
dpc-1025	333	268	(	(	PUNCT
dpc-1025	333	269	26.67	26.67	NUM
dpc-1025	333	270	)	)	PUNCT
dpc-1025	333	271	15	15	NUM
dpc-1025	333	272	(	(	PUNCT
dpc-1025	333	273	100	100	NUM
dpc-1025	333	274	)	)	PUNCT
dpc-1025	333	275	no	no	DET
dpc-1025	333	276	21	21	NUM
dpc-1025	333	277	(	(	PUNCT
dpc-1025	333	278	50	50	NUM
dpc-1025	333	279	)	)	PUNCT
dpc-1025	333	280	10	10	NUM
dpc-1025	333	281	(	(	PUNCT
dpc-1025	333	282	23.81	23.81	NUM
dpc-1025	333	283	)	)	PUNCT
dpc-1025	333	284	11	11	NUM
dpc-1025	333	285	(	(	PUNCT
dpc-1025	333	286	26.19	26.19	NUM
dpc-1025	333	287	)	)	PUNCT
dpc-1025	333	288	42	42	NUM
dpc-1025	333	289	(	(	PUNCT
dpc-1025	333	290	100	100	NUM
dpc-1025	333	291	)	)	PUNCT
dpc-1025	333	292	total	total	NOUN
dpc-1025	333	293	27(43.37	27(43.37	NOUN
dpc-1025	333	294	)	)	PUNCT
dpc-1025	333	295	15	15	NUM
dpc-1025	333	296	(	(	PUNCT
dpc-1025	333	297	26.32	26.32	NUM
dpc-1025	333	298	)	)	PUNCT
dpc-1025	333	299	15	15	NUM
dpc-1025	333	300	(	(	PUNCT
dpc-1025	333	301	26.32	26.32	NUM
dpc-1025	333	302	)	)	PUNCT
dpc-1025	333	303	57	57	NUM
dpc-1025	333	304	(	(	PUNCT
dpc-1025	333	305	100	100	NUM
dpc-1025	333	306	)	)	PUNCT
dpc-1025	333	307	patients	patient	NOUN
dpc-1025	333	308	with	with	ADP
dpc-1025	333	309	bmi	bmi	PROPN
dpc-1025	333	310	≤25	≤25	CCONJ
dpc-1025	333	311	melanoma	melanoma	NOUN
dpc-1025	333	312	located	locate	VERB
dpc-1025	333	313	in	in	ADP
dpc-1025	333	314	sun	sun	NOUN
dpc-1025	333	315	-	-	PUNCT
dpc-1025	333	316	exposed	expose	VERB
dpc-1025	333	317	body	body	NOUN
dpc-1025	333	318	parts	part	NOUN
dpc-1025	333	319	0.943	0.943	NUM
dpc-1025	333	320	yes	yes	NOUN
dpc-1025	333	321	12	12	NUM
dpc-1025	333	322	(	(	PUNCT
dpc-1025	333	323	46.15	46.15	NUM
dpc-1025	333	324	)	)	PUNCT
dpc-1025	333	325	8	8	NUM
dpc-1025	333	326	(	(	PUNCT
dpc-1025	333	327	30.77	30.77	NUM
dpc-1025	333	328	)	)	PUNCT
dpc-1025	333	329	6	6	NUM
dpc-1025	333	330	(	(	PUNCT
dpc-1025	333	331	23.08	23.08	NUM
dpc-1025	333	332	)	)	PUNCT
dpc-1025	333	333	26	26	NUM
dpc-1025	333	334	(	(	PUNCT
dpc-1025	333	335	100	100	NUM
dpc-1025	333	336	)	)	PUNCT
dpc-1025	333	337	no	no	DET
dpc-1025	333	338	8	8	NUM
dpc-1025	333	339	(	(	PUNCT
dpc-1025	333	340	50	50	NUM
dpc-1025	333	341	)	)	PUNCT
dpc-1025	333	342	5	5	NUM
dpc-1025	333	343	(	(	PUNCT
dpc-1025	333	344	31.25	31.25	NUM
dpc-1025	333	345	)	)	PUNCT
dpc-1025	333	346	3	3	NUM
dpc-1025	333	347	(	(	PUNCT
dpc-1025	333	348	18.75	18.75	NUM
dpc-1025	333	349	)	)	PUNCT
dpc-1025	333	350	16	16	NUM
dpc-1025	333	351	(	(	PUNCT
dpc-1025	333	352	100	100	NUM
dpc-1025	333	353	)	)	PUNCT
dpc-1025	333	354	total	total	NOUN
dpc-1025	333	355	20	20	NUM
dpc-1025	333	356	(	(	PUNCT
dpc-1025	333	357	47.62	47.62	NUM
dpc-1025	333	358	)	)	PUNCT
dpc-1025	333	359	13	13	NUM
dpc-1025	333	360	(	(	PUNCT
dpc-1025	333	361	30.95	30.95	NUM
dpc-1025	333	362	)	)	PUNCT
dpc-1025	333	363	9	9	NUM
dpc-1025	333	364	(	(	PUNCT
dpc-1025	333	365	21.43	21.43	NUM
dpc-1025	333	366	)	)	SYM
dpc-1025	333	367	42	42	NUM
dpc-1025	333	368	(	(	PUNCT
dpc-1025	333	369	100	100	NUM
dpc-1025	333	370	)	)	PUNCT
dpc-1025	333	371	patients	patient	NOUN
dpc-1025	333	372	with	with	ADP
dpc-1025	333	373	bmi>25	bmi>25	ADJ
dpc-1025	333	374	melanoma	melanoma	NOUN
dpc-1025	333	375	located	locate	VERB
dpc-1025	333	376	in	in	ADP
dpc-1025	333	377	sun	sun	NOUN
dpc-1025	333	378	-	-	PUNCT
dpc-1025	333	379	exposed	expose	VERB
dpc-1025	333	380	body	body	NOUN
dpc-1025	333	381	parts	part	NOUN
dpc-1025	333	382	0.926	0.926	NUM
dpc-1025	333	383	yes	yes	NOUN
dpc-1025	333	384	13	13	NUM
dpc-1025	333	385	(	(	PUNCT
dpc-1025	333	386	46.43	46.43	NUM
dpc-1025	333	387	)	)	PUNCT
dpc-1025	333	388	8	8	NUM
dpc-1025	333	389	(	(	PUNCT
dpc-1025	333	390	28.57	28.57	NUM
dpc-1025	333	391	)	)	PUNCT
dpc-1025	333	392	7	7	NUM
dpc-1025	333	393	(	(	PUNCT
dpc-1025	333	394	25	25	NUM
dpc-1025	333	395	)	)	SYM
dpc-1025	333	396	28	28	NUM
dpc-1025	333	397	(	(	PUNCT
dpc-1025	333	398	100	100	NUM
dpc-1025	333	399	)	)	PUNCT
dpc-1025	333	400	no	no	DET
dpc-1025	333	401	14	14	NUM
dpc-1025	333	402	(	(	PUNCT
dpc-1025	333	403	48.28	48.28	NUM
dpc-1025	333	404	)	)	PUNCT
dpc-1025	333	405	7	7	NUM
dpc-1025	333	406	(	(	PUNCT
dpc-1025	333	407	24.14	24.14	NUM
dpc-1025	333	408	)	)	PUNCT
dpc-1025	333	409	8	8	NUM
dpc-1025	333	410	(	(	PUNCT
dpc-1025	333	411	27.59	27.59	NUM
dpc-1025	333	412	)	)	PUNCT
dpc-1025	333	413	29	29	NUM
dpc-1025	333	414	(	(	PUNCT
dpc-1025	333	415	100	100	NUM
dpc-1025	333	416	)	)	PUNCT
dpc-1025	333	417	total	total	NOUN
dpc-1025	333	418	27	27	NUM
dpc-1025	333	419	(	(	PUNCT
dpc-1025	333	420	47.37	47.37	NUM
dpc-1025	333	421	)	)	PUNCT
dpc-1025	333	422	15	15	NUM
dpc-1025	333	423	(	(	PUNCT
dpc-1025	333	424	26.32	26.32	NUM
dpc-1025	333	425	)	)	PUNCT
dpc-1025	333	426	15	15	NUM
dpc-1025	333	427	(	(	PUNCT
dpc-1025	333	428	26.32	26.32	NUM
dpc-1025	333	429	)	)	PUNCT
dpc-1025	333	430	57	57	NUM
dpc-1025	333	431	(	(	PUNCT
dpc-1025	333	432	100	100	NUM
dpc-1025	333	433	)	)	PUNCT
dpc-1025	333	434	aresult	aresult	NOUN
dpc-1025	333	435	derived	derive	VERB
dpc-1025	333	436	from	from	ADP
dpc-1025	333	437	fisher	fisher	PROPN
dpc-1025	333	438	exact	exact	PROPN
dpc-1025	333	439	test	test	NOUN
dpc-1025	333	440	.	.	PUNCT
dpc-1025	334	1	sun	sun	NOUN
dpc-1025	334	2	-	-	PUNCT
dpc-1025	334	3	exposed	expose	VERB
dpc-1025	334	4	body	body	NOUN
dpc-1025	334	5	parts	part	NOUN
dpc-1025	334	6	=	=	NOUN
dpc-1025	334	7	extremities	extremity	NOUN
dpc-1025	334	8	and	and	CCONJ
dpc-1025	334	9	head	head	NOUN
dpc-1025	334	10	and	and	CCONJ
dpc-1025	334	11	neck	neck	NOUN
dpc-1025	334	12	;	;	PUNCT
dpc-1025	334	13	25(oh)d	25(oh)d	NUM
dpc-1025	334	14	=	=	SYM
dpc-1025	334	15	25	25	NUM
dpc-1025	334	16	-	-	PUNCT
dpc-1025	334	17	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	334	18	d	d	NOUN
dpc-1025	334	19	;	;	PUNCT
dpc-1025	334	20	bmi	bmi	PROPN
dpc-1025	334	21	=	=	SYM
dpc-1025	334	22	body	body	PROPN
dpc-1025	334	23	mass	mass	PROPN
dpc-1025	334	24	index	index	NOUN
dpc-1025	334	25	.	.	PUNCT
dpc-1025	335	1	10	10	NUM
dpc-1025	335	2	research	research	NOUN
dpc-1025	335	3	|	|	ADV
dpc-1025	335	4	dermatol	dermatol	NOUN
dpc-1025	335	5	pract	pract	NOUN
dpc-1025	335	6	concept	concept	NOUN
dpc-1025	335	7	2020;10(1):e2020010	2020;10(1):e2020010	NUM
dpc-1025	335	8	table	table	NOUN
dpc-1025	335	9	e2	e2	PROPN
dpc-1025	335	10	.	.	PUNCT
dpc-1025	336	1	association	association	NOUN
dpc-1025	336	2	of	of	ADP
dpc-1025	336	3	serum	serum	NOUN
dpc-1025	336	4	25(oh)d	25(oh)d	NUM
dpc-1025	336	5	levels	level	NOUN
dpc-1025	336	6	with	with	ADP
dpc-1025	336	7	breslow	breslow	NOUN
dpc-1025	336	8	in	in	ADP
dpc-1025	336	9	different	different	ADJ
dpc-1025	336	10	age	age	NOUN
dpc-1025	336	11	groups	group	NOUN
dpc-1025	336	12	serum	serum	VERB
dpc-1025	336	13	25(oh)d	25(oh)d	NOUN
dpc-1025	336	14	,	,	PUNCT
dpc-1025	336	15	n	n	CCONJ
dpc-1025	336	16	(	(	PUNCT
dpc-1025	336	17	%	%	INTJ
dpc-1025	336	18	)	)	PUNCT
dpc-1025	336	19	total	total	NOUN
dpc-1025	336	20	p	p	NOUN
dpc-1025	336	21	value	value	NOUN
dpc-1025	336	22	<	<	X
dpc-1025	336	23	20	20	NUM
dpc-1025	336	24	ng	ng	PROPN
dpc-1025	336	25	/	/	SYM
dpc-1025	336	26	ml	ml	PROPN
dpc-1025	336	27	21	21	NUM
dpc-1025	336	28	-	-	SYM
dpc-1025	336	29	29	29	NUM
dpc-1025	336	30	ng	ng	PROPN
dpc-1025	336	31	/	/	SYM
dpc-1025	336	32	ml	ml	PROPN
dpc-1025	336	33	>	>	SYM
dpc-1025	336	34	30	30	NUM
dpc-1025	336	35	ng	ng	NOUN
dpc-1025	336	36	/	/	SYM
dpc-1025	336	37	ml	ml	ADP
dpc-1025	336	38	age	age	NOUN
dpc-1025	336	39	≤40	≤40	PROPN
dpc-1025	336	40	years	year	NOUN
dpc-1025	336	41	breslow	breslow	VERB
dpc-1025	336	42	0.295a	0.295a	PROPN
dpc-1025	336	43	<	<	X
dpc-1025	336	44	1	1	NUM
dpc-1025	336	45	mm	mm	NUM
dpc-1025	336	46	8	8	NUM
dpc-1025	336	47	(	(	PUNCT
dpc-1025	336	48	66.67	66.67	NUM
dpc-1025	336	49	)	)	PUNCT
dpc-1025	336	50	0	0	NUM
dpc-1025	336	51	4	4	NUM
dpc-1025	336	52	(	(	PUNCT
dpc-1025	336	53	33.33	33.33	NUM
dpc-1025	336	54	)	)	PUNCT
dpc-1025	336	55	12	12	NUM
dpc-1025	336	56	(	(	PUNCT
dpc-1025	336	57	100	100	NUM
dpc-1025	336	58	)	)	PUNCT
dpc-1025	336	59	1	1	NUM
dpc-1025	336	60	-	-	SYM
dpc-1025	336	61	4	4	NUM
dpc-1025	336	62	mm	mm	NOUN
dpc-1025	336	63	9	9	NUM
dpc-1025	336	64	(	(	PUNCT
dpc-1025	336	65	64.29	64.29	NUM
dpc-1025	336	66	)	)	PUNCT
dpc-1025	336	67	3	3	NUM
dpc-1025	336	68	(	(	PUNCT
dpc-1025	336	69	21.43	21.43	NUM
dpc-1025	336	70	)	)	SYM
dpc-1025	336	71	2	2	NUM
dpc-1025	336	72	(	(	PUNCT
dpc-1025	336	73	14.29	14.29	NUM
dpc-1025	336	74	)	)	PUNCT
dpc-1025	336	75	14	14	NUM
dpc-1025	336	76	(	(	PUNCT
dpc-1025	336	77	100	100	NUM
dpc-1025	336	78	)	)	PUNCT
dpc-1025	336	79	>	>	PUNCT
dpc-1025	336	80	4	4	NUM
dpc-1025	336	81	mm	mm	NUM
dpc-1025	336	82	4	4	NUM
dpc-1025	336	83	(	(	PUNCT
dpc-1025	336	84	80	80	NUM
dpc-1025	336	85	)	)	SYM
dpc-1025	336	86	1	1	NUM
dpc-1025	336	87	(	(	PUNCT
dpc-1025	336	88	20	20	NUM
dpc-1025	336	89	)	)	PUNCT
dpc-1025	336	90	0	0	NUM
dpc-1025	336	91	5	5	NUM
dpc-1025	336	92	(	(	PUNCT
dpc-1025	336	93	100	100	NUM
dpc-1025	336	94	)	)	PUNCT
dpc-1025	336	95	total	total	NOUN
dpc-1025	336	96	21	21	NUM
dpc-1025	336	97	(	(	PUNCT
dpc-1025	336	98	67.74	67.74	NUM
dpc-1025	336	99	)	)	PUNCT
dpc-1025	336	100	4	4	NUM
dpc-1025	336	101	(	(	PUNCT
dpc-1025	336	102	12.90	12.90	NUM
dpc-1025	336	103	)	)	PUNCT
dpc-1025	336	104	6	6	NUM
dpc-1025	336	105	(	(	PUNCT
dpc-1025	336	106	19.35	19.35	NUM
dpc-1025	336	107	)	)	PUNCT
dpc-1025	336	108	31	31	NUM
dpc-1025	336	109	(	(	PUNCT
dpc-1025	336	110	100	100	NUM
dpc-1025	336	111	)	)	PUNCT
dpc-1025	336	112	age	age	NOUN
dpc-1025	336	113	>	>	SYM
dpc-1025	336	114	40	40	NUM
dpc-1025	336	115	years	year	NOUN
dpc-1025	336	116	breslow	breslow	VERB
dpc-1025	336	117	0.284a	0.284a	NOUN
dpc-1025	336	118	<	<	X
dpc-1025	336	119	1	1	NUM
dpc-1025	336	120	mm	mm	NUM
dpc-1025	336	121	14	14	NUM
dpc-1025	336	122	(	(	PUNCT
dpc-1025	336	123	35	35	NUM
dpc-1025	336	124	)	)	PUNCT
dpc-1025	336	125	17	17	NUM
dpc-1025	336	126	(	(	PUNCT
dpc-1025	336	127	42.50	42.50	NUM
dpc-1025	336	128	)	)	PUNCT
dpc-1025	336	129	9	9	NUM
dpc-1025	336	130	(	(	PUNCT
dpc-1025	336	131	22.50	22.50	NUM
dpc-1025	336	132	)	)	PUNCT
dpc-1025	336	133	40	40	NUM
dpc-1025	336	134	(	(	PUNCT
dpc-1025	336	135	100	100	NUM
dpc-1025	336	136	)	)	PUNCT
dpc-1025	336	137	1	1	NUM
dpc-1025	336	138	-	-	SYM
dpc-1025	336	139	4	4	NUM
dpc-1025	336	140	mm	mm	NUM
dpc-1025	336	141	7	7	NUM
dpc-1025	336	142	(	(	PUNCT
dpc-1025	336	143	36.84	36.84	NUM
dpc-1025	336	144	)	)	PUNCT
dpc-1025	336	145	4	4	NUM
dpc-1025	336	146	(	(	PUNCT
dpc-1025	336	147	21.05	21.05	NUM
dpc-1025	336	148	)	)	PUNCT
dpc-1025	336	149	8	8	NUM
dpc-1025	336	150	(	(	PUNCT
dpc-1025	336	151	42.11	42.11	NUM
dpc-1025	336	152	)	)	PUNCT
dpc-1025	336	153	19	19	NUM
dpc-1025	336	154	(	(	PUNCT
dpc-1025	336	155	100	100	NUM
dpc-1025	336	156	)	)	PUNCT
dpc-1025	336	157	>	>	PUNCT
dpc-1025	336	158	4	4	NUM
dpc-1025	336	159	mm	mm	NUM
dpc-1025	336	160	5	5	NUM
dpc-1025	336	161	(	(	PUNCT
dpc-1025	336	162	55.56	55.56	NUM
dpc-1025	336	163	)	)	PUNCT
dpc-1025	336	164	3	3	NUM
dpc-1025	336	165	(	(	PUNCT
dpc-1025	336	166	33.33	33.33	NUM
dpc-1025	336	167	)	)	PUNCT
dpc-1025	336	168	1	1	NUM
dpc-1025	336	169	(	(	PUNCT
dpc-1025	336	170	11.11	11.11	NUM
dpc-1025	336	171	)	)	PUNCT
dpc-1025	336	172	9	9	NUM
dpc-1025	336	173	(	(	PUNCT
dpc-1025	336	174	100	100	NUM
dpc-1025	336	175	)	)	PUNCT
dpc-1025	336	176	total	total	NOUN
dpc-1025	336	177	26	26	NUM
dpc-1025	336	178	(	(	PUNCT
dpc-1025	336	179	38.24	38.24	NUM
dpc-1025	336	180	)	)	PUNCT
dpc-1025	336	181	24	24	NUM
dpc-1025	336	182	(	(	PUNCT
dpc-1025	336	183	35.29	35.29	NUM
dpc-1025	336	184	)	)	PUNCT
dpc-1025	336	185	18	18	NUM
dpc-1025	336	186	(	(	PUNCT
dpc-1025	336	187	26.47	26.47	NUM
dpc-1025	336	188	)	)	PUNCT
dpc-1025	336	189	68	68	NUM
dpc-1025	336	190	(	(	PUNCT
dpc-1025	336	191	100	100	NUM
dpc-1025	336	192	)	)	PUNCT
dpc-1025	336	193	aresult	aresult	NOUN
dpc-1025	336	194	derived	derive	VERB
dpc-1025	336	195	from	from	ADP
dpc-1025	336	196	fisher	fisher	PROPN
dpc-1025	336	197	exact	exact	ADJ
dpc-1025	336	198	test	test	NOUN
dpc-1025	336	199	.	.	PUNCT
dpc-1025	337	1	25(oh)d	25(oh)d	NUM
dpc-1025	337	2	=	=	SYM
dpc-1025	337	3	25	25	NUM
dpc-1025	337	4	-	-	PUNCT
dpc-1025	337	5	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1025	337	6	d.	d.	NOUN